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Abstract
The aim of this work was to investigate different methods for the covalent attachment of
poly(ethylene glycol) onto the therapeutic peptide oxytocin, a highly important, but
thermally unstable therapeutic used globally. This peptide is the WHO recommended
therapeutic for prevention of postpartum haemorrhaging, sitting on the WHO list of
essential medicines. Tackling the currently unacceptable maternal mortality rate,
particularly in developing countries is of paramount importance and is currently one of the
WHOs main priorities. Within this project it was speculated that by attachment of PEG to
the peptide there would hopefully be an increase in stability, particularly for aqueous
formulations at elevated temperatures.
Chapter one gives a brief outline of the problem that the world is facing with respect to
maternal mortality, and particularly the gap between developed and developing countries
and previous strategies that have looked into improving the stability of oxytocin.
Additionally the various different site-specific conjugation approaches available for peptide
modification are discussed, alongside how these can be implemented with controlled
radical polymerisation techniques for the synthesis of alternative polymer architectures.
Chapter two discusses two particular targeting chemistries for site-selectively targeting the
N-terminal amine (the only amino group on the peptide structure). Some commercially
applicable linear PEGylation reagents (such as utilising NHS esters) were utilised for the
conjugation of polymers onto oxytocin in this manner. PolyPEGs were synthesised to
contain similar α-end group functionality as for the linear polymers and reacted with 
oxytocin in similar manners. The reversible nature of one of these chemistries was also
investigated, and the potential release of the native peptide dependence on conjugate
architecture and pH were evaluated.
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In Chapter 3 the potential for conjugation techniques targeting the sulfhydryl groups
arising from a reduction of the disulfide bond were approached in two different manners.
Disubstituted maleimide chemistry is particularly useful in this case as it allows the
rebridging of the disulfide bond, one of the main degradation sites on the peptide, with a
stronger 2-carbon bond. Dithiophenolmaleimide α-end functional polyPEGs were 
synthesised and conjugated onto the peptide via an in-situ approach alongside traditional
conjugations with both polyPEGs and linear PEGs. Another approach was evaluated for the
conjugation at the disulfide bond that treats both free cysteine residues for separate
conjugations utilising phosphine mediated thiol-ene chemistry. The facile synthesis of ABA
block copolymers containing a central ‘oxytocin’ block, however results in a loss of the
cyclic structure on the peptide, and likely complete suppression of biological activity.
Chapter 4 reports the investigation of the various conjugation strategies raised in chapters
2 & 3 for how the properties of the peptide might have changed post-conjugation
comparing linear PEG and polyPEG site selectively added at either position in comparison
to the native peptide. This is evaluated for the thermal stability, where oxytocin shows
high levels of degradation in aqueous solutions, particularly at elevated temperatures. Also
investigated is the potential retention of uterotonic activity, via ex-vivo electrophysiology
studies, as well as some previously investigated effects on the inhibition of cell
proliferation of the breast cancer cell line MDA-MB231.
Chapter 5 focusses on the conjugation to oxytocin, and another small disulfide containing
peptide of some different (non-PEG) polymers synthesised in similar manners to those
discussed in chapters 2 and 3. These few examples show that there is a large scope within
this polymer synthesis and conjugation chemistry for utilising these techniques for a wide
range of different monomer classes. Those described include the synthesis of a promising
PEG alternative, two different thermoresponsive polymers and polymers containing
pendant sugar functionality followed by the subsequent peptide conjugations.
1Chapter 1
1. Introduction
“Every day, approximately 830 women die from preventable causes related to
pregnancy and childbirth.”
- World Health Organisation, November 2015
Chapter 1 - Introduction
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1.1. Oxytocin
Oxytocin is a cyclic neurohypophyseal nonapeptide (cyclic [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-
Leu-Gly-NH2) naturally produced in the hypothalamus (figure 1.1). The uterine contracting
properties of oxytocin were first discovered in 1906 by Sir Henry Hallett Dale, on observing
the subsequent contractions caused from delivery of extractions from the pituitary.1 It was
not until the 1950s and the pioneering work of Vincent du Vigneaud that the structure of
oxytocin was elucidated2 and soon after biochemically synthesised,3 making it the first
polypeptide to be sequenced and synthesised, winning du Vigneaud the 1955 Nobel prize
in Chemistry.4
Figure 1.1. Structure of native oxytocin (cyclic [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2).
1.1.1. Oxytocin relation of maternal mortality
Approximately 300,000 women globally die every year from pregnancy or childbirth
related problems.5,6 This is particularly prevalent in communities within the developing
world, such as in Africa, Asia and Latin America, where tropical climates often have
daytime temperatures exceeding 40 °C and reliable cold chain transportation and storage
is not always achievable due to economic or social reasons. In developing countries there is
Chapter 1 - Introduction
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also less access to well-resourced healthcare facilities and particularly medical
professionals, which cause large increases in maternal deaths. The global differences in the
amount of women dying during childbirth are very high with maternal deaths occurring far
too commonly within the developing world (approximately 14 times more incidences than
developed countries). As a result the World Health Organisation (WHO) expect 99 % of
maternal deaths occurring in 2016 to be within less economically developed regions.7,8 The
UN has currently been focusing on reducing maternal mortality, with a goal of reducing
the maternal mortality rate to less than 70 deaths per 100,000 live births by 2030 (UN
sustainable development goal 3).
On consideration of maternal death statistics, at least 25% of these deaths are due to
excessive or uncontrolled bleeding after birth: postpartum haemorrhaging (PPH). This
usually results in haemorrhaging in excess of 500ml blood after delivery and occurs in 10%
of all births. This is mainly due to the atonicity of the uterus post birth (failure to
adequately contract). Oxytocin is the World Health Organisation (WHO) recommended
drug currently used globally as a uterotonic for the prevention of PPH9–12 and is on the
WHO list of essential medicines.13
1.1.2. Oxytocin for uterotonic activity
Oxytocin receptors are expressed on the cell surfaces of a variety of cells, not only
specifically at the uterus.14 The oxytocin receptor is a G protein-coupled receptor (GPCR), a
transmembrane receptor that works as a cell-signalling powerhouse, sensing molecules
outside cells and exhibiting cellular responses. When oxytocin binds into this receptor, this
elicits a response from the G-protein, with which it is coupled inside the cell. The
mechanism of action involves a combination of MLC kinase (activated by an influx of Ca2+),
alongside prostaglandin F2α (derived enzymatically inside the cell), ultimately causing a
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contraction of the uterus.15,16 Although the exact binding mechanism of oxytocin to the
oxytocin receptor is still unknown, the amino acids on the oxytocin structure important for
retaining activity have been determined. For receptor binding Ile3, Gln4, Pro7 and Leu8 are
all important whereas Asn5 and Tyr2 are key moieties required for stimulating activity and
proper function upon binding to the receptor.17,18 Any changes in the structure of the
peptide in general, but more specifically to these residues can lead to a loss of biological
activity, or the ability to bind into the receptor.
1.1.3. Degradation of oxytocin formulations
A major problem with the administration of oxytocin as a therapeutic is that it possesses a
very limited stability in aqueous solutions, particularly at elevated temperatures, such as
those found in tropical climates, which leads to a loss of activity of the drug.18–20 Injectable
(aqueous) oxytocin formulations therefore require refrigeration (2 – 8 °C) to ensure quality
and limit the degradation. The recommended shelf life for refrigerated oxytocin (<8 °C) is 2
years and for non-refrigerated oxytocin (< 25 °C) is less than 6 months.
There have been many investigations into the degradation profiles of oxytocin, in
particular to establish at which position on the peptide structure this degradation is
occurring.18,19,21 Tyr2 can readily undergo oxidation, and the amides located at Gln4,
Asn5and C-terminal Gly9 are all susceptible to deamidation under acidic conditions by acid
hydrolysis and at neutral / basic conditions via the formation of cyclic intermediates.22,23
The major position of degradation, however, was found to be the Cys1-Cys6 disulfide bond
where a large amount of degradation processes can occur following β-elimination at Cys1,
generating an N-terminal enamine and a cysteine persulfide. This facilitates the formation
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of trisulfide and tetrasulfide oxytocin, and can also promote formation of oxytocin dimers
and larger aggregation products (figure 1.2).19
Figure 1.2. Major disulfide degradation product formation from oxytocin according to
Wiśniewski.19
1.1.4. Current solutions for stabilising oxytocin
Previous research in this area has established several methods that may improve the
stability of solutions of oxytocin at higher temperatures, to further accommodate the
storage facilities in developing countries. Several methods are available, including changes
to the peptide structure, as in oxytocin analogues, however, this might not always be
desirable as can lead to a loss of affinity in receptor binding or a decrease in biological
activity. Another area that has received interest is in changing the storage conditions of the
peptide to suppress degradation. Some of these current approaches to improving oxytocin
stability are discussed in the following sub-chapters.
1.1.4.1. Oxytocin analogues: carbetocin and desamino-
oxytocin
Different analogues of oxytocin have been evaluated with respect to retaining uterotonic
activity whilst increasing stability.16,24–26 The most well-known oxytocin receptor agonists
are desamino-oxytocin and carbetocin, two synthetic peptides exhibiting similar receptor
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affinities to oxytocin and which induce contractions via the same mechanism. Both
carbetocin and desamino oxytocin exhibit much higher plasma half-lives than oxytocin due
to structural changes.27–29 Desamino-oxytocin and carbetocin differ from oxytocin by
lacking the free amino group at the N-terminus, although carbetocin also contains other
structural modifications, including replacement of one of the sulphurs at the disulfide
bridge with a CH2 group (figure 1.3).
Figure 1.3. Structures of oxytocin analogues: desamino-oxytocin and carbetocin.
Both these oxytocin analogues show a prolonged half-life, with the retention of some
uterotonic activity maintained, suggesting that the amino group in oxytocin is not required
for biological activity. For carbetocin the increase in half-life is 4- 10 times that of oxytocin,
resulting in administration as a single injection rather than a long infusion, and has resulted
in carbetocin being approved for medical and veterinary use in many different countries as
an effective oxytocin receptor agonist.30
1.1.4.2. Disulfide bond engineering on oxytocin
As the major position of degradation on the peptide is known to be at the disulfide bond a
significant amount of research has evolved around different oxytocin analogues where the
disulfide bond is replaced in part with other heteroatoms. This is with an aim to avoiding β-
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elimination at Cys1, and as the Cys1-Cys6 disulfide bond is not one of the positions that is
directly involved in receptor binding or action it was envisaged that not all biological
activity would be lost.
This was initially investigated in the 1960s and 1970s, to establish whether activity was
maintained if either one or both thiols within the disulfide bond were altered to CH2
groups, as in carbetocin.31–33 It was found that activity was still observed, although this was
moderately suppressed, particularly on altering the ring size of the peptide, but that
overall the presence of a disulfide bridge was not a prerequisite for biological activity to be
maintained.
Recent studies by Alewood and co-workers have focussed on the replacement of the
disulfide with thioether, selenylsulfide, diselenide and ditelluride bridges, and the synthesis
of a variety of oxytocin analogues containing altered disulfide bonds (figure 1.4). The
resulting binding and activity at the human oxytocin receptor was investigated alongside
any changes to the metabolic stability in human plasma.34,35
Figure 1.4. Oxytocin analogues, with disulfide bond replacements investigated for uterotonicactivity and plasma stability by Alewood.34
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They found that a reduction in ring size ([--S]-OT) cause a dramatic (1000-fold) loss of
binding affinity and biological activity, although replacement of the S atom in cysteine with
a CH2 group ([CH2-S]-OT) retained binding affinity and activity. The replacement of cysteine
with selenocysteine or tellurocysteine did not have a large effect on the functional activity,
although a 10-fold decrease in binding affinity was observed upon replacement of both
cysteines (although not when only replacing one cysteine). It was also discovered that by
replacing the disulfide bridge (-S-S-) with non-reducible selenoether bonds (-Se-CH2-), large
improvements (1.5 – 3-fold) can be observed in the stability in human plasma, as well as
under high thermal stressing (55 °C), as observed by RP-HPLC and LC-MS.
1.1.4.3. Storage buffers containing metal ions
Oxytocin is well-known to be most stable at slightly acidic pH (pH ~ 4.5). At highly acidic
pHs (pHs < 3) the peptide can undergo hydrolysis, while at neutral or basic pHs the
dimerisation or formation of aggregates around the disulfide bond result in deactivation of
the peptide.18,36 Work was carried out by Avanti et al. on the stabilisation of aqueous
solutions of oxytocin by using different storage buffers (citrate, acetate or aspartate, pH
4.5) in combination with various monovalent (Na+ and K+) or divalent (Ca2+, Mg2+ and Zn2+)
metal ions.37–40
Upon storage of oxytocin in unbuffered solutions containing Ca2+ (50 mM) and Zn2+ (2-50
mM), recovery was promoted from ~ 60 % to ~ 100 % on storage at 4 °C, however, the
improvement at higher temperatures were not significant. The combination of divalent
metal ions and citrate buffer, however, vastly improved the stability to high temperatures
(55 °C), at metal ion concentrations as low as 2 mM.40 Similar results were achieved when
the metal ions were used in combination with aspartate buffer, where Zn2+ ions were
shown to be the most effective in increasing solution stability.38,39
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It was also proven that after high temperature stressing at 70 °C the degradation products
arising from the disulfide bond (trisulfide and tetrasulfide) were severely suppressed by
the addition of zinc metal ions in citrate buffer by 20 – 70 %. NMR studies confirmed that
the Cys1-Cys6 disulfide bond was being more efficiently protected, by minor conformational
changes, suppressing intermolecular interactions at this position.38
1.1.4.4. Dry powder formulations
A further approach that has been evaluated for providing heat stability to oxytocin is the
formulation of oxytocin as a dry powder for potential use via an inhalation administration
technique as opposed to the more common parenteral delivery route. Oxytocin can be
spray-dried as an ultrafine powder or in particle form, and is adsorbed very rapidly on
delivery to the lungs and counteracts the need for aqueous solutions. Work carried out by
McIntosh et al. formulated oxytocin particles using a carrier mixture of 1:1:1 glycine:
leucine: mannitol resulting in particles with a size of 1–5 µm.41
The formulations proved effective in ex-vivo isolated tissue contractility studies (human
and bovine uterine samples), with similar results for the spray dried formulation compared
to the native peptide, and no contractility response observed for tracheal tissue. In-vivo
activity was monitored by electromyographic activity and was found to mimic that of the
normal parenteral route, with significantly faster onset of contractions. Importantly, these
formulations should remain stable even under extreme environmental conditions
(including temperatures up to 50 °C).42
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1.1.4.5. Previous oxytocin conjugation strategies
To the best of our knowledge, upon commencing this project we could only find three
incidences of conjugation strategies focused upon attachment of macromolecules and
oxytocin, none with an aim to improving the solution stability of this vital therapeutic.
Due to the overexpression of cell-surface oxytocin receptors on specific cancer cells,
Cavallaro et al. used oxytocin as a targeting moiety for a macromolecular conjugate
containing the well-known antitumor agent paclitaxel.43 N-succinyl-oxytocin was
functionalised at the N-terminal amine with α,β-poly(N-2-hydroxyethyl)-DL-aspartamide-
poly(ethylene glycol)2000 (PHEA-PEG2000) followed by introduction of 2’-O-succinylpaclitaxel
resulting in PHEA-PEG2000-succinyloxytocin-succinylpaclitaxel. In-vitro hydrolysis studies
revealed that the conjugates were stable at pH 7.4 and in plasma, and in-vitro cell activity
testing suggested that the incorporation of oxytocin slightly improved the activity
compared to paclitaxel and the carrier without the peptide.
In a further study, β-cyclodextrin, a water soluble cyclic oligosaccharide, was successfully 
employed in the functionalisation of oxytocin using carboxy coupling chemistry (activated
using 1-hydroxybenzotriazole and dicyclohexylcarbodiimide).44 The β-CD-OT conjugate was 
evaluated for contractile potency and, although this was found to be less than the native
peptide, contractions were still evident at <µM concentrations. It was further believed that
this hydrophilic targeted carrier could form a host-guest complex with prostaglandins used
as labour inducers, or with anticancer drugs.
Hudnut and Cook filed a patent in 2004 for the incorporation of oxytocin (and some
oxytocin analogues) into poly(lactic-co-glycolide) microcapsules, and their subsequent in
vitro release.45 This was for the application of potential therapeutic treatment of a variety
of social and behaviour conditions, under which oxytocin plays a role.
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1.2. Site-selective protein/peptide conjugation
strategies
1.2.1. PEGylation
The most commonly utilised polymer for protein or peptide conjugation is poly(ethylene
glycol) (PEG) usually in the form of monomethoxy PEG (mPEG), synthesised by anionic ring
opening polymerisation. PEG has many advantages which have inspired use within the
polymer therapeutics and drug delivery fields, particularly for covalent attachment to
peptides and proteins (PEGylation) (figure 1.5). PEGylation was first achieved in 1977 by
Abuchowski et al. for the covalent attachment of 2 kDa and 5 k Da PEGs using cyanuric
chloride coupling.46,47
PEG has a high solubility in both aqueous and organic solvents, making modifications
simple. The hydrophilicity of PEG is not observed for similar structured polymers (e.g.
poly(methylene oxide) or poly(propylene oxide).48 PEG is classified as a Generally Regarded
As Safe (GRAS) chemical, with toxicity only observed at high doses and overall very high
biocompatibility.49 PEGylation can have beneficial properties on stability, protecting
against enzyme degradation and prolonging in-vivo half-lives of the conjugate, providing
shielding of the protein or peptide, and thus reduce dosage requirements.50,51 The addition
of this multi-functional polymer can also improve water solubility and shield potential
charges thereby creating a ‘stealth’ effect.52
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Figure 1.5. Structure of mPEG and some functional site-selective conjugating groups.
PEGylation, however, is not completely without disadvantages, with PEGylated products
often leading to the suppression of biological activity post-conjugation due to a shielding of
the active residues on the biomolecule, by the polymer.53–55 Additionally, PEG does not
biodegrade in the body, and this can lead to accumulation and vacuolisation in the liver,
kidneys and other vital organs, particularly at molar masses above 20 kDa, alongside the
potential for containing toxic side-products if non-pharmaceutical grade PEG is used.52,56 A
further major problem is that PEG products can cause an immunological response by
activation of the immune system.52
Even with these disadvantages PEG is still the number one polymer utilised in polymer
therapeutics and drug formulations, and the gold standard for conjugation of proteins and
polymers.
1.2.1.1. Current FDA approved PEG conjugates
Since the introduction of covalent attachment of PEG to proteins, there have been various
reports on the attachment of PEG to proteins, peptides and therapeutics. It has been
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demonstrated that PEGylation can improve a variety of characteristics for the biomolecule
including pharmacological properties. This has resulted in several PEGylated proteins
receiving Food and Drug Administration (FDA) approval. Many others, including some
peptide polymer conjugates, are currently in clinical trials seeking approval. In 2011,
Alconcel, Baas and Maynard reviewed the current FDA approved PEGylated products
available on the market, and the possible outlooks for the protein PEGylation field.57
Table 1.1. Different FDA approved PEGylated products available on the commercial market.57
# Protein PEGSize Drug Name
Site of
attachment Drug Use
1 Adenosinedeaminase 5 kDa Adagen Lys, Ser, Tyror His Enzyme- treat severecombinedimmunodeficiencydisease
2 Anti-TNGα Fab’ 40 kDa Cimzia C-TerminalCys Monoclonal antibodydrug- treat Crohn’sdisease andrheumatoid arthritis
3 Anti-VEGF 40 kDa Pegaptanib/Macugen Lys Anti-angiogenic –Treat age-relatedmaculardegeneration
4 L-Asparaginase 5 kDa Oncaspar Lys, Ser, Tyror His Antineoplastic drug-treat lymphoblasticleukemia
5
Continuouserythropoietinreceptoractivator 30 kDa Mircera Lys52 orLys46
Treat renal anemia inpatients with chronickidney disease
6 G-CSF 20 kDa Neulasta N-TerminalMet Growth factor –manage febrileneutropenia
7 hGH antagonistB2036 5 kDa Somavert Lys or N-TerminalPhe Growth hormonereceptor antagonist –treat acromegaly
8 Interferon α-2a 40 kDa PEGASYS 
Lys31, Lys121,Lys131 orLys134 Treat chronichepatitis C
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9 Interferon α-2b 12 kDa PEGINTRON His34 Treat chronichepatitis C
10 Mammalianurate oxidase 10 k Da Krystexxa Lys Treat chronic goutrefractory
A variety of different conjugation chemistries are used for PEG attachment to the protein
of interest including N-hydroxy succinimidyl ester (NHS): (1,4,5,7,8,9), maleimide (2),
aldehyde (6) and p-nitrophenol (10). Overall the attachment of PEG can reduce clearance
of drugs, shield drugs from the immune system and slow enzymatic degradation; however,
most of these FDA approved drug conjugates show multisite attachment, which can lead to
reductions in remaining biological activity and heterogeneity in the product distribution.
A wide variety of different functional PEGs are available for conjugation at site-selective
positions on proteins or peptides using different coupling chemistries, including at amino
and thiol functionalities found naturally within peptide structures. There are various
different strategies which have been developed over the last 40 years that can be used for
selective conjugation.
1.2.2. Amine targeting strategies
The most common strategy for site selective targeting within peptides or proteins is the
targeting of amino groups located either on lysine side chains or at the N-terminal amine.
Most proteins usually have ~ 10 % lysine within the amino acid sequences, and therefore
this gives a convenient target for attachment of several side chains. Multiple attachments,
however, may not always be desirable as this can lead to more complicated
characterisation of conjugation and potentially high losses of biological activity.
Conjugations are also able to take advantage of the difference in pKa between the α-amino 
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residue of the N-terminus (pKa = 7.6 – 8) and ε-amino residue of lysine chains (pKa = 9.3 –
9.5) for more selective couplings to occur.58
1.2.2.1. N-Hydroxysuccinimidyl esters (NHS)
One of the most utilised conjugation strategies for conjugation of amino groups is the use
of activated esters, of which N-hydroxysuccinimide (NHS) activated esters have been
commonly employed, as acylating reagents, since their introduction to peptide conjugation
in the 1960s.59 NHS ester reagents react with nucleophiles (such as nucleophilic amines),
with the release of N-hydroxy succinimide resulting in a stable amide linkage to the
peptide or protein (figure 1.6).
Figure 1.6. Reaction of NHS ester and a model peptide.
The NHS reagent, however, undergoes rapid hydrolysis in water resulting in a loss of the
succinimidyl ester conjugating group, with half-life decreasing dramatically upon increasing
pH.60–62 Sulfonated-NHS esters add a charged sulfonate group, for which molecules
undergo hydrolysis more gradually, as well as improving water solubility, allowing coupling
reactions to be carried out in aqueous conditions. It has also been reported that
succinimidyl reagents may not react site-specifically with amines, exhibiting reactivity to
other nucleophilic amino acids residues such as tyrosine, histidine and serine, although
generally at a slower rate to amino coupling.
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1.2.2.2. Aldehyde
Aldehyde reagents readily react with amino groups, initially via the formation of imine
(Schiff base) products. These reversible Schiff bases are readily reduced into stable
secondary amines by the addition of a reducing agent such as sodium borohydride (NaBH4)
or sodium cyanoborohydride (NaCNBH3), in a process referred to as reductive amination
(figure 1.7). NaCNBH3 is generally preferred for the reductions as it is a milder reducing
agent, thus selectively reducing the Schiff base product without also reducing the aldehyde
or other less reactive carbonyls present in the reaction.63,64
Figure 1.7. Two step reductive amination of aldehyde via Schiff base intermediate.
pH is highly important in aldehyde couplings, where reductive amination proceeds fastest
at pH 6.5-8.5, although manipulating the pH to slightly acidic conditions can also allow for
selective coupling of the N-terminus over more basic lysine residues.65–67
1.2.2.3. Carboxylic acid
The coupling of carboxylate groups with amines has been well reported, leading to the
formation of amide linkages.68 This is generally performed through the use of coupling
reagents including carbodiimides such as 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide.HCl (EDC) or dicyclohexylcarbodiimide (DCC), which
activate the carboxyl groups for substitution by reactive amines (figure 1.8).69,70
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Figure 1.8. Carbodiimide mediated reaction between amino group and carboxylic acid reagent.
1.2.2.4. Other amine reactive groups
Other than those already discussed, there are a variety of other functional groups which
can be utilised for conjugation to amino groups on peptides or proteins via alkyation or
acylation reactions. These include cyanuric chloride,46,47 isocyanate,71 imidoester,72
epoxide,73 and several activated ester routes such as p-nitrophenyl carbonates,74
trichlorophenyl carbonate,74 imidazole carbamate75–77 and pentafluorophenyl ester.78
1.2.3. Thiol targeting strategies
An alternative approach for the conjugation of polymers onto peptides or proteins is the
site specific targeting of thiol groups presented by free cysteine residues, or from the
reduction of disulfide bonds. This can be beneficial as often there are fewer thiol
functionalities (particularly as free cysteines) present on peptide or protein structures
compared to amino groups allowing a more site-specific modification. The thiol side chain
acts as a mild nucleophile, which can be exploited in the chemical modification of proteins,
usually via alkylation reactions with a variety of reagents, although intra- and/or
intermolecular formation of disulfides is also possible.79,80
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1.2.3.1. N-Substituted maleimide reagents
One of the most widely used reactive groups for selective cysteine modification within
conjugation chemistry are maleimides.81 There are several N-functionalised maleimide
reagents available for the selective alkylation reaction to thiols using the maleimide double
bond in an irreversible manner. This occurs by an irreversible thiol-Michael addition
reaction, changing the nature of the conjugating reagent by removing the double bond
(where the product becomes a substituted succinimide). Maleimides may also react with
amino groups, but the reaction can be pH controlled to be selective towards the sulfhydryl
groups (pH 6.5 -7.5).82,83
Figure 1.9. Conjugation reactions of sulfhydryls utilising maleimide (addition) orbromomaleimide (substitution).
In 2009-2010 Baker et al. reported the use of a new bromomaleimide reagent, similar to
maleimides, for selective and rapid conjugation to cysteine residues (figure 1.9).84,85
Utilising bromomaleimide allowed reversible conjugations, via a substitution reaction, to
occur for temporary cysteine modification, which could allow protein/peptide release
upon the addition of phosphines, or excess thiols, thereby restoring activity to the protein
or peptide of interest. Competitive reactions for the conjugation of cysteine between
maleimide and bromomaleimide also show that bromomaleimide reacts more rapidly than
maleimides.84
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1.2.3.1. 'Thiol-ene’
It is well known that thiol groups can undergo hydrothiolation reactions with unsaturated
bonds (alkenes or alkynes), called ‘thiol-ene’ or ‘thiol-yne’, which can be exploited for
bioconjugation at cysteine residues within peptides or proteins (figure 1.10).86–90 Thiol-ene
reactions are able to proceed via anti-Markovnikov, via light- and/or initiator induced
radical addition, or alternatively by nucleophile or base catalysed Michael addition to
activated alkenes.91,92
In research conducted by Jones et al. the disulfide bond of a peptide could be reduced and
modified in situ through the α,β-unsaturated vinyl group of PEG acrylate, utilising a water-
soluble phosphine for the reduction of the disulfide and subsequent catalyst for thiol-ene
Michael addition.93 This resulted in the PEGylation of both sulfhydryl residues and was
further expanded upon for the synthesis of a peptide macroinitiator for a grafting-from
approach.94 Overall this provides an accessible route to non-bridging thiol reactive
chemistry, with quantitative modifications and short reaction times, alongside aqueous
compatibility and mild reaction conditions.
Figure 1.10. Thioether bond formation using ‘thiol-ene’ chemistry, and double conjugation atreduced disulfide bond.
1.2.3.2. Pyridyl disulfide
An alternative strategy which takes advantage of the synthesis of a disulfide linkage
between the polymer and protein is the use of pyridyl disulfide functional groups, which
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readily undergo disulfide exchange reactions.95 The resulting disulfide bonds are
biochemically labile, thus in-vivo regeneration of active biomolecules is possible using this
methodology, and as such provides a valuable releasable conjugation approach.96–98
1.2.4. Disulfide bridging chemistry
Alongside the addition to cysteines, it may not always be advantageous to reduce the
disulfide bond within proteins or peptides, as this could be vital for maintaining
tertiary/quaternary structure and/or biological activity.99–101 Recently some conjugation
strategies have been reported to circumvent these problems by allowing rebridging of
reduced disulfide bonds with 2 or 3 carbon disulfide bridges, thereby causing less
disruption to the native structure.
1.2.4.1. Dibromo/dithiophenolmaleimide two-carbon
disulfide bridging
Following on from their work on bromomaleimide as a cysteine conjugating reagent, Baker
and Caddick reported that dibromomaleimides could function as potential disulfide
bridging agents, that can insert into a reduced disulfide bond, introducing a two carbon
maleimide linkage.85 The maleimide insertion is still reversible under a high excess of thiol
reagents, and the dibromomaleimide reagent can easily be modified for the addition of
desired functionality to the peptide in a reversible manner.102 Jones et al. reported the use
of PEGylated dibromomaleimide as a convenient (and reversible) reagent for disulfide
bridging PEGylation of peptides.103
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Figure 1.11. Disubstituted maleimides for disulfide bridging of peptides.
Maleimide disulfide bridging chemistry was then expanded upon with the introduction of
dithiomaleimides, which were able to undergo disulfide bridging reactions in a similar
manner to dibromomaleimide (figure 1.11).104,105 In 2013 O’Reilly and coworkers reported
that when disubstituted maleimides are used for peptide conjugations, fluorescence is
induced within the peptide conjugate structure.106 This fluorescence is quenched prior to
conjugation (as in dithiophenolmaleimide), with fluorescence being exhibited on
dithioalkylmaleimides (in the case of peptide conjugation, the peptide acts as a long alkyl
group). This provides a convenient method for confirming peptide conjugation as well as
fluorescently labelling biomolecules of interest.107,108
1.2.4.1. Arsenic compounds for disulfide bridging
A more recent and elegant strategy that has been developed by Wilson and coworkers is
the use of arsenic containing molecules as disulfide bridging agents.109 The reactions
exploit the affinity of the As(III) group for closely spaced chelating thiols (such as those
derived from reduced disulfide bonds). This allows the efficient rebridging of reduced
disulfide bonds to be realised as an alternative to dibromo/dithiophenolmaleimide
bridging. The arsenic conjugates were found to be reversible in the presence of stringer
chelating dithiols, such as reduced lipoic acid, allowing a release mechanism to be realised.
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1.2.4.2. Vinyl sulfone conjugation/bis-sulfone three-carbon
disulfide bridging
Vinyl sulfones are a class of reagents which site-specifically react via sequential Michael-
type addition of sulfhydryl groups at slightly alkaline pHs, to yield stable β-thioether 
linkages.110–112 In 2006 Brocchini et al. suggested a selective method for targeting and
rebridging disulfide bonds, via a three carbon bond linker based on the reactions of thiols
with vinyl sulfone (figure 1.12).113–117
A bis-sulfone reagent was synthesised which can be used for site-specific peptide
modification, and in particular the rebridging of reduced disulfide bonds, in a similar
manner to dibromo/dithiophenolmaleimides. After reduction of the disulfide bond using
standard procedures, an addition elimination of the α,β-unsaturated β’-monosulfone is 
undertaken with the first thiol. This in turn generates a second double bond which can
undergo another addition with the second thiol. The conjugation yields a three-carbon
bridge across the previous position of the disulfide retaining the structure of the peptide,
and potentially preventing a complete loss of activity.113
Figure 1.12. Mechanism of bissulfone three carbon disulfide bridging.
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1.2.5. Other site specific targeting strategies
As well as the conjugation at amino and thiol functionalities on peptides or proteins, which
will be discussed throughout this thesis, other amino acids can be presented as target sites
for selective conjugation. These include specific conjugations at tyrosine, tryptophan and
histidine amongst other natural amino acids.118
Tyrosine is another amino acid that is only moderately represented within peptides, where
modifications have been reported via iodination,119,120 diazonium reagents,121–123 Mannich-
type modifications124,125 and dicarboxylates/dicarboxamides.126,127 Tryptophan residues
have a low natural abundance (~ 1 %) and accessibility of the residues is often limited. As
such, residue specific modifications have been reported for the indole nitrogen of the Trp
side chain by the use of malondialdehydes128 and metallocarbenoids, such as rhodium
carbenoids.129,130 Histidine possesses a pKa in the physiological range, meaning both acid
and basic forms are present at physiological pH and is therefore vital in several enzyme
mechanisms as abstraction or donation of protons can occur. Histidine modifications have
previously been reported including the use of aldehydes131 or epoxides,132,133 although
reactions are not always site-specific, and other amino acid sidechains will often react
preferentially. Histidine modifications are also possible with the use of an engineered
polyhistidine-tag amino acid motif (His-tag) of at least 6 histidine residues which can be
targeted.134,135 Arginine is another amino acid that has previously been targeted, including
with phenylglyoxal analogues,136 geminal diones137 and  α-oxo-aldehydegroups.138 Arginine
conjugation strategies however can be limited by the accessibility of amino acids or
expression on the surface, alongside protonation generally occurring at physiological pHs,
with less reactivity observed than with lysine residues.
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Alongside the targeting of natural amino acids, unnatural amino acids can be introduced
thereby incorporating unique chemistries for a fully site-selective approach and
dramatically expanding the field of potential conjugation reactions.139–141
Overall the most popular method for the targeting of sites on peptides or proteins is
through using amine groups, advantageous due to the high natural abundance on
structures. Virtually all proteins contain easily accessible primary amino groups in their
structures, and the reactions are particularly ideal for the conjugation at multiple sites.
Cysteine modifications are preferential to some other amino acid selective approaches,
due to the convenience of a high reactivity coupled with general rarity. Even in proteins
containing multiple cysteine residues there is usually a small amount of free sulfhydryls
which are accessible on the protein surface, which is ideal if a more site-specific approach
is required than could be delivered with amino targeting.118
1.3. Reversible-Deactivation Radical Polymerisations
techniques (RDRP)
Following the development of ‘living’ anionic polymerisations by Szwarc in 1956142, many
polymerisation techniques have been developed which maintain living characteristics
coupled with robustness of conventional free radical polymerisations. These so called
‘living’ radical or controlled radical polymerisation techniques are often referred to as
reversible-deactivation radical polymerisation (RDRP), and achieve control by establishing
equilibrium between active radical species and dormant chains.
In RDRP techniques it is assumed that radical concentrations remain low, as the dormant
species is favoured which limits termination events and ensures that all polymer chains are
growing at similar rates. The field of polymer chemistry has been revolutionised by the
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precise control over molecular weight, the molecular weight distribution, or dispersity (Ɖ), 
and the high end group fidelities these polymerisation techniques.
1.3.1. Nitroxide mediated polymerisation (NMP)
One of the first examples of RDRP techniques to be explored, nitroxide mediated
polymerisation (NMP), relies on a nitroxide free-radical to establish an equilibrium
between active and dormant species.143,144 The propagating polymer chain is reversibly end
capped by a stable alkoxyamine radical, such as that generated by 2,2,6,6,-
tetramethylpiperidynyl-N-oxy (TEMPO) (figure 1.13). The equilibrium is controlled by the
strong bond formation between the alkyoxyamine radical and the polymeric radical chain
end, stabilising the dormant species resulting in a low concentration of the propagating
radical.
Figure 1.13. NMP polymerisation mechanism.
An advantage of NMP is that it can result in polymers that are not contaminated with
metals halides or sulphur, allowing simple purifications. However, disadvantages include
the high temperatures required to activate the dormant species (120 – 150 °C) and long
reaction times (> 48 hours) required for high yields to be achieved. Since the development
of NMP, the technique has been expanded to different monomers, with access to styrene,
acrylate, methacrylate and acrylamide polymers, alongside the synthesis of copolymers
(block and random), stars and other structures.145
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1.3.2. Reversible addition-fragmentation chain-
transfer polymerisation (RAFT)
A polymerisation technique that has more recently been heavily utilised for the controlled
synthesis of a wide range of polymeric materials for a variety of purposes is reversible
addition-fragmentation chain-transfer polymerisation (RAFT). RAFT was developed in the
1990s by Moad, Rizzardo and Thang, and utilises thiocarbonyl thio species as reversible
chain transfer agents (CTAs) to control the polymerisation.146 A simplified mechanism is
displayed in figure 1.14, where initially radicals are generated, e.g. thermally from azo- or
peroxide compounds, after which these initiate a polymer chain which can add to the CTA.
Fragmentation occurs, releasing a radical which can reinitiate polymerisation. Control is
maintained by having a smaller number of ‘active’ chains, compared to ‘dormant’ CTA end
capped chains.
RAFT is particularly useful for its tolerance to a wide range of functional monomers for
which it has been previously been applied. These include some monomers less susceptible
to polymerisation under other controlled radical polymerisation techniques (for example
less activated monomers like vinyl acetate, and N-vinyl pyrrolidone).147
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Figure 1.14. RAFT polymerisation mechanism.
The polymerisation system can be tuned to better suit specific monomers or reaction
conditions, by careful selection of an appropriate RAFT agent.148,149 The introduction of
redox RAFT, means there is no longer a requirement for high temperatures to decompose
the azo or peroxide initiator, which is useful for a variety of polymers including those
exhibiting LCST (lower critical solution temperature) transitions.150–152
1.3.3. Copper mediated polymerisation techniques
Several different techniques have been exploited which utilise transition metals as tools for
controlling polymerisation. Transition metal mediated living radical polymerisation
(TMMLRP) and atom transfer radical polymerisation (ATRP) were developed by Sawamoto
and Matyjaszewski independently in 1995, using ruthenium and copper halide
complexes.153,154 In the last 20 years the synthesis of polymers utilising various copper salts
has generated a high amount of interest alongside a high level of controversy regarding the
mechanisms of polymerisation.
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1.3.3.1. Atom transfer radical polymerisation (ATRP)
Polymerisations by ATRP generally occur when a copper halide (either Cl or Br) complexed
with a nitrogen based ligand [Cu(I)(L)X] extracts a halogen from an alkyl halide initiator (or
dormant polymer chain) forming the oxidised complex, [Cu(II)(L)X]X and a radical (either on
the initiator or polymer chain) (figure 1.15). The radical formed is able to react with
monomer thereby adding to the propagating chain (in an active state) until the chain is
reversibly deactivated by the re-addition of the halogen (dormant state) from the
[Cu(II)(L)X]X complex formed during activation. The equilibrium is highly in favour of the
dormant chains, therefore allowing radical concentrations to remain low limiting the
amount of termination that is able to occur, resulting in uniform growth of polymer chains.
Figure 1.15. ATRP polymerisation mechanism.
In ATRP, at a given monomer conversion assuming 100 % initiator efficiency, molecular
weight is predetermined by the ratio between monomer and (alkyl halide) initiator which
determines the degree of polymerisation (number of monomer repeat units in the polymer
chain). ATRP has been employed for a wide range of monomers including styrenes,
(meth)acrylates, acrylonitrile and (meth)acrylamides, and in general polymerisation
requires an electron withdrawing group adjacent to the vinyl group. Various polymer
architectures can be prepared including linear, star and comb structures. Facile synthesis
of block copolymers is also possible, owing to the retention of ω-end group fidelity.155
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1.3.3.2. SET-LRP – Cu(0) mediated polymerisation
In 2006 Percec first reported the synthesis of polymers by single electron transfer living
radial polymerisation (SET-LRP) utilising Cu(0) as the active species at 25 °C using nitrogen
based ligands and an alkyl halide initiator in polar solvents.156 Through this work the
‘ultrafast’ polymerisation of ‘ultrahigh’ (Mn >106) molecular weight polymers of acrylates,
methacrylates and vinyl chloride, with exceptional control (Ð = 1.1) was achieved.157
This polymerisation proceeds in a similar mechanism to ATRP with an equilibrium between
an active (propagating polymer chain) and dormant species, however rather than using
[Cu(I)(L)X], Cu(0) is used and referred to as the activating species, with [Cu(II)(L)X]X still
available as the deactivating group (figure 1.16). In this proposed mechanism, the key step
is the disproportionation of the [Cu(I)(L)X] species into Cu(0) and [Cu(II)(L)X]X required for
the polymerisation to occur.
Figure 1.16. SET-LRP mechanism (as proposed by Percec).
Typical ligands used for SET-LRP are nitrogen containing ligands such as Me6TREN, TREN,
PMDETA, and HMTETA, which are able to stabilise CuII in preference to CuI. Initiators and
monomers utilised for SET-LRP are similar to those for ATRP, with alkyl halide initiators
most often being used for the synthesis of poly(meth)acrylates, usually in polar solvents.
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Initiator efficiency is generally very high, with molecular weights predetermined as in ATRP
by adjusting the ratio between monomer and initiator.158
SET-LRP is a very useful tool for the designed synthesis of complex polymers and has been
used in the synthesis of star polymers159,160 and highly sequence controlled multiblock
polymers161,162 (including glycopolymers)163,164 amongst other applications.
1.3.3.3. Aqueous Cu(0) mediated polymerisation
In 2013 members of the Haddleton group reported that efficient polymerisations could be
achieved by exploiting the rapid and quantitative disproportionation of Cu(I)Br(L) (L =
Me6TREN) in aqueous solutions into Cu(0) powder and Cu(II)Br2(L), prior to addition of
monomer and initiator.165 This technique has since been exploited for the controlled
polymerisation of acrylates,166 acrylamides167 and methacrylates168,169 in aqueous,
complex,170 or biologically relevant171 solvent systems.
Polymerisations can achieve high or even quantitative conversions in less than 30 minutes
at (or below) ambient temperatures, with controlled chain lengths and narrow molecular
weight distributions (Ð < 1.1). The resulting polymers exhibit high chain-end fidelity and
this has further been exploited for the synthesis of multiblock copolymers.172
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1.4. Controlled radical polymerisations and conjugation
chemistry
Figure 1.17. Protein polymer conjugation achieved by ‘grafting-to’ or ‘grafting-from’approaches.
With the development of controlled radical polymerisation techniques, the synthesis of
innovative bioconjugates has become highly achievable, with a focus on tailoring design to
introduce specific and desired properties.173,174 There are generally two approaches to
polymer-peptide/protein conjugation (figure 1.17). Firstly the synthesis of polymers and
subsequent attachment onto the biomolecule of interest, so called ‘grafting-to.’
Alternatively, polymerisation can occur directly from the peptide/protein with initiating or
chain transfer species incorporated, known as ‘grafting-from’.
1.4.1. ‘Grafting-to’
The simplest way to facilitate post-polymerisation conjugation is via the incorporation of
functionality on the α- or ω-chain ends of the polymer chain, and then to utilise these for 
site-directed covalent attachment at complementary amino acid residues present in the
target protein/peptide. This is easily incorporated into the ATRP/SET-LRP system by using a
functional initiator, and in RAFT with a functional CTA, which can either directly, or after
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modification, be used for the conjugation. Side chains can be deprotected during
polymerisation, or require post-polymerisation deprotection and work up, if desired
functionalities are not compatible with polymerisation techniques. There are a wide variety
of different polymers reported in the literature that have been synthesised by RDRP
techniques and subsequently attached onto proteins, peptides or other biomolecules.
1.4.1.1. Amino targeting
The incorporation of NHS ester groups into ATRP initiators was used by Lecolley et al. for
the synthesis of poly(poly(ethylene glycol) methyl ether methacrylate) poly(mPEGMA)
using two different N-succinimidyl ester functional alkyl halide initiators.62 These were
subsequently conjugated onto lysozyme with the addition of 6 to 7 polymeric chains. The
same initiators were used by Lutz et al. for the controlled ATRP synthesis of copolymers of
2-(2-methoxyethoxy)ethyl methacrylate (MEO2MA) and poly(ethylene glycol) methyl ether
methacrylate (mPEGMA) and subsequent conjugation onto trypsin.175 More recently a PEG
alternative, poly(carboxybetaine methacrylate) has been synthesised by ATRP and
conjugated onto α-chymotrypsin using the same chemistry.176 Nicolas et al. reported the
synthesis of N-hydroxysuccinimidyl ester containing alkoxyamines for the synthesis of
polyPEGs by NMP and the conjugation onto a model amine, a tripeptide and lysozyme.177
RAFT has also been utilised for the synthesis and post-polymerisation conjugation of NHS
polymers including poly(vinyl pyrrolidone).178
Aldehyde chemistry can also be utilised for grafting-to approaches and a protected
aldehyde ATRP initiator was introduced by Haddleton and co-workers in 2004.179 This
incorporates an acetal protecting group which can easily be removed post-polymerisation
for conjugation onto the amino groups within peptides or proteins. Polymers synthesised
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in this manner have been described for conjugation onto lysozyme,179 salmon
calcitonin65,180and interferon-alpha.181
1.4.1.2. Thiol targeting
Maynard reported in 2004 the incorporation of a pyridyl disulfide RAFT CTA for the post-
polymerisation conjugation of sulfhydryl groups found at cysteine residues.98 The same
group has recently reported the synthesis of trehalose glycopolymers utilising a different
pyridyl disulfide CTA and conjugation to thiolated hen egg white lysozyme as a method for
increasing protein stability to lyophilisation or heating.182 The incorporation of RAFT CTAs
within the polymer result in an easy location for post polymerisation modification, wherein
the dithioester or trithiocarbonate can easily be reduced to a thiol and subsequently
modified such as with divinyl sulfone functionality for post-polymerisation conjugation.111
As an alternative approach, Mantovani et al. reported the preparation of furan protected
maleimide end functional poly(mPEGMA),183 multifunctional triblock copolymers184 and
glycopolymers185 by ATRP, which could be deprotected post polymerisation and
conjugated onto BSA by thiol-maleimide coupling. Stenzel et al. reported the use of a
similar furan protected maleimide CTA for the RAFT synthesis of poly(mPEGMA) and
poly(methyl methacrylate) which, after deprotection via reflux, were conjugated onto the
thiol group of Cys34 on albumin.186–188
Disulfide bridging chemistry has also been exploited using RDRP techniques for the
synthesis of polymers containing end groups capable of rebridging reduced disulfide
bonds. This was used by Jones and co-workers for two carbon disulfide rebridging of
salmon calcitonin using disubstituted maleimide α-end functional polymers synthesised by 
ATRP.103,105 This could be performed by post-polymerisation modification of polymers to
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contain dibromomaleimide end group functionality, or by directly using a dithiophenol
maleimide initiator which, unlike dibromomaleimide, is compatible with the
polymerisation conditions.
Additionally three carbon disulfide bridging has been reported with a bissulfone functional
poly(2-methacryloyloxyethyl phosphorylcholine) synthesised by ATRP.189 Wilson reported
the use of an arsenic functional initiator for SET-LRP and subsequent bridging of disulfide
bonds with a non-carbon arsenic linker.109
1.4.2. ‘Grafting-from’
As well as employing polymers synthesised in a traditional manner by copper mediated
polymerisation or RAFT polymerisation that involve the post-polymerisation conjugation,
strategies are available that utilise a peptide macroinitiator (or a macro CTA) in a ‘grafting-
from’ technique. This method of protein/peptide modification can prove highly useful as
purification of polymers prior to addition is not required, and the characterisation of the
macroinitiator/macro CTA is often simpler than a polymer-conjugate in terms of
identification of the specific site of conjugation. Additionally there is no longer any excess
polymer present as an impurity within the conjugate solutions, which would generally lead
to difficult purification procedures.
This was first reported by Bontempo and Maynard in 2005 where an ATRP initiator
incorporating biotin was conjugated onto streptavidin,190 followed by BSA191 and
lysozyme191 using pyridyl disulfide thiol coupling, from which N-isopropylacrylamide was
polymerised.
Jones reported the utilisation of thiol-ene chemistry for the synthesis of a protein
macroinitiator and used this to polymerise ethylene glycol containing monomers using SET-
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LRP. The peptide modification for incorporation of RAFT macro CTAs and alternative halide
initiators has also been achieved utilising different conjugation chemistries.192–194
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Chapter 2
2. Amine targeted PEGylation of oxytocin
A common method for the conjugation of polymers onto peptides or proteins is via the
reactive amine groups found either on lysine residues or at the N-terminus in an acylation
or alkylation reaction. Within the structure of native oxytocin there is only one amine group
present at the N-terminus, allowing for site specific amine targeting chemistries. Different
conjugation chemistries arising from the use of NHS-ester and aldehyde end functional
polymers were used to attach different architectures of PEG onto oxytocin.
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2.1. Introduction
Of the large library of potential conjugation routes available for the modification of
proteins and peptides, by far the most commonly exploited are those involving conjugation
onto amino groups. A large range of different functional groups are available for targeting
of lysine or terminal amino groups available on almost all protein or peptide biomolecules.
Primarily, these coupling reactions are available via acylation or alkylation, with reactions
usually occurring efficiently and in high yields to give stable conjugates.1
The PEGylation of proteins or peptides in this manner is a research area that is constantly
expanding, with many PEGylated products undergoing preclinical trials, or going as far as to
achieving FDA approval.2 This field has also been making progress in the incorporation of
different polymer architectures such as branched ‘comb’ PEGs. The development of living
radical polymerisation techniques allows for simple and controlled synthesis by
implementing (meth)acrylate PEG monomers to generate tailor-made polymers bearing
low molar mass PEG side chain ‘teeth’. Comb polymers can provide potential advantages
over linear equivalents due to viscosity changes resulting from a change in structure of the
polymers in solution with linear PEGs behaving like random coils, and polyPEGs being rigid
rods leading to changes in the hydrodynamic volume of polymers.3,4 This can lead to
reduced polymer crystallisation and subsequent organ vacuolisation.5
Modification of the Cys1 amino terminus of oxytocin could provide a route to the synthesis
of PEGylated oxytocin analogues which, due to an absence of any lysine groups or
additional amines in the structure of the peptide, would allow site-selective conjugation
when selecting appropriate conjugation techniques. Previous amino modifications to
oxytocin have had varying levels of success with regard to retained activity or
improvements in stability. The amino group has been discovered to not be vital for
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oxytocin activity, as its removal (i.e. desamino-oxytocin) has still led to high levels of
uterine contractility, potentially proving more potent than the native peptide itself.6–8
One of the main degradation sites of oxytocin is focused around the Cys1-Cys6 disulfide
bond, where degradation products can include the formation of oxytocin trisulfide or
tetrasulfide, as well as leading to dimerisation and the formation of larger aggregates.9,10
The amino terminus is sterically close to this disulfide bond, and it was speculated that the
addition of polymers at this position could provide some stabilisation or protection to the
peptide structure.
In this chapter the use of two different polymer end group functionalities are discussed for
potential conjugation onto the small peptide therapeutic oxytocin. Commercial linear
monomethoxy PEG (mPEG) polymers are available with a variety of different reactive end
groups, including NHS ester and aldehyde functionality for PEGylation at amino groups on
peptides and proteins. These polymers, alongside synthetic engineered ‘comb’ polymer
equivalents, will be investigated for the conjugation of different architectures of PEGs onto
oxytocin, as well as comparing the different conjugation chemistries employed. For the
controlled synthesis of these polymers, copper mediated chemistry provides an ideal route
to α-end functional polymers which can undergo post-polymerisation conjugation. The 
utilisation of aldehyde functional polymers for conjugation is of particular interest as the
conjugation reaction can occur reversibly (with the formation of a Schiff base) or
irreversibly (by reductive amination). The potential exploitation of the reversible nature of
this bond with two different peptide-polymer architectures, alongside a non-polymer
conjugated oxytocin analogue, will be explored.
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2.2. Results & Discussion
2.2.1. Activated ester linear PEGylation
The use of activated esters, such as N-hydroxysuccinimidyl (NHS) esters, for the site
selective targeting of peptides or proteins is one of the most commonly used methods for
conjugation of polymers to both lysine and terminal amino groups.11,12 A large variety of
different commercial NHS ester PEGs are available for using in this manner, which react
with nucleophilic amines resulting in stable amide linkages.
A large problem associated with using NHS ester functionalised reagents (such as NHS PEG)
is that the NHS ester is highly liable to rapid hydrolysis under storage conditions, which
leads to a loss of the NHS functionality.13 The pH is also found to have a strong impact on
the stability and half-life of reagents, with hydrolysis occurring more rapidly on increasing
pH causing problems in coupling reactions, with regards to side products, and excess of
polymer required.14,15 Nevertheless, NHS ester PEG reagents are commonly used for
routine PEGylation of peptides and proteins and the majority of FDA approved protein-PEG
conjugate drugs are from the use of this type of conjugation chemistry.2 Due to the issues
resulting from the hydrolysis associated with NHS ester reagents, commercially a large
excess of polymer is generally used for conjugations.
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2.2.1.1. Oxytocin conjugation using succinimidyl ester PEG
Scheme 2.1. Conjugation of NHS ester functional linear PEG onto oxytocin site specifically at N-terminalamine in DMF (containing 1% TEA) at 10 °C.
Two different molecular weights (Mw= 2 kDa & Mw= 5 kDa) of linear α-methoxy-ω-
succinimidyl ester poly(ethylene glycol) (NHS ester PEG) were used for site selective
conjugation to oxytocin (scheme 2.1). The reaction was performed in anhydrous DMF
(containing 1 % TEA) to prevent hydrolysis of the polymers during the conjugation reaction.
A slight excess of polymer (1.5 equivalents) was added to oxytocin and an overnight
reaction performed at 10 °C.
After 18 hours an aliquot (equivalent to 0.2 mmol of the peptide) was removed and
dissolved in water for analysis by RP-HPLC (λ = 280 nm). In the chromatogram from the UV 
detector of the HPLC it was observed that there was a decrease in the peak area of the
peak corresponding to oxytocin (retention time t = 7.8 minutes), and the appearance of a
broad peak at a longer retention time (t = 14.7 minutes). The polymer does not exhibit any
peaks with high absorptions under the conditions used for RP-HPLC analysis (UV, λ= 280 
nm), suggesting that the new peak observed has arisen from a reaction with the peptide.
For the conjugations of both Mw of polymer there was still the presence of some remaining
oxytocin observed in the solution after conjugation (figure 2.1). The % yield of the reaction
can be calculated by monitoring the disappearance of the native peptide, and after 24
hours this was found to be 70 %.
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Figure 2.1. RP-HPLC of conjugation of succinimidyl functional linear PEG onto oxytocin.
In order to further confirm the conjugation product, a portion of the 2kDa oxytocin-
polymer conjugate was purified by semi preparative RP-HPLC (λ = 280 nm) to remove any 
remaining oxytocin as well as excess, or potentially hydrolysed, polymer. In changing to
semi preparative RP-HPLC the conditions first had to be optimised for efficient separation
to be achieved whilst using the preparative column. The conditions adopted provided
good peak separation, and the pure conjugate product was collected. After lyophilisation
RP-HPLC analysis of the separated product revealed the appearance of a singular broad
peak free of impurities at a retention time of t = 14.7 minutes (figure 2.2).
Figure 2.2. RP-HPLC analysis of purified oxytocin-polymer (NHS) conjugate (2 kDa).
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The purified 2 kDa oxytocin-polymer sample and the unconjugated polymer were analysed
by matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) using
2,5-dihydroxybenzoic acid (DHB) as the MALDI matrix. MALDI-TOF MS of the commercial
polymer contains two major distributions, which are attributable to that of the NHS ester
functional polymer and the polymer without the succinimidyl functionality, after
hydrolysis. After conjugation only one major distribution remained, with a clear shift in
molecular weight of approximately 1 kDa (molar mass of oxytocin is 1007 Da) between the
NHS ester polymer and the oxytocin conjugate. A closer inspection of the MALDI-TOF MS
spectrum of the oxytocin-polymer conjugate shows good agreement between the
theoretical (calculated) values and the experimental values (figure 2.3 for polymer repeat
units of n = 37 & n = 38) and the differences between the peaks correlating to the ethylene
glycol repeat unit (44.03 Da).
Figure 2.3. MALDI-TOF MS analysis of oxytocin-polymer (NHS) 2 kDa conjugate.
These results indicate that the conjugation of the NHS ester PEG has occurred in the
expected singular site specific manner onto oxytocin, resulting in the N-terminal amino
PEGylated oxytocin conjugate product. This MALDI-TOF MS data provides promising
confirmation of the observed conjugate structure, which will be useful for the conjugation
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of the ‘comb’ type polymers, where exact structural characterisation is more difficult due
to the repeat unit itself being a macromonomer.
2.2.2. Aldehyde functional linear PEG conjugation
It is reported that amine groups, such as those occurring on lysine residues or at the N-
terminal amine within a peptide, will react with carbonyl groups such as aldehydes in the
presence of suitable reducing agents in a two-step reductive amination process to form
stable secondary amines (scheme 2.2). The first step is via the formation of a Schiff base /
imine linked intermediate which is in equilibrium with the aldehyde and amine. Commonly
the intermediate is then reduced by the addition of a reducing agent, which forms a stable
secondary amine linkage. Sodium cyanoborohydride is a common reducing agent used in
this manner and is preferable to sodium borohydride as the reducing agent.16,17 Due to
milder reductions being performed, the Schiff base reductions occur efficiently but there is
no reduction of any remaining aldehyde, which would potentially prevent higher yields in
the reaction. Aldehyde modification of peptide or protein amino groups may also be
preferable to NHS reactions, as potential charges can be maintained on the secondary
amine product, which are not the case for the amide linkages associated with NHS
conjugates.
Scheme 2.2. Schiff base formation of reaction between aldehyde and amine followed by reduction byNaCNBH3 forming stable secondary amine linkage.
Multiple different chain length spacers between the aldehyde functionality and polymer
chain have been used for the reductive amination of biomolecules by aldehyde
conjugation, with varying levels of success (figure 2.4). The use of acetaldehyde reagents
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have previously been used to couple to peptides, although these can be ineffective due to
a limited stability, particularly under basic conditions, and a susceptibility to form
undesirable by-products. Functional mPEG-propionaldehyde and mPEG-butyraldehyde
contain longer linker chains between the aldehyde functionality and the PEG chain and
have proven to have higher stabilities proving more useful under a variety of conditions for
reductive amination.18–20
Figure 2.4. Commercially available aldehyde functional PEG reagents.
A further property that is often utilised within these reductive amination conjugation
reactions is the tuning of pH for more selective targeting of amine groups on proteins or
peptides. As there are two different commonly occurring types of amines that can be
presented within peptides and proteins, those found on lysine residues throughout the
structure or the singular amine located at the N-terminus, it can be beneficial to selectively
target the N-terminus for a singular attachment.1,13,21 The pKa values for the lysine amines
(10 - 10.2) are much higher than for the N-Terminus (pKa ≈ 7) and under acidic or neutral 
conditions, the terminal amine can usually be selectively modified.
For the discussion of the conjugation of these polymers onto oxytocin pH controls are not
required as there are no lysine groups within the structure, which have associated
problems with regards to multiple sites of attachment. In the case of the oxytocin, the
singular available amine within the peptide that could potentially react in this manner is
that located at the N-Terminus and will lead to a site specific attachment.
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2.2.2.1. Oxytocin conjugation using aldehyde functional PEG
Scheme 2.3. Formation of stable linear PEGylated oxytocin following reaction with aldehyde PEG andsubsequent reduction by NaCNBH3.
Two different molecular weights (Mw= 2 kDa & Mw= 5 kDa) of α-methoxy-ω-formyl 
poly(ethylene glycol) (aldehyde PEG) were conjugated onto oxytocin with reduction by
NaCNBH3 (scheme 2.3). Oxytocin was dissolved in sodium phosphate buffer (pH 7.5, 100
mM) and reacted with 1 equivalent of the PEG reagent and a freshly prepared 25 mM
solution of NaCNBH3 (2.5 eq.) added before the reaction proceeded at 10 °C overnight.
After the conjugation an aliquot of the solution (equivalent to 0.2 mM oxytocin) was
removed and diluted in water for RP-HPLC monitoring of the reaction. The HPLC UV
coupled (λ = 280 nm) chromatogram revealed the appearance of a newly formed broad 
peak at a longer retention time (t = 14.0 minutes) to oxytocin (t = 7.4 minutes) alongside
and approximate 60 % decrease in the native peptide remaining in the solution. RP-HPLC
analysis of the unconjugated (aldehyde functional) polymer showed the appearance of one
narrow peak at a retention time of t = 5.2 minutes. Post conjugation analysis of the
reaction solution revealed that the presence of this peak is still observed alongside
evidence of unreacted peptide for both Mw of PEGs conjugated (figure 2.5).
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Figure 2.5. RP-HPLC monitoring of conjugation reaction of aldehyde PEG (2 kDa) onto oxytocin, afterstirring for 24 hours at T = 10 °C.
In the same method as the succinimydyl conjugated oxytocin, a portion of this newly
formed aldehyde conjugated oxytocin was removed and purified by semi-preparative RP-
HPLC. The gradient of the semi-preparative system was optimised for efficient peak
separation allowing efficient purification of the product. After lyophilisation, analysis of the
purified polymer conjugate by analytical RP-HPLC revealed the appearance of a single
broad peak (figure 2.6). There is some peak tailing leading to a shoulder appearing on the
RP-HPLC chromatogram for the purified conjugate, potentially due to side reactions
occuring, leading to the formation of additional products, which will be discussed later in
this chapter.
Figure 2.6. RP-HPLC analysis of purified oxytocin-polymer (aldehyde) 2 kDa conjugate.
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MALDI-TOF MS analysis was performed on this oxytocin-polymer conjugate using DHB as
the MALDI matrix and compared to the native aldehyde functional polymer. Similarly to
the other linear (succinimidyl ester) conjugate, the peaks observed by MALDI-TOF MS were
in good agreement with those expected for the stable (reduced with NaCNBH3) aldehyde
PEG – oxytocin conjugate. The peaks in the MALDI-TOF MS show very similar calculated
(theoretical) and observed (experimental) values (figure 2.7 for n = 43 and n = 44 for the
PEGn chain) and the ethylene glycol difference between the peaks is maintained (44.03 Da).
There is a clear shift in molecular weight from the unconjugated aldehyde polymer to the
peptide-polymer conjugate corresponding to the molecular weight of the peptide (1007
Da).
Figure 2.7. MALDI-TOF MS analysis of oxytocin-polymer (aldehyde) 2 kDa conjugate.
These results assist in confirmation of the conjugate structure, ensuring that covalent
attachment of the polymer onto oxytocin was in a site-specific manner with only one unit
of polymer per peptide (mono-addition).
2.2.3. PolyPEGylation strategies
Along with the more commonly commercially utilised linear PEGylation strategies, various
methods are being established for the synthesis of branched (comb) PEG and conjugation
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to peptides and proteins resulting in a higher PEG density in the conjugates. The arrival of
controlled radical polymerisations has rendered the synthesis of polymers with PEG side
chains highly accessible.22,23 Functional initiators that contain conjugatable groups can be
utilised for the synthesis of α end functional polymers containing short PEG side chains, 
which can post-polymerisation be grafted onto the desired peptide or protein.24,25 The use
of polyPEGs compared to linear equivalents presents a few advantages, which include a
decreased viscosity compared to linear equivalents, due to acting as rigid rods within
solution as opposed to random coils.3 Other advantages include longer circulation
times,26,27 and reduced polymer crystallisation and subsequent organ vacuolisation,5,28 as
well as the opportunity to tailor polymers as desired for specific applications.
Conjugations were performed onto oxytocin in a similar method to the linear equivalents
by using ‘grafting–to’ chemistry, where the polymer is first synthesised with α end group 
conjugating functionality followed by conjugation yielding the poly(mPEGA) – peptide
conjugate.
2.2.3.1. Activated ester polymer synthesis
Previously Haddleton et al. has successfully employed activated ester (NHS ester) based
initiators for the synthesis of polyPEG polymers and subsequently conjugated these onto
lysozyme.24 The polymers were synthesised in a controlled manner and after conjugation
the multisite attachment of 6-7 polymeric chains per protein was confirmed. Within the
literature the same initiator has been successful in the synthesis of a variety of polymers
and the attachment of these to proteins.29,30 This NHS ester initiator has also previously
been utilised in the synthesis of lysozyme protein macroinitiator, from which polymers can
be grown in a ‘grafting-from’ type manner.31
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The NHS ester functional initiator N-succinimidyl 2-bromo-2-methylpropionate was
synthesised in a high yielding, one-step reaction as previously described in the literature
(scheme 2.4).24 N-Hydroxysuccinimide was reacted with 2-bromoisobutyryl bromide in
anhydrous DCM with triethylamine at 0 °C for 4 hours. The white crystals were purified by
recrystallisation in diethyl ether resulting in an overall yield of 83 %.
Scheme 2.4. Synthesis reaction for NHS ester functional initiator.
The activated ester group, as described earlier in this chapter with reference to the linear
succinimidyl ester PEGs is still very prone to hydrolysis.13 Consequently care must be taken
to minimise water content within storage and particularly storage time, where long storage
times prior to use are not ideal. Figure 2.8 shows the 1H NMR spectra of the NHS ester
initiator after fresh preparation and subsequent storage for 12 months in a closed
container. The hydrolysis of the NHS functionality can clearly be recognised leading to the
loss of 75 % of NHS ester functionality. The products released as a result of hydrolysis,
bromoisobutyryl acid and N-hydroxysuccinimide can clearly be identified highlighting the
need to ensure storage times are kept to a minimal level.
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Figure 2.8. 1H NMR (CDCl3, 400.05 MHz) of freshly prepared succinimide initiator and 75 % hydrolysedsuccinimide initiator with a loss of NHS ester functionality.
Using this NHS ester functional initiator, controlled living radical polymerisation of
poly(ethylene glycol) methyl ether acrylate (av. Mn = 480 g mol-1, mPEGA480) was carried
out in anhydrous DMSO using Cu(II)Br2, Cu(0) wire and tris[2-(dimethylamino)ethyl]amine
(Me6TREN) as a ligand ([I]:[M]:[Me6TREN]:[CuBr2] = 1:20:0.18:0.05 and 5 cm Cu(0) wire)
(scheme 2.5).
Scheme 2.5. Cu(0) mediated living radical polymerisation of mPEGA480 using NHS initiator resulting in α-succinimidyl ester functionality poly(mPEGA480).
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In order to follow the kinetics of the reaction samples were periodically removed and
diluted in DMF for SEC molecular weight data and δ6-DMSO for 1H NMR conversion analysis
(figure 2.9). Conversions were measured by comparing the three vinyl protons of the
monomer (δ = 5.8 - 6.4 ppm) with the first CH2 group in the PEG monomer repeat unit
within the polymer (δ = 4.1 ppm). After 60 minutes no polymer could be observed by
either 1H NMR or SEC highlighting that there was a potential initial inhibition time to the
polymerisation. After 2 hours however, the conversion had risen to 23 %, with an almost
quantitative conversion (98 %) attained after 24 hours. Analysis by SEC showed that only
mono-modal peaks were obtained with molecular weights increasing throughout the
polymerisation as well as low dispersities being maintained (Ð < 1.15).
Figure 2.9. 1H NMR (δ6-DMSO) and SEC (DMF) analysis monitoring the polymerisation of NHS-poly(mPEGA480)20.
The kinetic experiments revealed a linear increase of ln([M]0/[M]) with time during the
polymerisation (excluding the initial inhibition time) which yields information about the
apparent rate for the polymerisation (kp) (kpapp = 4.24 x 10-3 min-1) (figure 2.10). A linear
conversion of number average molecular weight (Mn) with conversion (which also
correlated well with theoretical molecular weights) gives evidence of the “living” nature of
this polymerisation.
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Figure 2.10. Kinetic plots for the polymerisation of NHS-poly(mPEG480)20.
2.2.3.2. Activated ester functional polymer conjugation
The conjugation of these synthesised polyPEG ‘comb’ α-succinimide functional polymers 
could be carried out in a site-specific manner similar to the conjugation carried out for the
linear polymers (scheme 2.6). This would again lead to an amide linked oxytocin conjugate,
except that with polyPEGylation the PEG density (and ultimately the peptide-polymer
architecture) is different to that of the linear example. This difference in structure would
likely lead to different properties being observed such as in the potential stability of the
peptide, and pharmacokinetic properties or retained biological activity.3,32
Scheme 2.6. Conjugation of α-succinimide functional poly(mPEGA480) polymer onto oxytocin.
To prevent the previously observed readily occurring hydrolysis of the polymer end group
from occurring before conjugation onto the peptide, an ‘in-situ’ method was initially
developed to minimise water interaction. An aliquot of the polymerisation solution (with
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no purification of the polymer) was added to the peptide in anhydrous solvents, thereby
not exposing the conjugatable polymer to an aqueous environment. A colour change was
observed during the reaction as the solution changed from a faint green (as within the
polymerisation solution) to a brown colour. Monitoring of the conjugation by RP-HPLC
analysis (λ = 280 nm) showed the formation of a number of side products, with minimal 
concentration changes of the peak on the RP-HPLC chromatogram representing the native
peptide (figure 2.11). There is the presence of some potential peptide-polymer conjugate
(a broad peak at retention time t = 26.6 minutes), however, the number of impurities in
the solution mean that purification and further conjugate confirmation would be difficult.
Figure 2.11. RP-HPLC trace of conjugation of NHS-poly(mPEGA)20 from ‘in-situ’ conjugation of aliquot ofpolymerisation solution.
An alternative method was established for conducting this conjugation, which involved
prior purification of a second batch of succinimide polymer synthesised targeting a
molecular weight of 6.5 kDa. This succinimide functional polymer was synthesised using
the same conditions for the polymerisation as for the kinetic experiment but with [M]:[I]
ratio = 13:1. After polymerisation the removal of residual monomers and purification of
the polymer was carried out by repeated precipitation into Et2O: hexane (1: 1) whilst
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carefully minimising the chance of hydrolysis of the succinimide ester end group. The
retention of the α-end group succinimide ester functionality was confirmed by 1H NMR of
the purified polymer, where the peak at δ= 2.81 ppm represents the 4 protons in the 
succinimide ring (figure 2.12). The experimental molecular weight could be calculated by
1H NMR (CDCl3) by a comparison between these protons and the protons from the first CH2
of the PEG repeat unit (δ = 4.1 ppm) yielding an average DPn of 13 (a molecular weight of
6500 g mol-1). Analysis of the purified polymer by SEC confirmed that the polymer
molecular weight distribution remained narrow and mono-modal with final Mn of 6400 g
mol-1 and dispersity = 1.08.
Figure 2.12. 1H NMR (CDCl3, 300.13 MHz) of succinimidyl ester functional poly(mPEGA480)13.
Conjugation of purified succinimide – poly(mPEGA)
After confirmation that the α-end group functionality was retained the polymer was 
subsequently conjugated onto oxytocin using the same conditions as for the linear
succinimide ester conjugation (1.5 equivalents of polymer in anhydrous DMF containing 1
% TEA). However, when the reaction was sampled at t = 24 hours, or at longer reaction
times (t = 4 days; t = 10 days), analysis by RP-HPLC (UV, λ = 280 nm) did not show the 
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formation of any desired conjugate product (figure 2.13). It was again believed that this
was potentially due to hydrolysis of the succinimide ester end group meaning the
functionality required for an efficient conjugation was no longer present.
As the conjugation can only occur at one position on the peptide structure, the addition of
a large amount of polymer should have no adverse effect on the conjugation reaction,24
although would lead to a higher amount of the polymer as an impurity in the final product.
Therefore, in an alternative procedure, a large excess of the succinimide functional
polymer (10 equivalents) was added to oxytocin; it is noted that this is similar to industry
used reaction conditions. The high amounts of equivalents were used in order to maintain
some level of polymer end functionality and therefore allow conjugation to occur in the
expected manner. Although, there is a large excess of polymer, some amount of this is not
expected to be reactive with NHS end functionalisation due to hydrolysis.
Figure 2.13. RP-HPLC trace monitoring conjugation of NHS-poly(mPEGA)13 with 1 or 10 equivalences.
Analysis of the reaction by RP-HPLC (UV λ= 280 nm) revealed the appearance of a 
characteristic broad conjugate peak at a longer retention time (t = 23.8 minutes) than the
native peptide (t = 12.2 minutes), attributed to the poly(mPEGA)-oxytocin conjugate (figure
2.13). RP-HPLC analysis of the unconjugated polymer did not reveal any peaks with high
absorptions, therefore the appearance of a new broad conjugate peak can be attributed to
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the desired conjugation occurring. The resulting conjugate was purified by dialysis against
water (1 kDa MWCO, 3 days) to remove unreacted peptide and N-hydroxysuccinimide
released during conjugation, after which RP-HPLC analysis revealed one single broad
product (figure 2.14). It must be noted however, that there would still be a significant
amount of the polyPEG reagent remaining in the purified conjugate.
Figure 2.14. RP-HPLC of oxytocin-poly(mPEGA) conjugate after purification.
It should be noted that in the original work regarding the synthesis and conjugation of NHS
functional poly(mPEGMA) by Haddleton and co-workers, similar issues were raised with
the conjugation of polymers wherein no conjugation was observed after 24 hours.24
However, on changing the initiator functionality from that of a methyl propionate group to
a propionate, the reactivity was enhanced and the coupling could take place more
efficiently.
2.2.3.3. Protected aldehyde polymer synthesis
Previously reported by Haddleton et al. has been the use of an acetal-protected aldehyde
initiator to synthesise poly(mPEG)methacrylates using copper (I) mediated living radical
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polymerisation.25 The deprotected ‘comb’ poly(mPEG)methacrylates were then
successfully conjugated onto lysozyme as a model peptide, resulting in multisite
attachments as well as site specifically onto the N-terminus of salmon calcitonin.21,32 The
same polymers have also been used in the preparation of PEGylated interferon and
showed a lower increase in viscosity, and longer half-life post conjugation compared to
conventional linear reagents.3
The use of a protected aldehyde initiator is particularly beneficial as it ensures that the
aldehyde functionality will not undergo undesirable side reactions during polymerisation,
but it does involve a post-polymerisation step for the removal of the acetal group. After
deprotection the α-aldehyde end functional polymers can undergo identical reactions to 
that of the linear PEGs with amines either on lysine residues or at the N-terminal amine.
Scheme 2.7. Two step synthesis rout for protected aldehyde initiator.
The acetal protected initiator was synthesised in a two-step procedure (scheme 2.7). The
first step was carried out by reacting ethylene glycol with chloroacetaldehyde dimethyl
acetal in the presence of potassium hydroxide at 115 °C and stirring for 72 hours. This
yielded the protected alcohol 2-(2,2-dimethoxy-ethoxy)-ethanol as a yellow oil which was
used without purification. To a solution of this alcohol, in the presence of triethylamine, 2-
bromo-3-methylpropionyl bromide was added dropwise at 0 °C and left to stir overnight.
Purification was carried out by silica column chromatography, yielding the desired acetal
functional initiator as a colourless oil (figure 2.15).
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Figure 2.15. 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of acetal protected aldehydeinitiator.
Using the same conditions as for the succinimide initiator and targeting a molar mass of 10
kDa, the Cu(0)-mediated polymerisation of poly(ethylene glycol) methyl ether acrylate (av.
Mn = 480 g mol-1, mPEGA480) was carried out ([I]:[M]:[Me6TREN]:[CuBr2] = 1:20:0.18:0.05
and 5 cm Cu(0) wire) (scheme 2.8).
Scheme 2.8. Cu(0) mediated polymerisation of mPEGA480 with protected aldehyde initiator.
In order to follow the kinetics of the reaction samples were removed periodically and
diluted with δ6-DMSO for 1H NMR conversion data and DMF for SEC molecular weight
analysis (figure 2.16). Conversions were measured by a comparison of the three vinyl
protons of the monomer (δ = 5.8 - 6.4 ppm) to the first CH2 group of the PEG monomer
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repeat unit on the polymer (δ = 4.1 ppm). This polymerisation using the acetal functional 
initiator proceeded at a faster rate (kp) to that observed with the succinimide initiator and
the induction period previously observed was also absent. Analysis by 1H NMR revealed 33
% conversion after 1 hour, rising to 66 % at t = 2 hours and complete conversion being
achieved after 24 hours. Molecular weight distributions remained mono-modal and
increased throughout the polymerisation whilst dispersities remained low (Ð < 1.12), with
good correlation achieved between experimental and theoretical molecular weights
throughout.
Figure 2.16. 1H NMR (δ6-DMSO) and SEC (DMF) analysis of polymerisation of acetal-poly(mPEGA480)20.
The kinetics of the reaction again revealed good ‘living’ characteristics with a linear
increase in the evolution of molecular weight (Mn) vs. conversion (figure 2.17). A linear
evolution of ln([M]0/[M]) with time was also observed, which highlights a constant radical
concentration. This also showed that the rate of polymerisation for the protected aldehyde
initiator (kpapp = 8.64 x 10-3 min-1) is approximately double that of the succinimide
polymerisation (kpapp = 4.24 x 10-3 min-1). There is high molecular weight tailing observed
on the SEC chromatogram, although this is regularly observed for the polymerisation of
mPEGA, previously assigned to the possible presence of diacrylate impurities in the
monomer reagent.33,34
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Figure 2.17. Kinetic plots for the polymerisation of acetal-poly(mPEGA480)20.
The previously reported polymerisation with this initiator was conducted by ATRP using
copper chloride and N-(ethyl)-2-pyridylmethanimine ligand in toluene at 80 °C ([I]:[CuCl]:[L]
= 1:1:2).25 Although molecular weight dispersities remained low the initiator efficiency was
reported as being only 50-60 % which meant molecular weights differed significantly from
those anticipated. By performing the polymerisation under SET-LRP conditions, which have
previously been reported as having a high initiator efficiency,35 desirably a lower
temperature (20 °C), and less equivalences of copper (0.05 Eq.) can be used maintaining
controlled polymerisations and more accurate targeted molecular weights.
After well-controlled polymerisations were achieved, two further polymers were
synthesised in the same manner to be used for future post-polymerisation conjugation
onto oxytocin. Molecular weights were targeted at 10 kDa and 25 kDa (equivalent to
[M]:[I] of 20 and 50) with [I]:[Me6TREN]:[CuBr2] = 1:0.18:0.05 and 5 cm Cu(0) wire. These
polymerisations were performed for 24 hours under a nitrogen atmosphere after which
samples were removed for NMR (δ6-DMSO), which confirmed that quantitative, or near
quantitative, conversions had been reached. SEC analysis (DMF) showed that narrow
molecular weight distributions were maintained, with final dispersity values of Ð = 1.12
and 1.16.
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After the polymerisation the polymers were purified by dialysis against water (1 kDa
MWCO, 3 days) and after lyophilisation analysed by 1H NMR for retained α end 
functionality (figure 2.18). This revealed the presence of the acetal protecting groups at δ= 
4.4 ppm (singular proton of CH(OCH3)2) and δ= 3.3 ppm (6 x methyl groups of CH(OCH3)2).
The experimental molecular weight could also be calculated by a comparison between the
6 protons of the isobutyryl group in the α-end group of the polymer (δ = 1.07 ppm) and the 
first CH2 group of the PEG repeat unit (δ= 4.1 ppm) giving final DPns of 21 and 53,
representing molecular weights of 10 kDa and 26 kDa.
Figure 2.18. 1H NMR (δ6-DMSO, 300.13 MHz) of poly(mPEGA480)21 with acetal protected aldehyde endgroup functionality.
The polymers were then deprotected by addition of aqueous solutions of trifluoroacetic
acid (50% v/v), resulting in removal of the acetal protecting group, yielding α-aldehyde
functionality on the polymer chains (scheme 2.9).25
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Scheme 2.9. Deprotection of acetal protecting group yielding aldehyde functional poly(mPEGA480).
The aldehyde functional polymers were purified by dialysis against water (1 kDa MWCO, 3
days) and lyophilised, after which α-end group functionality was confirmed by 1H NMR (δ6-
DMSO) (figure 2.19). This was shown by the appearance of a characteristic aldehyde peak
at 9.5 ppm and the disappearance of the acetal peaks at 4.4 ppm and 3.3 ppm. After
deprotection of the acetal group the polymers were resubmitted for SEC analysis (DMF)
which revealed that the molecular weight distributions remained narrow (Ð = 1.15 / 1.18)
and mono-modal, with no cleavage of the PEG chain from the polymer confirmed by only a
very small decrease in average molecular weight being observed.
Figure 2.19. NMR and SEC analysis of DPn 20 & DPn 50 polymers before and after deprotection.
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Figure 2.20. 1H NMR (δ6-DMSO, 300.13 MHz) of poly(mPEGA480)21 after deprotection resulting in α aldehyde end group functionality.
Table 2.1. Comparison of molecular weights and dispersities of acetal protected and aldehyde(deprotected) DPn 20 & DPn 50 polymers.
PolyPEG Conversion
(NMR)
Mn (Da)
(SEC)
Ð
(SEC)
Mn (Da)
(Deprotected)
(SEC)
Ð
(Deprotected)
(SEC)10 kDa - Acetal 100 % 11000 1.12 10500 1.15
25 kDa - Acetal 99 % 21300 1.16 20500 1.18
2.2.3.4. Aldehyde functional polymer conjugation
The resulting aldehyde functional polymers could then be conjugated onto oxytocin in a
similar manner to the linear PEG to result in a secondary amine linked ‘comb’ oxytocin-
polymer conjugate (scheme 2.10). 1.5 equivalents of the aldehyde functional polymer were
added to oxytocin in phosphate buffer (pH 6.2, 0.1 M) with the addition of a freshly
prepared solution of NaCNBH3 (25 mM).
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Scheme 2.10. Conjugation reaction of poly(mPEGA480) to oxytocin with reduction by NaCNBH3.
RP-HPLC analysis of the reaction after 72 hours revealed the appearance of a previously
unobserved broad peak at a longer retention time (t = 20.6 minutes) compared to the
native peptide (t = 7.1 minutes), signifying the incorporation of the ‘comb’ polymer onto
the peptide (figure 2.21). Detailed inspection of the RP-HPLC chromatogram revealed a
variety of smaller baseline peaks were observed, but these were also present when the
purified polymer was analysed by RP-HPLC on its own, suggesting minor impurities in the
polymer solution.
Figure 2.21. RP-HPLC trace of aldehyde poly(mPEGA480)20 polymer conjugation.
As with the conjugations of the linear polymers, both molecular weights of aldehyde
poly(mPEGA) for conjugation onto oxytocin did not reach completion, resulting in
remaining oxytocin in the reaction solution. Recently Maynard et al. have reported the
importance on the polymer linker length for conjugation yields, which may impact reaction
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efficiency.36 However, for this conjugation reaction any residual peptide is removed by
dialysis (1 MWCO, 3 days) resulting in a purified sample of oxytocin-polymer conjugate,
with a different architecture to that of the linear equivalent.
2.2.4. Potential reversible Schiff base conjugation of oxytocin
The reaction utilised for the conjugation of aldehyde functional polymers onto oxytocin is
accessed via a two-step reaction including a Schiff base intermediate. The generation of
this Schiff base is via a reversible equilibrium reaction between the initial aldehyde
polymer/ amine peptide and this imine intermediate, with reduction to the non-reversible
product only occurring after addition of a reducing agent (such as NaCNBH3). It was
therefore proposed that the Schiff base linkage could be utilised in the formation of
reversibly PEGylated oxytocin, whereby the polymer could be completely removed by
externally adjusting the pH, allowing the therapeutic to maintain complete activity.
2.2.4.1. Linear PEG reversible conjugation
Initially, the potential for reversible conjugation was investigated with the linear aldehyde
PEG, with the conjugation performed under the same conditions (pH 6.2 phosphate buffer,
0.1 M) as for the non-reversible reaction, simply with exclusion of the reducing agent. After
24 hours a sample was removed and submitted for RP-HPLC analysis whereby the RP-HPLC
chromatogram (figure 2.22) showed the appearance of a newly formed bimodal peak at a
longer retention time (t = 14.3 / 14.9 minutes) compared to the native peptide (t = 7.3
minutes). This bimodal peak was observed to form with both available linear PEGs, and as
this phenomenon was not observed for the conjugation with the addition of NaCNBH3 as a
reducing agent, warranted further inspection.
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Figure 2.22. RP-HPLC analysis of conjugation of linear aldehyde PEG (2 kDa) onto oxytocin without theaddition of NaCNBH3 reducing agent.
The reaction was subsequently performed at a higher pH to investigate the formation of
the bimodal nature of this peak under mildly basic conditions (pH 8.0 phosphate buffer, 0.1
M), where potential acidic hydrolysis would be minimised (figure 2.23). The presence of
the bimodal product peak could further be observed suggesting that the potential
formation of two distinct conjugate products was occurring. In order to further investigate
the formation of these products these conjugation reactions were repeated at these two
pHs as well as in an organic solvent (DMF), with samples removed periodically for RP-HPLC
monitoring (using an alternative RP-HPLC gradient with a more gradual increase in aqueous
content). It was found that the reaction occurred faster at pH 8 than at pH 6, with a more
rapid disappearance of the native peptide being observed, theorised to be due to the
reverse reaction (back to the native peptide) being favoured under more acidic pHs.
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Figure 2.23. RP-HPLC analysis of 2 kDa and 5 k Da linear aldehyde Schiff base conjugation formation atpH 8.0 after 1 and 6 days.
The ratios between the two peaks remained approximately equivalent for the two
different buffered pHs, although, after longer reaction monitoring, the second peak
became more prominent, particularly in the acidic solution (table 2.2, figure 2.24).
However, when the reaction was performed in DMF there was a much larger imbalance
between the two peaks throughout the reaction.
Table 2.2. Conjugation of 2 kDa and 5 kDa aldehyde PEG onto oxytocin without reduction – decrease inoxytocin and conjugate peak ratios at t = 6 days.
Solvent
2 kDa PEG conjugation 5 kDa PEG conjugation
Oxytocin
(% decrease)
Peak 1: Peak 2
Ratio
Oxytocin
(% decrease)
Peak 1: Peak 2
Ratio
pH 6.2 53.7 0.45 : 0.55 50.0 0.49 : 0.51
pH 8 78.3 0.43 : 0.58 63.3 0.41 : 0.59
DMF 58.9 0.26 : 0.74 65.7 0.32 : 0.68
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Figure 2.24. Rates of formation of conjugates and disappearance of oxytocin in different solvents for bothMw of PEG aldehyde conjugated onto oxytocin.
A Schiff base is the expected product formed in the reaction; therefore it was proposed
that these two peaks could be due to the stereo isomers (E/Z) that could be formed during
the reaction.
2.2.4.2. Investigation of conjugation with model small
aldehydes
Further characterisation of the polymer Schiff base product is challenging due to the
nature of the polymer. The products observed by RP-HPLC exist as one bimodal product,
rather than two distinct units, making semi-preparative separation problematic. For
additional characterisation into the two potential isomers to be undertaken, an
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investigation was performed using a small molecule (non-polymer) aldehyde as a model
system, under similar conjugation conditions.
Butyraldehyde reversible conjugation
Butyraldehyde, a small, water soluble aldehyde was utilised as a model aldehyde for the
reversible conjugation to oxytocin (scheme 2.11). The reaction was performed in
phosphate buffer (pH 8, 0.1 M) with a sample removed after 24 hours for analysis by RP-
HPLC.
Scheme 2.11. Reversible conjugation of butyraldehyde and oxytocin.
As observed for the PEGylation, the Schiff base reaction showed the formation of two new
products with longer retention times (t = 15.9 / 16.5 minutes) compared to the native
peptide (t = 11.7 minutes) upon RP-HPLC analysis (figure 2.25). However, for this reaction it
was observed that the appearance of products was that of two distinct sharp peaks after
conjugation, with sufficient separation between the products rather than one broad
bimodal product, as observed for the aldehyde linear PEG conjugation. Another difference
observed for the conjugation of butyraldehyde onto oxytocin in comparison to conjugation
of aldehyde PEG was that the reaction had a much higher efficiency, as there was an
almost total disappearance of the native peptide after 24 hours. The peaks observed on
the RP-HPLC chromatogram for the oxytocin conjugate were also more similar to that of
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the native peptide with respect to peak shape, and absorption, compared to the PEGylated
products which were much broader, and of a much lower absorbance.
Figure 2.25. Conjugation of butyraldehyde onto oxytocin showing formation of two products.
The two butyraldehyde conjugates were then separated and individually collected using
RP-HPLC and analysed by ESI-MS. The major products observed in the two separated
samples were confirmed as the expected oxytocin-butyraldehyde Schiff base product
[M+H]+ = 1061.4 Da, suggesting that the two peaks formed correspond to two different
isomers. Native oxytocin was also observed as a minor product [M+H]+ = 1007.3 Da. The
mobile phases used for RP-HPLC (either analytical, or for separation) include TFA as an
acidic additive, giving the resting solution of the separation a pH of 2.1. As the reverse
reaction is favoured under acidic conditions, some reversibility was observed after the
separation, restoring unmodified oxytocin (figure 2.26). The amount of oxytocin released
after overnight storage in the acidic solution was evaluated and differed significantly
between the two separated peaks with 30.1 % oxytocin released from the first peak (t =
15.9 minutes ) and 9.3 % released from the second peak (t = 16.5 minutes).
A further acidic separation study was carried out, whereby the acidic solutions of the
separated conjugates were left for 8 weeks before repeated analysis by ESI-MS and RP-
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HPLC (figure 2.26). After this time the majority of quantitative % peak area by RP-HPLC for
the separation of conjugate peak 1 had disappeared (0.5 % remaining), with a strong
increase in the amount of native peptide present (85.2 %), although some oxytocin
degradation products could also be observed (total degradation: 13.9%). Similar behaviour
was observed for the separated acidic solution of conjugate peak 2, although for this
isomer there was a higher proportion of conjugate left (12.4 % remaining), but still a large
increase in reformed oxytocin (75.1 %) accompanied by peptide degradation (total
degradation: 12.3 %).
Figure 2.26. HPLC traces of separated butyraldehyde conjugates after t = 24 hours and t = 8 weeksstorage in acidic solutions.
These results suggest that the oxytocin conjugate isomer responsible for the second peak
has a higher stability than that observed for the first product and is less prone to reversing
allowing restoration of the native peptide. The released oxytocin was confirmed by ESI-MS,
where the major peaks observed could only be attributable to reformation of the native
peptide [M+H]+ = 1007.3 Da and [M+Na]+ = 1029.3 Da.
This data provides key insights into the reversible nature of this type of conjugation
chemistry and will be important for the later investigation of the reversibility of the
PEGylated conjugates. It now becomes relatable as to why there might have been a small
excess of the second conjugate peak post conjugation. If the PEGylated conjugate is
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showing similar stability trends to the butyraldehyde conjugate, the second product is less
susceptible to the reverse reaction, and is overall more stable.
Non-reversible conjugation with butyraldehyde
To confirm that the appearance of two different products is a particular characteristic of
the reversible conjugate, the conjugation of butyraldehyde was also carried out with the
addition of NaCNBH3 as a reducing agent (scheme 2.12). This would lead to the in-situ
reduction of the Schiff base resulting in the irreversibly linked stable secondary amine
conjugate, previously examined with the aldehyde PEGs.
Scheme 2.12. Second step for the irreversible conjugation of butyraldehyde onto oxytocin.
When the reaction was monitored by RP-HPLC there was an almost complete
disappearance of the native peptide and the appearance of one newly formed conjugate
peak at a retention time of 13.6 minutes (figure 2.27). This is a lower retention time than
either of the peaks monitored for the Schiff base product formation (t = 15.9 / 16.5
minutes) and higher than the native peptide (t = 12.1 minutes). The reduced butyraldehyde
conjugate was confirmed by ESI-MS, where the major product corresponded to that
predicted [M+Na]+ = 1085.3 Da.
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Figure 2.27. Conjugation of butyraldehyde with addition of NaCNBH3.
A further experiment was conducted where the reduced and non-reduced conjugations
were performed alongside each other. Following the observation of the two isomer peaks
by RP-HPLC to have partially formed, NaCNBH3 was then added. This led to a convergence
of both isomer peaks, with the major product peak observed at the end of the reaction
being identified as the reduced butyraldehyde conjugate due to occurring at the same
retention time in the RP-HPLC chromatogram as for the ‘in-situ’ reduction experiment
(figure 2.28). This strongly purports that these two peaks are both the Schiff base
conjugates, and both can be reduced allowing formation of the singular stable irreversible
product.
Figure 2.28. RP-HPLC analysis of reduced butyraldehyde conjugate, non-reduced butyraldehydeconjugate and non-reduced butyraldehyde conjugate upon addition of NaCNBH3.
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Further investigation into the irreversible conjugation of butyraldehyde, with reduction by
NaCNBH3, revealed that when a greater number of equivalents of the butyraldehyde
reagent (5 and 10 equivalents) were used for the reduced conjugate formation, two peaks
could be observed on the RP-HPLC. Analysis by ESI-MS showed that the major products
appear at [M+Na]+ = 1085.3 Da (the expected N-butyl oxytocin product) and [M+Na]+ =
1141.4 Da (an increase of + 56.1 Da from that of the expected product). This suggests that
a second addition of the butyraldehyde (C4H8= 56.06 Da) was able to take place, leading to
a doubly conjugated product. The fundamental concept behind the attachment of
polymers onto oxytocin via the use of amine targeting is that due to the peptide only
possessing one conjugatable position (at the N-Terminus), only singular, site-specific
conjugation could occur. The only position that another possible attachment could
therefore take place is at the secondary amine still present after the initial butyraldehyde
conjugation, and this explains why this second product is only observed for high
equivalents of aldehyde reagent (scheme 2.13).
Scheme 2.13. Double conjugation of butyraldehyde onto oxytocin from second reaction at the secondaryamine.
The ‘double conjugation’ reaction was monitored for several different equivalents of
butyraldehyde reagent, investigating differences in % of peak area by RP-HPLC (UV λ = 280 
nm) of the two observed products (and the native peptide) (figure 2.29). For all reactions,
the only major peaks that could be observed were those of oxytocin (retention time t =
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12.1 mins), and the two (mono and disubstituted) conjugate products (retention times t=
13.6 / 16.3 mins).
Figure 2.29. RP-HPLC analysis of product distributions with different equivalents of butyraldehyde.
Table 2.3. HPLC peak area % of oxytocin, monosubstituted product and disubstituted product onincreasing equivalents of aldehyde reagent.
# Equivalents
Butyraldehyde
Oxytocin Peak (%)
t =12.1 min
Conjugate Peak 1 (%)
t =13.6 min
Conjugate Peak 2 (%)
t =16.3 min0.5 71.1 28.9 -
1 48.5 51.5 -
2 13.9 86.1 -
5 1.0 94.6 4.4
10 0.1 61.4 38.5
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These results show that it is possible to acquire the doubly conjugated product, but that
this does not become a hindrance for the conjugation until there is a large excess of the
aldehyde reagent (table 2.3). The most often used excess in these reactions is 1-2
equivalents, therefore double conjugation should not often be presented as a problem,
although it is something that must still be considered.
In the linear aldehyde PEG (reduced) conjugations discussed earlier within this chapter, the
conjugate peak showed the presence of a potential second product appearing as a
shoulder / peak tailing from the confirmed singular conjugate. This could have arisen from
the double conjugation of the aldehyde PEG reagent, as the results for the butyraldehyde
conjugation have confirmed that this is a possibility. However, in this case the shoulder
peak was present to only a small degree within the overall product, and double
conjugation was not evident upon analysis by MALDI-TOF MS.
Conjugations with other small aldehydes
There is a large range of other common aldehyde reagents available, which could be
utilised in the same manner as butyraldehyde for conjugation onto peptides or proteins for
further characterisation and analysis. The majority of commercially available PEG reagents
have small alkyl links, such as propyl or butyl, between the aldehyde functionality and the
beginning of the PEG polymer repeat unit. Therefore identical (reduced and non-reduced)
conjugation reactions were also performed using propionaldehyde, a small, water soluble
aldehyde with similar structure and properties to butyraldehyde (figure 2.30).
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Figure 2.30. Small molecule aldehydes conjugated onto oxytocin in a similar manner to PEGs.
For the reaction of propionaldehyde without addition of a reducing agent, sampling for RP-
HPLC (UV λ=280 nm) after 24 hours revealed the same behaviour as observed for the 
butyraldehyde equivalent. Two distinct peaks were observed in the RP-HPLC
chromatogram at higher retention times (t = 15.3 & 15.8 minutes) compared to oxytocin (t
= 12.0 minutes ) alongside an almost complete disappearance of the native peptide,
showing again the efficiency of these ‘small aldehyde’ reactions (figure 2.31). The
conjugation with the addition of NaCNBH3 was also very similar to that observed for
butyraldehyde with the appearance of a singular major product peak (t = 12.9 minutes).
Figure 2.31. Conjugation of propionaldehyde with and without the addition of NaCNBH3.
However, when the reactions were repeated with small aromatic aldehydes (2-pyridine
carboxaldeheyde and 2-hydroxy benzaldehyde), RP-HPLC analysis of the resulting reaction
solutions showed either the appearance of a large number of side products, or no
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observed conjugation. This is likely due to the aromatic nature of these small molecule
aldehydes, preventing efficient conjugation.
Due to the similarities between the results attained for the conjugations of butyraldehyde
and propionaldehyde and the linear PEGylations (appearance of two distinct products
without addition of NaCNBH3 and one with the addition of NaCNBH3), valuable information
about the reaction of oxytocin and alkyl aldehydes has been attained. It has become
increasingly evidenced that the Schiff base formation occurs in the expected manner
leading to the formation of the E and Z isomers, however, further confirmation of the
structures would be beneficial.
NMR analysis of small aldehyde conjugates
For further characterisation of the N-alkyl oxytocin product, solutions of the reaction
mixtures (pH 8, phosphate buffer, 0.1 M) from the reversible conjugations of
butyraldehyde and propionaldehyde onto oxytocin (2 mM) were submitted for NMR
analysis (10 % D2O, 600 MHz) (figure 2.32). The native peptide (2 mM) was also analysed
under the same conditions, with results correlating well with previous NMR assignments of
oxytocin in pH 6.2 phosphate buffer.37
For the butyraldehyde Schiff base conjugate, the presence of two new doublet peaks could
clearly be observed within the imine region of the spectra (δ = 7.55 / 7.82 ppm), likely due 
to the two different isomers formed, although the peak at 7.55 ppm also overlaps with an
amide peak on the peptide. Analysis by 2D NMR revealed TOCSY connectives from these
imine peaks of two different signals at δ = 4.4 ppm, both assignable to α protons of the 
Cys1 residue, which are then coupling to protons at δ = 2.7 ppm, likely the β Cys1 proton.
Additionally, the peaks representing the aromatic groups on the tyrosine residues show a
chemical shift post-conjugation (native peptide: δH = 7.16, εH = 6.83 ppm; butyraldehyde
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conjugate: δH = 7.09, εH = 6.85 ppm), where Tyr2 is the next amino acid from the N-terminal
amine within the peptide structure.
Figure 2.32. 1H NMR analysis of butyraldehyde conjugation reaction mixture (pH 8) with 10 % D2Oincluding a zoom in of the imine region (6 – 9 ppm) and accompanying TOCSY spectra.
When the propionaldehyde Schiff base conjugate was investigated in the same manner,
very similar behaviour was observed (figure 2.33). There was the presence of the two new
imine peaks at similar positions to those found for the butyraldehyde conjugate (δ = 7.56 / 
7.83 ppm) and comparable tyrosine shifts were also observed (δH = 7.08, εH = 6.82 ppm).
Figure 2.33. 1H NMR analysis of propionaldehyde conjugation reaction mixture (pH 8) with 10 % D2Oincluding a zoom in of the imine region (6 – 9 ppm).
As the NMR analysis was taken as a sample of the reaction mixture, the excess aldehyde
reagent is still present (figure 2.34). In aqueous solutions (as within the NMR) this aldehyde
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reagent undergoes hydrolysis leading to the hydrate product, for which the NMR shows
particularly prominent peaks at approximately δ = 5.00 ppm. This can be observed for the 
reaction mixtures of the aldehyde reagent, in both the propionaldehyde and
butyraldehyde samples, as well as in the conjugation mixtures.
Figure 2.34. 1H NMR of butyraldehyde and propionaldehyde in CHCl3 and D2O showing formation ofhydrate under aqueous conditions.
These NMR results support the assignment of the two small aldehyde conjugates as
existing as two different imine products predicted during the reaction. From these results
however, it is difficult to determine which conjugate product is the E / Z isomer, which,
given that one product has a potentially much higher stability, would be beneficial
information.
2.2.4.3. PolyPEG reversible conjugation
The aldehyde functional polyPEG (10 kDa) was also conjugated onto oxytocin without the
aid of a reducing agent leading to the formation of a Schiff base linked ‘comb’ polymer-
conjugate. This conjugation was carried out in phosphate buffer (0.1 M. pH 8) and
sampling by RP-HPLC after 24 hours revealed the presence of a newly formed singular
broad peak at a higher retention time (t = 24.1 minutes) to the native peptide (t = 12.1
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minutes ) (figure 2.35). The peak observed in the HPLC chromatogram is broader than that
observed for the linear polymer or the small molecule studies. It is possible that there
could be two distinct isomer peaks observed for the polyPEG, but that only one peak is
observed due to disperse nature of the polymer.
Figure 2.35. RP-HPLC trace of Schiff base oxytocin-poly(mPEGA480)20 conjugate formed without theaddition of a reducing agent.
2.2.5. Reversibility studies of oxytocin Schiff base conjugates
Following the synthesis and characterisation of the Schiff base linked conjugates;
controlled reversibility studies were conducted to ascertain whether the conjugates could
be promoted to release a significant amount of native peptide. From the reversibility
observed upon storage of the purified butyraldehyde conjugates in acidic solutions, the
potential for regeneration of the native peptide is possible, but being able to tune the
amount of peptide released would be desirable. In order to investigate oxytocin release,
the initial peptide concentration is required to be very low, so that any increases in peptide
peak intensity could only be caused by and attributed to the reverse of Schiff base
conjugate formation. The samples were monitored by RP-HPLC, tracking the oxytocin
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content of the solutions and respective conjugate concentrations over the period of the
reversal study.
2.2.5.1. Butyraldehyde Schiff base conjugate reversibility
For reversibility measurements on the butyraldehyde-oxytocin conjugate these were
carried out immediately post conjugation, due to the high efficiency of the reaction
signifying minimal remaining oxytocin. A sample of the conjugation solution was diluted
with two buffers at pH 5.0 (citrate buffer, 0.1 M) and pH 7.4 (phosphate buffer, 0.1 M) to
yield overall concentrations of 0.2 mg/ml of peptide. A t = 0 sample was submitted to RP-
HPLC whereby the oxytocin concentration (RP-HPLC peak area) would be at its lowest point
before any potential reversibility of the conjugation. After 4 days of stirring in the buffered
solutions there were clear differences observed by RP-HPLC between the two different pHs
(table 2.4, figure 2.36).
Table 2.4. RP-HPLC (UV, λ = 280 nm) peak areas (mAUs) for oxytocin and the two conjugate peaks upon reversal at different pHs for butyraldehyde-oxytocin conjugate.
Conjugate pH
Oxytocin
Peak
t = 0
Oxytocin
Peak
t = 4 d
Conj
Peak 1
t = 0
Conj
Peak 1
t = 4 d
Conj
Peak 2
t = 0
Conj
Peak 2
t = 4 d
Butyraldehyde 5.0 68.2 681.8 814.6 402.9 584.8 570.0
Butyraldehyde 7.4 68.2 199.4 814.6 580.5 584.8 710.8
In the pH 5.0 solution, analysing peptide peak area on HPLC revealed a ten-fold increase in
oxytocic content. This was accompanied by a decrease in peak area for both conjugate
products (overall 30 % decrease in conjugate peaks). Analysis of the two conjugate peaks
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revealed that the second peak showed a much smaller decrease in area (-3 %) compared to
the first peak (-49 %), signifying that there was not a large change in concentration for this
isomer. In the pH 7.4 buffer a moderate three-fold increase in the amount of oxytocin
present in solution was observed, but there was not a large accompanying decrease
(overall -8%) in the area of the combined conjugate peaks. There was, however, a shift in
the ratios observed for the isomers; a decrease in the first peak and an increase in the
second peak suggesting the re-formation of the more stable second conjugate product
(0.58 : 0.42 to 0.45 : 0.55).
Figure 2.36. RP-HPLC trace showing reappearance of oxytocin under reversible conditions, and bar graphhighlighting concentration changes of both butyraldehyde conjugates and oxytocin at pH 5.0 and pH 7.4.
These differences observed at the two pHs are significant in clearly highlighting that the
reversal of the conjugation can be partially controlled by using pH as a means to induce
release of the native peptide. This highlights the potential for using this system to
stimulate oxytocic release, after which the reversible nature of the Schiff base linked
PEGylated oxytocin (both linear and polyPEG) were further investigated.
2.2.5.2. Linear PEG Schiff base conjugate reversibility
Prior to investigating the pH-induced reversible nature of the linear PEG, complete
removal of any remaining oxytocin was performed by dialysis against pH adjusted water
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(pH 8). Immediately post dialysis a sample was submitted for RP-HPLC as a t = 0 sample, to
assess the minimum level of oxytocin present in the solution before two different pH
conditions were examined (pH 5.0 and pH 7.4). For the linear PEGylated conjugate (5 kDa
PEG) the oxytocin release was initially monitored by RP-HPLC after storage in the different
pH solutions for 18 days (table 2.5, figure 2.37). After this time there is clearly a significant
reappearance of native oxytocin stimulated at both pHs in comparison to the t = 0 sample.
Table 2.5. RP-HPLC (UV, λ = 280 nm) peak areas (mAUs) for oxytocin and the two conjugate peaks upon reversal at different pHs for linear PEG-oxytocin conjugate.
After 18 days the concentration of oxytocin had dramatically increased in the pH 5.0
solution indicating that oxytocin had been released from the conjugate (twelve-fold
increase), whilst the pH 7.4 solution showed a more modest release of the native peptide
(six-fold increase). This demonstrates that there was some pH control over the release, as
observed with the butyraldehyde conjugates. The disappearance of conjugates was also
monitored, which further highlighted that the first conjugate peak is much more prone to
reversion releasing the native peptide. The loss of conjugates was observed at both pH
values but is particularly prominent under acidic conditions (pH 5.0: 60 % decrease; pH 7.4:
38 % decrease).
Conjugate pH
Oxytocin
Peak
t = 0
Oxytocin
Peak
t = 18 d
Conj
Peak 1
t = 0
Conj
Peak 1
t = 18 d
Conj
Peak 2
t = 0
Conj
Peak 2
t = 18 d
Linear PEG 5.0 25 302.3 242.4 97 407.1 338.5
Linear PEG 7.4 25 168.4 242.4 149.9 407.1 423.8
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Figure 2.37. RP-HPLC trace showing reappearance of oxytocin under reversible conditions, and bar graphhighlighting concentration changes of both linear PEG conjugates and oxytocin at pH 5 and pH 7.4.
The release study was repeated with further monitoring at different time points over a two
week period, which revealed interesting characteristics (figure 2.38). Investigations at both
pHs show approximately the same initial level of release of oxytocin, however, the release
at pH 7.4 reaches a plateau after 4-5 days. The oxytocin concentration however continued
to gradually increase in the pH 5 solution across the two week study, showing potential for
a prolonged release of oxytocin from the conjugates over time.
Figure 2.38. Concentration changes monitored for oxytocin release from linear PEGylated conjugateacross a 2 week period at pH 5 and pH 7.4.
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2.2.5.3. PolyPEG Schiff base conjugate reversibility
For the polyPEG conjugates when the same pH dependant analysis was undertaken there
was no change in the peak area for the (singular) conjugate peak. There was an
observation of some appearance of oxytocin, but not in an appreciable concentration,
particularly in comparison to the linear PEG or butyraldehyde conjugate releases (table 2.6,
figure 2.39).
Table 2.6. RP-HPLC (UV, λ = 280 nm) peak areas (mAUs) for oxytocin and the singular conjugate peaks upon reversal at different pHs for polyPEG-oxytocin conjugate.
Conjugate pH
Oxytocin Peak
t = 0
Oxytocin Peak
t = 21 d
Conjugate Peak
t = 0
Conjugate Peak
t = 21 d
PolyPEG 5.0 0 6.6 658.4 620.3
PolyPEG 7.4 0 7.5 658.4 619.7.
A peak area of 7 mAUs for oxytocin corresponds to a concentration of approximately 2
µmol (0.002 mg ml-1). This suggests that the reverse reaction was not being promoted in
this case, or at least not to the same degree as previously observed for the other oxytocin
aldehyde conjugates.
Figure 2.39. RP-HPLC traces for polyPEGylated oxytocin release study at pH 5 and pH 7.4.
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This leads to valuable information about the reversible conjugation of these architectures
of Schiff base conjugated oxytocin analogues. From the reversibility experiments the
smallest (and least branched) Schiff base conjugate released the highest concentration of
oxytocin under acidic conditions followed by the linear PEG conjugate, where there was
still an appreciable regeneration of the native peptide. On increasing the conjugate size
(and structure), the branched ‘comb’ PEGylated analogue did not show any appreciable
conversion of the conjugate back to native oxytocin. It can therefore be assumed that the
structural design of the conjugates plays an important role in the ability to reverse the
conjugation under stimulated conditions, with larger and more branched polymers proving
less prone to reversion.
2.3. Chapter 2 Conclusions
Multiple PEGylation strategies were employed for singularly attaching different polymer
architectures to the small peptide oxytocin, site specifically at the N-terminal amine. Comb
PEG polymers were synthesised by copper (0) mediated controlled radical polymerisation
containing succinimide ester end group functionality, with control over molecular weights
and low dispersities. The polymers retained their end group functionality and were
successfully conjugated onto oxytocin alongside their commercially available linear
equivalents.
Comb PEG polymers containing protected aldehyde end group functionality were also
synthesised in the same manner, and easily deprotected post-polymerisation, yielding
aldehyde end functional polyPEG. These polymers, along with their corresponding linear
analogues, were also conjugated onto oxytocin in a two-step reaction via a Schiff base
intermediate, with the addition of NaCNBH3, leading to stable peptide-polymer conjugates.
The singular attachment of the linear PEG conjugation was confirmed by MALDI-TOF MS,
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which shows a good indication that the polyPEG conjugates would react in the same
manner. All conjugates were characterised by RP-HPLC, revealing the presence of new
peaks at different retention times to the native peptide.
Without the addition of the reducing agent the reaction leads to reversible Schiff base
products, and this was evaluated for linear PEG, poly(mPEGA) and one non-polymer small
organic aldehyde functional reagent. The use of a non-polymer reagent allowed further
characterisation of the Schiff base products formed by ESI-MS and NMR as a model for the
polymer reaction. The Schiff base linked peptide-polymer conjugates were envisaged to be
able to release the native peptide under certain stimulated conditions therefore the
reversibility was evaluated for the oxytocin Schiff bases of linear and polyPEG polymers as
well as the small molecule equivalent. This suggested that acidic conditions were able to
promote oxytocin release. Furthermore, it was found that the nature of polymer
architecture was a highly important factor and, therefore, consideration of the polymers
must be undertaken within exploiting these reversible reactions.
2.4. Experimental
2.4.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received. Functional poly(ethylene glycol)s:
NHS ester functional poly(ethylene glycol) (MW: 2,000 Da / 5,000 Da) and aldehyde
functional poly(ethylene glycol) (MW: 2,000 Da / 5,000 Da) were purchased from Rapp
Polymere (Germany) and stored in a freezer (-18 °C). Poly(ethylene glycol) methyl ether
acrylate (average Mn: 480; containing 100 ppm BHT & 100 ppm MEHQ as inhibitors) was
purchased from Sigma Aldrich and stored at 4 °C. Copper (0) wire was pre-treated by
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washing in hydrochloric acid (35%) for 20 min, then rinsed with water, and dried under
nitrogen immediately prior to use. N,N,N′,N′,N″,N″-Hexamethyl-[tris(aminoethyl)amine] 
(Me6-TREN) was synthesised according to a previously reported procedure and stored at -
18 °C prior to use.38
2.4.2. Instrumentation & Analysis
Nuclear magnetic resonance (NMR) spectra were acquired with a Bruker DPX-300, Bruker
DPX-400, Bruker HD-300 and Bruker HD-400 spectrometers with samples prepared in
deuterated solvents (CDCl3 or δ6-DMSO) and chemical shifts were reported in parts per
million (ppm) with reference to solvent residual peaks. 1D 1H and 2D 1H NMR of peptide
conjugates were acquired on a Bruker Avance III 600 NMR spectrometer using the reaction
mixture ( 2mM) with 10 % D2O by Dr Claudia Blindauer.
Size exclusion chromatography (SEC) was performed on an Agilent Polymer Laboratories
GPC50 fitted with differential refractive index (RI) detector. Separations were performed
on a pair of Agilent Polargel Medium Columns eluting with N,N dimethylformamide
containing 0.1 M LiBr as an additive at 50 °C with a flow rate of 1 ml/min. Molecular
weights were calculated relative to narrow PMMA standards (550 – 955,000 gmol-1) and
fitted with a 3rd order polynomial.
Infrared absorption spectra were recorded on a Bruker VECTOR-22 FTIR spectrometer
using a Golden Gate diamond attenuated total reflection cell.
Analytical high performance liquid chromatography (HPLC) was performed on Agilent 1260
Infinity series stack equipped with an Agilent 1260 binary pump and degasser. 50 µl
samples were injected using Agilent 1260 autosampler with a flow rate of 1 ml/min. The
HPLC was fitted with a Phenomenex Luna C18 column (250 x 4.6 mm) with 5 micron
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packing (100Ǻ).  Detection was achieved using an Agilent 1260 variable wavelength 
detector monitoring at 280 nm. Mobile phase A consisted of either 100 % water containing
0.04 % TFA as an additive or 90 % water, 10 % acetonitrile containing 0.04 % TFA as an
additive. Mobile Phase B consisted of 100 % acetonitrile containing 0.04 % TFA as an
additive. The column was equilibrated by washing with the starting % of mobile phase A
for 10 minutes prior to injection for all conditions. The method gradient (1) HPLC analysis:
90 % mobile phase A decreasing to 40 % mobile phase A over 27 minutes, and remaining at
40% mobile phase A for 8 minutes, before resetting to the starting conditions in 1 minute
and remaining in these conditions for at least 10 minutes to re-equilibrate the column
before subsequent injections. The method gradient (2) HPLC analysis: 95 % mobile phase
A decreasing to 80 % mobile phase A across 15 minutes, and to 40 % mobile phase A at 22
minutes and remaining at 40% mobile phase A for 5 minutes, before resetting to the
starting conditions in 1 minute and remaining in these conditions for at least 10 minutes to
re-equilibrate the column before subsequent injections.
Semi-preparative HPLC was performed on the same HPLC system as above fitted with a
Phenomenex Jupiter C18 column (250 x 21.2 mm) with 5 micron packing (300Ǻ).  Detection 
was achieved using an Agilent 1260 multiple wavelength detector monitoring at 280 nm
and 225 nm. Mobile phase A consisted of 100 % water containing 0.04 % TFA as an
additive and Mobile phase B consisted of 100 % acetonitrile containing 0.04 % TFA as an
additive. The flow rate was set to 5 ml/min and general gradients were as follows: 81 %
mobile phase A for 4 minutes decreasing to 58 % mobile phase A for 30 minutes, and
remaining at 58 % mobile phase A for 10 minutes, before decreasing to 50% mobile phase
A for 10 minutes and remaining at 50 % mobile phase A for 5 minutes before returning to
starting conditions in 1 minute and remaining in these conditions for at least 10 minutes to
re-equilibrate the column before subsequent injections.
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MALDI-TOF MS was conducted using a Bruker Daltonics Autoflex MALDI-ToF mass
spectrometer. MALDI-TOF samples were made by mixing a saturated solution of α-cyano-
4-hydroxycinnamic acid (CHCA) in methanol as a matrix (10.8 µl), sodium iodide in
tetrahydrofuran (THF) (1.0 mg/ml) as cationisation agent (4.2 µl) and sample in THF with 1
drop of water (1.0 mg/ml) (10.8 µl) and 0.7 µl of the mixture was applied to target plate.
Spectra were recorded in reflector mode calibrating with mPEG 2000 Da. Electrospray
ionisation mass spectra (ESI) were recorded on an Agilent 6130B Single-Quad.
2.4.3. Synthetic procedures for chapter 2
2.4.3.1. NHS ester linear PEG conjugation onto oxytocin
Oxytocin (20 mg, 20 µmol) and NHS-PEG (Rapp-Polymere, 2,000 Da) (60 mg, 30 µmol)
were separately dissolved in 1 ml of DMF and the solutions added together at 10 °C and 20
µl triethylamine was added. After stirring overnight at T= 10 °C, 20 µl of the solution was
removed and dissolved in 1 ml H2O for RP-HPLC analysis (λ = 280 nm). 
2.4.3.2. Aldehyde linear PEG conjugation onto oxytocin
Aldehyde functional linear PEG (40 mg, 20 µmol) was dissolved in sodium phosphate
buffer (5 ml, pH 6.2, 100 mM) and left at 10 °C for 1 hour. Oxytocin (15 mg, 15 µmol) was
stirred in the same buffer (5 ml) at 10 °C for 15 minutes. Both solutions were added
together and a freshly prepared solution of NaCNBH3 (25 mmol) was added. After stirring
overnight at T= 10 °C a 100 µl aliquot was taken and dissolved in 1 ml H2O for RP-HPLC
analysis.
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2.4.3.3. Synthesis of N-hydroxysuccinimide-2-bromo-2-
methylpropionate
N-Hydroxy succinimide (4.45 g, 38.7 mmol) was dissolved in anhydrous DCM (100 ml) and
triethylamine (7.16 ml, 51.5 mmol) was added. The flask was cooled to 0 °C before the
addition of α-bromoisobutyryl bromide (5.25 ml, 42.6 mmol) in DCM (20 ml) dropwise
under flow of nitrogen. The mixture was stirred at 0 °C for 45 minutes, before warming to
room temperature and stirring for a further 3 hours. The reaction mixture was then poured
into ice-water (200 ml) and the organic layer was separated and washed with NaHCO3 (2 x
50 ml) followed by water ( 2 x 50 ml) and again with NaHCO3 (2 x 50 ml). The organic layer
was dried with MgSO4 and the solvent removed under reduced pressure. The crude
product was purified by recrystallisation with Et2O to afford the product as an off white
powder (8.46 g, 32.0 mmol, 83 %).
1H NMR (CDCl3, 400.05 MHz) δ (ppm): 2.06 (6H, s, C(CH3)2Br), 2.85 (4H, s, (CH2CO)2N). 13C
NMR (CDCl3, 100.59 MHz) δ (ppm): 25.54 ((CH2CO)2N), 30.59 (C(CH3)2Br), 51.17 (C(CH3)2Br),
167.40 (NOCO), 168.59 (((CH2CO)2N).
2.4.3.4. Cu(0) mediated NHS ester α-functional poly(mPEGA-
480) synthesis
Copper wire (1.25 mm diameter) was activated by washing in hydrochloric acid for 10
minutes, before being rinsed with water and dried under a nitrogen blanket. In a Schlenk
tube, Cu(II) bromide (3.73 mg, 0.0167 mmol) was dissolved in DMSO (1.5 ml, anhydrous)
and Me6TREN ligand (16.1 µl, 0.0602 mmol) was added. NHS-ester functional initiator (88
mg, 0.334 mmol) in DMSO (1 ml, anhydrous) and mPEGA (2.94 ml, 6.68 mmol) in DMSO (1
ml, anhydrous) were added. The solution was degassed by bubbling with nitrogen for 20
Chapter 2 – Amine targeted PEGylation of oxytocin
Jennifer Collins 102
minutes before the addition of pre-activated copper wire under a positive nitrogen
pressure and the Schlenk tube sealed with a rubber septum. The polymerisation was
sampled under a positive pressure of nitrogen for NMR (δ6-DMSO) and SEC analysis (DMF).
The polymers were purified by repeated precipitation into diethyl ether / hexane (1:1).
2.4.3.5. Synthesis of 2-(2,2-dimethoxyethoxy)ethyl-2-bromo-2-
methylpropionate
The two step protected aldehyde initiator synthesis was adapted from a reported
procedure.25 Potassium hydroxide (40 g, 0.71 mol) and ethylene glycol (100 ml, 1.79 mol)
were added together and gradually heated to 115 °C with stirring. Chloroacetaldehyde
dimethyl acetal was slowly added dropwise and the solution stirred at 115 °C for 48 hours.
The solution was cooled to room temperature before the addition of water (200 ml). The
solution was then extracted with dichloromethane (2 x 150 ml) and washed with brine (2 x
100 ml) before the organic fractions were dried with MgSO4 and the solvent removed
under reduced pressure yielding 2-(2,2-dimethoxy-ethoxy)-ethanol as a yellow oil (18.12 g,
0.12 mol, 17 %) which was used for the following step without further purification.
1H NMR (CDCl3, 300.13 MHz) δ (ppm): 3.37 (6H, s, CH(OCH3)2), 3.52 (2H, t, J = 5.09 Hz,
CHCH2O), 3.56-3.73 (4H, m, OCH2CH2OH), 4.50 (1H, q, J = 5.09 Hz, CH(OCH3)2). 13C NMR
(CDCl3, 75.47 MHz) δ (ppm): 52.83 (CH(CH3O)2), 61.54 (CH2CH2OH), 70.51 (CH2CH2OH),
72.82 (CHCH2O), 102.47 (CH(CH3O)2).
A solution of 2-(2,2-dimethoxyethoxy)-ethanol (11 g, 73.2 mmol) and triethylamine (12 ml,
86.2 mmol) were dissolved in DCM (150 ml) and cooled to 0 °C under nitrogen. α-
Bromoisobutyryl bromide (8.5 ml, 69.7 mmol) in DCM (50 ml) was added dropwise. The
solution was stirred for 1 hour at 0 °C and overnight at ambient temperature and the
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resulting suspension was filtered. The solution was then washed with saturated NaHCO3
solution (3 x 100 ml) and dried with MgSO4 and the solvent removed under reduced
pressure yielding a yellow oil (18 g). 6.5 g of this oil was purified by silica column
chromatography (petroleum ether: diethyl ether; 19:1 to 3:1) yielding a colourless oil (4.06
g, 12.9 mmol).
1H NMR (CDCl3, 300.13 MHz) δ (ppm): 1.89 (6H, s, C(CH3)2Br), 3.34 (6H, s, (OCH3)2CH), 3.51
(2H, d, J = 5.09 Hz, CHCH2O), 3.71 (2H, t, J = 4.71 Hz, OCH2CH2OCO), 4.27 (2H, t, J = 4.71 Hz,
OCH2CH2OCO), 4.45 (1H, t, J = 5.09 Hz, (OCH3)2CH). 13C NMR (CDCl3, 75.47 MHz) δ (ppm):
30.09 (C(CH3)2Br), 53.31 ((CH3O)2CH), 55.00 (C(CH3)2Br), 64.44 (CH2O), 68.41 (CH2O), 70.32
(CH2O), 101.98 ((CH3O)2CH), 170.85 (COC(CH3)2Br).
2.4.3.6. Cu(0) mediated protected α-aldehyde poly(mPEGA480)
synthesis
Copper wire (1.25 mm diameter) was activated by washing in hydrochloric acid for 10
minutes, before being rinsed with water and dried under a nitrogen blanket. In a Schlenk
tube, Cu(II) bromide (3.7 mg, 0.0167 mmol) was dissolved in DMSO (1.5 ml) and Me6TREN
ligand (16 µl, 0.0602 mmol) was added. Protected aldehyde initiator (0.1 g, 0.334 mmol) in
DMSO (1ml) and mPEGA (2.94 ml, 6.68 mmol) in DMSO (1 ml) were added. The solution
was degassed by bubbling with nitrogen for 20 minutes before the addition of pre-
activated copper wire under a positive nitrogen pressure and the Schlenk tube sealed with
a rubber septum. The polymerisation was sampled under a positive pressure of nitrogen
for NMR (δ6-DMSO) and SEC analysis (DMF). The polymers were purified by dialysis against
water (1 kDa MWCO, 3 days).
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2.4.3.7. Deprotection of acetal α-end group
The acetal groups were removed by dissolving polymer (1 g) in a (1:1) solution of TFA: H2O
(30 ml) and stirring for 48 hours. The aldehyde functional deprotected polymer was
purified by dialysis against water (regenerated cellulose, 1 kDa MWCO, 3 days).
2.4.3.8. NHS ester α-functional poly(mPEGA480) conjugation
onto oxytocin
Oxytocin (1 mg, 0.99 µmol) was dissolved in 1 ml phosphate buffer (pH 6.5, 0.1 M) and
added to succinimide functional polyPEG (65 mg, 10 µmol) dissolved in 1ml of the same
buffer. The reaction was stirred overnight at ambient temperature before a sample was
removed for RP-HPLC analysis.
2.4.3.9. Aldehyde α-functional poly(mPEGA480) conjugation
onto oxytocin
Aldehyde functional polyPEG (30 mg, 3 µmol) was dissolved in sodium phosphate buffer
(2.5 ml, pH 6.2, 100 mM) and left at 10 °C for 1 hour. Oxytocin (2 mg, 2 µmol) was stirred in
the same buffer (1 ml) at 10 °C for 15 minutes. Both solutions were added together and a
freshly prepared solution of NaCNBH3 (25 mmol, 0.5 ml) was added. After stirring
overnight a sample was taken and dissolved in 1 ml H2O for RP-HPLC analysis.
Chapter 2 – Amine targeted PEGylation of oxytocin
Jennifer Collins 105
2.4.3.10. Reversible conjugation of aldehyde linear PEG onto
oxytocin
Aldehyde functional linear PEG (200 mg, 40 µmol) dissolved in phosphate buffer (3 ml, pH
8, 0.1 M) was added to oxytocin (20 mg, 20 µmol) dissolved in the same buffer (2 ml). The
reaction was allowed to proceed at ambient temperature overnight before a sample was
removed for RP-HPLC analysis.
2.4.3.11. Reversible conjugation of butyraldehyde onto
oxytocin
To oxytocin (5 mg, 5 µmol) in H2O (5 ml) was added butyraldehyde (1.5 µl, 15 µmol). The
reaction was stirred at room temperature overnight before a sample was removed for RP-
HPLC analysis.
2.4.3.12. Irreversible conjugation of butyraldehyde onto
oxytocin
To oxytocin (5 mg, 5 µmol) in H2O (5 ml) butyraldehyde (1.5 µl, 15 µmol) was added, after
which freshly prepared NaCNBH3 (25 mM, 1 ml) was added. The reaction was stirred at
room temperature overnight before a sample was removed for RP-HPLC analysis.
2.4.3.13. Reversible and irreversible conjugation of
propionaldehyde onto oxytocin
To two separate solutions of oxytocin (5 mg, 5 µmol) in H2O (2.5 ml) was added
propionaldehyde (1.07 µl, 15 µmol), after which freshly prepared NaCNBH3 (25 mM, 1 ml)
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was added to one of the solutions. The reactions were stirred at room temperature
overnight before a sample was removed for RP-HPLC analysis.
2.4.3.14. Reversible conjugation of α-aldehyde
poly(mPEGA480) onto oxytocin
Aldehyde functional polyPEG (200 mg, 20 µmol) dissolved in phosphate buffer (3 ml, pH 8,
0.1 M) was added to oxytocin (10 mg, 10 µmol) dissolved in the same buffer (2 ml). The
reaction was allowed to proceed at room temperature overnight before a sample was
removed for RP-HPLC analysis.
2.4.3.15. Reversibility experiments of Schiff base conjugated
butyraldehyde
Butyraldehyde Schiff base conjugated oxytocin solution directly succeeding conjugation
(0.5 ml, 4 mM) was diluted with 1.5 ml of different pH solutions (1 mM). After stirring for
96 hours, the samples were analysed by RP-HPLC for any increase in concentration of
oxytocin.
2.4.3.16. Reversibility experiments of Schiff base conjugated
linear PEG
Immediately post-conjugation, the conjugation solution was dialysed (3.5 kDa MWCO, 3
days) against water which had been pH adjusted with 0.1 M NaOH to pH 8. After removal
from dialysis a sample was submitted for RP-HPLC for minimum oxytocin content. 0.5 ml of
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the dialysis solution was diluted with 1.5 ml of pH 5.0 and pH 7.4 buffered solutions, and
stirred for 18 days with periodic sampling by RP-HPLC.
2.4.3.17. Reversibility of Schiff base conjugated
poly(mPEGA480)
Post-conjugation, the solution was dialysed (3.5 kDa MWCO, 3 days) against water which
had been pH adjusted NaOH (0.1 M, pH 8). After dialysis a sample was submitted for RP-
HPLC minimum oxytocin content. 0.5 ml of the dialysis solution was diluted with buffer (1.5
ml, pH 5.0 & 7.4) and stirred for 18 days with periodic sampling by RP-HPLC.
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Chapter 3
3. Disulfide bond targeted PEGylation of
oxytocin
A popular targeting method for the conjugation of polymer onto peptides/proteins is
through the use of thiol groups arising from cysteine residues. These often have a less
frequent occurrence within the peptide structure, allowing for a more site-specific
approach. Conjugation strategies were developed that targeted the pair of thiols arising
from the reduction of the Cys1 – Cys6 disulfide bond within oxytocin, either with two
separate Michael addition reactions with both of the thiols, or by the rebridging of the
disulfide bond using maleimde chemistry, maintaining the cyclic structure.
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3.1. Introduction
An approach that is becoming more prevalent in protein/peptide–polymer conjugation
strategies is the targeting of thiols found within the protein/peptide structure. Cysteine
residues present a convenient target for modifications to take place, due both to the
nucleophilicity and reactivity and rarity with peptide and protein structures.1 The lesser
abundance of thiol functionalities (particularly as accessible and free thiols) within the
protein/peptide compared to lysine (amine) residues makes site-selective targeting more
simple. Often thiols will be generated by reduction of natural disulfide bonds within the
structure using reagents such as dithiothreitol (DTT),2 2-mercaptoethanol or tris(2-
carboxyethyl) phosphine (TCEP).3
One of the major sites where degradation occurs in oxytocin is the Cys1-Cys6 disulfide
bond, where a variety of different degradation products can form, including
tri/tetrasulfide, dimerization and the formation of larger peptide aggregates.4,5 Therefore
conjugation strategies with a focus on applying changes to the disulfide bond could be of
vital importance for increasing the overall stability of oxytocin.
Reports within the literature from the 1970s present alternative oxytocin structures
wherein the disulfide bond has been engineered to contain alternative functionality, that
may have an effect on the peptide stability or activity.6,7 More recent work by Alewood and
co-workers reported that by replacing the S-S disulfide bond with CH2-S, Se-Se, Se-S or Te-
Te the stability of the peptide and biological activity could be conserved.8,9 This provides
further evidence that the disulfide bond is not always required in its native form for
biological activity to occur, and thus provides a potentially highly important site for peptide
modification.
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In this chapter the use of functional PEGs will be described for specific conjugation at the
disulfide bond of oxytocin, after reduction leads to two accessible sulfhydryl residues.
Polymer conjugation utilising both linear and polyPEG architectures will be explored, as
discussed in the previous chapter, as well as the potential for singular conjugation (with
disulfide bond rebridging) or double conjugation (with a loss of cyclic structure) of
polymers at the peptide disulfide bond.
3.2. Results & Discussion
3.2.1. General considerations for disulfide based chemistry
with respect to oxytocin
The Cys1-Cys6 disulfide bond of oxytocin presents a convenient alternative approach that
can be utilised for the polymeric modification of oxytocin. The conjugation routes utilising
this position, however, first require complete reduction of the disulfide bridge (scheme
3.1). This releases two cysteine thiols, each capable of undergoing a large library of
sulfhydryl chemical reactions resulting in covalent attachment.
Scheme 3.1. Reduction of oxytocin disulfide bond generating two free thiols.
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3.2.1.1. Reducing the disulfide bond in oxytocin
As there is very little literature focused on the chemical modification of the oxytocin
disulfide bond (most oxytocin analogues with disulfide changes are synthesised by solid
phase protein synthesis (SPPS) techniques to contain desired functional groups),6,8–10 the
efficiency of the disulfide reduction was investigated initially. Two different routes were
investigated for the initial reduction of the disulfide bond in oxytocin resulting in the two
reactive sulfhydryl groups which can then be used for subsequent thiol targeted
conjugation reactions. The most commonly used reagent for the reduction of disulfide
bonds is the commercially available, water-soluble phosphine reagent tris(2-carboxyethyl)
phosphine (TCEP), which has previously been reported in many incidences for efficient
disulfide bond reductions (scheme 3.2).3
Scheme 3.2. Mechanism of TCEP disulfide bond reduction.
In the initial investigation an aqueous solution of oxytocin was treated with 1.5 equivalents
of TCEP at ambient temperature. After 2.5 hours the reaction was monitored by RP-HPLC
whereby there was a shift in retention time between the peptide (7.3 minutes) and the
reduced peptide (7.9 minutes), alongside the appearance of a distinct odour, characteristic
of thiol containing compounds. The reduction of the disulfide bond was then monitored
over time at three different temperatures, where reduction was much faster at 30 °C
(complete reduction after 2 hours) than 20 °C (within 4 hours), and at 10 °C complete
reduction was much slower (only 91.2 % reduction after 6 hours) (figure 3.1).
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Figure 3.1. RP-HPLC monitoring of oxytocin reduction with TCEP.
An alternative fast, efficient and mild method that can be used to reduce the disulfide
bond in peptides is through the use of metallic zinc in acidic solutions.11 The use of zinc
dust can offer some advantages over more traditional methods for reducing disulfide
bonds, including providing an inexpensive and less hazardous reagent than TCEP, and the
reagent can be removed by a simple work up procedure by centrifugation. Furthermore,
TCEP has previously been reported to react with maleimides, thus making efficient
conjugations after reduction of disulfide bonds more difficult.12–14
The disulfide bond of oxytocin (1 mg) was reduced with zinc dust (< 10 µm, 20 mg) in water
containing TFA (1 % v/v). After 60 minutes analysis by RP-HPLC revealed that complete
reduction could be obtained (figure 3.2). The reaction was worked up by centrifugation
(10,000 G, 5 minutes) after which the peptide solution could be easily removed from the
metal zinc pellet. When there was no acid added to the zinc reaction solution, no reduction
of the peptide disulfide bond could be observed by RP-HPLC. On visual inspection of the
two solutions, the zinc solution not containing any acid became cloudy, whereas for the
solution containing TFA, the zinc dust remained highly granular.
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Figure 3.2. Oxytocin disulfide bond reduction using zinc powder, with and without the additionof TFA additive, and images of the two solutions.
The use of zinc as a reducing agent provides a fast and efficient route to dithiol oxytocin;
although the addition of acid may lead to challenges if pH control is required for
conjugation. Therefore, the route commonly used for the reduction of the disulfide bond
of oxytocin throughout this chapter was by a reduction with TCEP, although having an
alternative route available is advantageous.
3.2.2. Maleimide linear PEG disulfide bridging
The utilisation of disubstitued N-functional maleimides (such as dibromo- or
dithiophenolmaleimide) for disulfide bridging addition of polymers to peptides is a
relatively new area within protein/peptide modifications. The ability of maleic acid imides
(maleimides) to react efficiently and completely with thiol groups, however, have been
well known for over 50 years.15 In that time the development of maleimides for site-
specific peptide conjugation has largely evolved, including for the attachment of polymers
to biomolecules (figure 3.3).
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Following on from the irreversible conjugations of maleimides, more recently
bromomaleimide reagents were developed, which first broached the concept of reversible
maleimide conjugation for cysteines.16,17 The introduction of dibromomaleimide (DBM)
reagents in 2010 was particularly beneficial, as this allowed rebridging of previously
reduced disulfide bonds in peptides and proteins, through which desired functionality
could also be introduced at the N substituent.17,18
Figure 3.3. Different ‘N’ Substituted maleimides developed over the last 60 years for proteinand peptide modification at cysteine residues.
3.2.2.1. Maleimide linear PEG synthesis
Previously within our group the preparation method for N- substituted dibromomaleimide
(or dithiophenolmaleimide) with desired functional groups was by using the Mitsonobu
reaction. These conditions involve the addition of triphenylphosphine, diisopropyl
azodicarboxylate and neopentyl alcohol, to 2,3 dibromomaleimide and the hydroxy
substituent to be incorporated, in dry conditions at – 78 °C. This resulted in very low yields
for the synthesis of N-PEG-dibromomaleimides (20 %), and several purification steps were
required, quite often with the PEG reagents retaining impurities.18 This synthesis route was
initially followed, and figure 3.4 outlines 1H NMR analysis of the crude reaction mixture and
after many purification steps, which shows only the expected PEG peaks. This method for
synthesis of the DTM-PEG does result in the polymers able to undergo bioconjugation, but
overall requires a long and intense purification procedure resulting in low yields.
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Figure 3.4. 1H NMR (CDCl3) of crude dibromomaleimide PEG and after purification (2 x columnchromatography, dialysis, 4 x precipitation) synthesised using Mitsonobu route.
Fortunately, in 2013 Caddick and Baker et al. reported a method for the relatively simple
functionalisation of dibromo- or dithiophenolmaleimides under mild conditions via N-
methoxycarbonylmaleimides.19 The formation of the N-methoxycarbonylmaleimide
reagent is simple and quick (less than 30 minutes), resulting in a pink powder in a high yield
without further purification required. From the N-methoxycarbonylmaleimide, the
addition of an amine allows the N-functionalisation on the maleimide reagent, and is
carried out at ambient temperature (scheme 3.3).
Scheme 3.3. Dithiophenolmaleimide/dibromomaleimide reagent synthesis.
PEG functional dibromomaleimide (DBM-PEG) was synthesised in a simple two step
procedure from commercially available 3,4-dibromomaleimide. Firstly N-methoxycarbonyl
activated dibromomaleimide was by synthesised by the reaction of 3,4-dibromomaleimide
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with methylchloroformate and N-methylmorpholine (NMM). This reaction is very efficient,
proceeding to completion within 30 minutes, with little work up or purification required,
resulting in a purple-pink powder. The activated dibromomaleimide is then able to
undergo a mild reaction with a range of amines at ambient temperature. In this case, α-
methoxy ω-amino PEG (5 kDa) was added and stirred at ambient temperature for 24 hours. 
The DBM PEG reagent was purified by precipitation, resulting in off-white powder in a high
yield (76 %). Figure 3.5 shows different steps in the reaction followed by 1H and 13C NMR.
Figure 3.5. 1H and 13C NMR of synthesis route of DBM PEG.
After the discovery of the ease and efficiency of reactions of dibromomaleimides with
thiols, such as on cysteine residues, including for disulfide bridging, Baker investigated this
further by employing alternative bis-substituted maleimide reagents.20
Dithiophenolmaleimides (DTM) are in some ways preferential to dibromomaleimides as
the reagents are less susceptible to side reactions (such as with TCEP), still maintaining
efficient couplings, and acting as disulfide bridging reagents. This also allowed the
incorporation of ‘in-situ’ protocols for more efficient bridging conjugations, where the
retention of cyclisation structure of the protein or peptide during the reaction is vital. This
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method can prevent side-reactions and structure unfolding by allowing immediate
disulfide bridging with the maleimide reagent.
In a similar manner to DBM functionalisation described, N-functional
dithiophenolmaleimides, such as N-PEG-dithiophenolmaleimide (DTM PEG), can be
synthesised using N-methoxycarbonyl activated dithiophenolmaleimide undergoing
reactions with different amine functional reagents (scheme 3.4). Dithiophenolmaleimide is
easily synthesised from dibromomaleimide by addition of thiophenol in the presence of
sodium acetate, resulting in nucleophilic displacement of the bromine atoms. The N-
methoxycarbonyldithiophenolmaleimide was synthesised in the same manner as the
dibromomaleimide analogue, resulting in an orange solid in a high yield. It was reported
that for the synthesis of N-functional dithiophenolmaleimides via the use of this N-
methoxycarbonyl activated reagent it can be beneficial to add silica, thereby maintaining
cyclisation.
Scheme 3.4. Reaction scheme of dithiophenolmaleimide reagent functionalisation.
The PEG functionalisation can clearly be observed after the final step in the synthesis of
the PEG reagent by 1H NMR (figure 3.6). The aromatic groups of the thiophenol
substituents on the maleimide can still be clearly identified, however, there is a
disappearance of the methoxycarbonyl group (δ = 3.9 ppm) and the appearance of new 
PEG peaks (δ = 3.3 - 3.7 ppm). This shows that the dithiophenolmaleimide has been 
functionalised to contain one linear (5 kDa) PEG chain for peptide-polymer modifications.
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Figure 3.6. 1H NMR (CDCl3) for final step in synthesis of N-PEG-dithiophenolmaleimide(reaction of N-methoxycarbonyldithiophenolmaleimide with PEG-amine).
3.2.2.2. Maleimide linear PEG conjugation
Upon conjugation the dithiophenol or dibromo groups from the maleimide PEGs are
substituted by the dithiol- peptide chain of oxytocin, which become covalently bonded
onto the maleimide PEG instead. This means that regardless of whether the dibromo or
dithiophenolmaleimide-PEG polymers are used, the resulting conjugate will have the same
structure (scheme 3.5).
Scheme 3.5. Disulfide bridging conjugation of oxytocin with linear maleimide PEG.
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After the disulfide bond of oxytocin had been completely reduced (as confirmed by RP-
HPLC), the DBM-PEG or DTM-PEG bridging reagent was added in pH 6.2 phosphate buffer
(100 mmol) and stirred at 10 °C for 24 hours. The reactions of dithiophenolmaleimide and
dibromomaleimide functional PEGS were monitored by RP-HPLC (figures 3.7 & 3.8). In both
reactions a shift in retention time of the major product was observed from the PEG
reagents, alongside the appearance of a coincidental fluorescence peak.
There are several impurities observed in both the DBM and DTM PEG reagents as well as in
the disulfide-bridging maleimide conjugate, although, in both cases, these are in small
amounts compared to the major products. Overall, there is a clear shift in retention time
for the major peak observed in both cases, with only one of the peaks in the conjugate
product showing a high level of fluorescence.
Figure 3.7. RP-HPLC of maleimide bridging conjugation of DBM PEG onto oxytocin.
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Figure 3.8. RP-HPLC of maleimide bridging conjugation of DTM PEG onto oxytocin.
As the products from the conjugation with dibromo- and dithiophenolmaleimide are
expected to give the same product, the RP-HPLC retention times should be precisely the
same. The major product for both reactions appears at the same retention time, which
shows a shift to shorter retention time than the maleimide reagent (for which each
maleimide reagent had a different retention time). An alternative HPLC gradient with a
more gradual decrease in aqueous content was used to confirm that the products were
eluting at the same retention time when the solvent gradient was elongated (figure 3.9).
This adds evidence that the disulfide bridging conjugation of the two different maleimide
reagents results in the same product. As with the conjugate observed for the standard
HPLC gradient, after purification the conjugation with DBM PEG is cleaner with less side
products than the conjugation with DTM.
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Figure 3.9. RP-HPLC chromatograms comparing DBM and DTM reagents used for disulfidebridging conjugation of oxytocin analysed under two different HPLC gradients.
When the dibromomaleimide PEG was inserted into the disulfide bond of oxytocin, an
obvious colour change was observed (figure 3.10). Solutions of dibromomaleimide PEG
reagent and the reduced native peptide were not coloured, however, rapidly after addition
of the two, a bright yellow colour could be observed.
Figure 3.10. Photographs showing colour change upon addition of DBM PEG to reducedoxytocin.
Additional to the change in colour, it has previously been observed that the UV shift for the
maleimide functionality changes to reflect the maleimide substituents.21 This can be
observed for the three different maleimide products investigated: dibromomaleimide PEG,
dithiophenolmaleimide PEG and PEG maleimide disulfide bridged oxytocin. Previous
studies have suggested that by UV-vis analysis dibromomaleimides absorb at
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approximately λ = 320 nm, with dithioalkylmaleimide (such as maleimide disulfide bridging 
peptide conjugates) at approximately λ = 390 nm.21 UV-vis analysis (between λ = 300 nm – 
600 nm) was undertaken for the two PEG reagents, and the peptide-polymer conjugate
synthesised from both cases. Both of the oxytocin conjugates revealed the same UV
response (λ = 380 nm), consistent with the λmax of previous dithioalkylmaleimides, with no
peaks apparent from the dibromo- or dithiophenol- reagents (figure 3.11). The
dibromomaleimide reagent has one peak at a smaller wavelength (λ = 321 nm), whilst the 
dithiophenolmaleimide reagent shows a major peak with an absorbance at a much higher
wavelength (λ = 432 nm). 
Figure 3.11. UV wavelength shifts of maleimide PEGs with different maleimide functionality.
Additional to providing a shift in the UV spectra of the maleimide functionality, the
utilisation of maleimide chemistry can induce fluorescence on the peptide structure due to
changing the nature of the maleimide substituents.22 This has previously been observed
when analysing the reaction by RP-HPLC equipped with both UV and fluorescence
detectors. To further investigate the fluorescence, measurements of the oxytocin polymer
conjugates and unconjugated polymers were analysed by a fluorescence
spectrophotometer (figure 3.12). The fluorescence excitation wavelengths were set to 314
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nm (the same λex used for RP-HPLC) and the fluorescence emission region monitored
between 400 – 650 nm. For the conjugation with DTM, the polymer exhibits negligible
fluorescence under these conditions, however, after peptide conjugation with DTM-PEG
fluorescence was increased 20 x (λem = 547 nm). This has previously been ascribed to the
fluorescence being quenched by the aromatic groups on the dithiophenolmaleimide
reagent.22 In the analysis of the dibromomaleimide polymer, the fluorescence spectra of
the polymer showed some evidence of fluorescence before conjugation onto the peptide.
This is possibly due to fluorescent impurities within the polymer, such as from undesired
nucleophilic substitution of the dibromomaleimide. Regardless, the fluorescence spectrum
after conjugation onto oxytocin is very similar to that observed for the DTM conjugation,
with one peak observed within the monitored region at λem = 535 nm.
Figure 3.12. Fluorescence spectra of DTM PEG, DBM PEG and maleimide disulfide bridged
oxytocin using an excitation wavelength (λex) of 314 nm.
The conjugation of dithiophenolmaleimide and dibromomaleimide linear PEGs onto
oxytocin provided an efficient route for the PEGylation and enhancement of the peptide
disulfide bond, which is prone to degradation. The conjugation can be characterised in a
number of different ways, allowing for easy monitoring of the reaction (table 3.1).
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Table 3.1. Overview of characterisation methods for maleimide enhanced PEGylation ofoxytocin.
Oxytocin DBM PEG DTM PEG Oxytocin-PEG
RP-HPLCRetention time 7.4 min 25.8 min 22.3 min 16.7 min
Colour Colourless Colourless Yellow Orange/Yellow
UV wavelength ~ 280 nm 321 nm 432 nm 380 nm
Fluorescence None (<500 nm) None Yes (535-550 nm)
3.2.3. α-Maleimide polyPEG
For the synthesis of comb polymers capable of undergoing post-polymerisation ‘grafting-
to’ conjugation, a suitable maleimide initiator must be synthesised, capable of facilitating
controlled polymerisations and available for subsequent peptide conjugation. It has
previously been established that dibromomaleimide functionality can disrupt the
polymerisation characteristics of copper mediated controlled radical polymerisations, as
observed by Jones et al. for polymerisations using ATRP conditions.18
Dithiophenolmaleimide alkyl halide initiators have, however, previously proven ‘radical
compatible’ and were utilised for the synthesis of poly(poly(ethylene glycol) methyl ether
methacrylate) (poly(mPEGMA)) under the same conditions which were unsuccessful for
the bromo- substituted maleimide (ATRP, 60 °C, toluene, Cu(I)/pyridine imine catalyst).23
This allowed the direct incorporation of α-end dithiophenolmaleimide functionality 
without disrupting the polymerisation. This results in a simple synthesis and peptide
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modification of disubstituted maleimide functional polymers without the requirement for
any post-polymerisation modifications.
For the maleimide bridging of polyPEGs described in this chapter, a dithiophenolmaleimide
initiator was synthesised that was similar to the ATRP initiator described for efficient
copper mediated polymerisations by Jones et al..23 This was achieved using the relatively
simple functionalisation method described for the synthesis of linear PEG maleimide
reagents, via the use of N-methoxycarbonylmaleimides. Using N-
methoxycarboxydithiophenolmaleimide, the addition of propargylamine allowed the
introduction of alkyne functionality onto the maleimide, as described previously.19 The
incorporation of alkyne functionality onto the maleimide results in an easily modifiable
group, and this was used to attach an azide functional alkyl halide initiator by CuAAC
chemistry, resulting in the dithiophenolmaleimide initiator (figure 3.13). This initiator is
suitable for undergoing copper mediated polymerisations and for subsequent post-
polymerisation disulfide bridging within a peptide.
Figure 3.13. 1H & 13C NMR (CDCl3) of dithiophenolmaleimide alkyl halide initiator.
During 2012, Haddleton et al. reported a new approach for the Cu(0) mediated
polymerisation as an alternative to the Cu(0) wire method described in the previous
chapter.24 This has allowed for controlled polymerisations to be achieved in aqueous
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solutions24–26 as well as the utilisation of other solvents including; phosphate buffer,24
blood serum27 and commercial mixed water-alcohol systems.28 This utilises an initial rapid
disproportionation step wherein Cu(I)Br is allowed to disproportionate in the presence of
an N containing ligand (Me6TREN), producing both Cu(0) particles and CuBr2 as the catalyst
system prior to the addition of deoxygenated monomer and initiator. Controlled
polymerisations have been achieved for acrylates and acrylamides, and more recently
methacrylates,29,30 with full conversions reported within 30 minutes at temperatures less
than 25 °C, with resulting dispersities reported in many cases of < Ð = 1.1.
Due to the aromatic nature of the dithiophenolmaleimide initiator it is not soluble in
aqueous solutions, therefore a cosolvent mixture is required for efficient polymerisations
to occur whilst still utilising the full disproportionation of Cu(I)Br in water with Me6TREN
into Cu(II)Br2 and Cu(0). The total disproportionation achieved is greatly affected by the
addition of co-solvents, and this was investigated by Haddleton and co-workers for a
variety of polar organic solvents.31 In the tested solvents, methanol reached the highest
disproportionation (66 % of [Cu(L)]Br into Cu(0) and [Cu(L)]Br2), and for DMSO (a popular
solvent for organic Cu(0) mediated polymerisation) disproportionation was much lower (~
30 %). Therefore in order to maintain ideal disproportionation characteristics it is essential
to maintain water as the solvent for the initial step wherein Cu(0) and [Cu(L)]Br2 are
generated from [Cu(L)]Br. There is, however, scope to change the solution containing the
monomer and initiator before injection into the post-disproportionation generated catalyst
solution. This would thereby change the overall water content of the polymerisation, but
only after total disproportionation had already occurred.
Solubility studies on the dithiophenolmaleimide initiator found that it was soluble in
DMSO-water solutions up to 25 % aqueous content. The aqueous polymerisation system
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conditions were adapted to reflect these changes. It was however, predicted that the
addition of DMSO was expected to have an adverse effect on the polymerisation control.
To investigate whether this was a viable solvent system for performing the polymerisation,
an investigation was carried out using a water soluble initiator (WSI), changing the % of
DMSO present in the reaction (table 3.2). The polymerisations of poly(ethylene glycol)
methyl ether acrylate (av. Mn = 480 g mol-1, mPEGA480) were carried out using Cu(I)Br, and
Tris[2-(dimethylamino)ethyl]amine (Me6TREN) as ligand ([I]:[M]:[Me6TREN]:[CuBr] =
1:20:0.4:0.4) (scheme 3.6). The reaction was stirred under nitrogen and a sample was
removed after 24 hours for 1H NMR (D2O) and SEC (DMF) analysis. For all reactions the
disproportionation of Cu(I)Br was always carried out in an 100 % aqueous solution
followed by addition of the initiator and monomer in solutions containing the co-solvent
(DMSO).
Scheme 3.6. Polymerisation of mPEGA480 with water soluble initiator using[M]:[I]:[CuBr]:[Me6TREN] = 1:20:0.4:0.4 in DMSO/Water.
Table 3.2. Polymerisation data for the synthesis of poly(mPEGA480)20 using water solubleinitiator with different DMSO/water content.
Water content (%) Conversion (%) (NMR) Mn (Da) (SEC) Ð (SEC)
100 >99 12500 1.30
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50 >99 11200 1.12
33 >99 11800 1.30
20 99 11600 1.08
The results showed that in this co-solvent mixture the polymerisation remained viable for
different DMSO concentrations in water including up to 80 % organic content (figure 3.14).
A sample was removed after 24 hours, which revealed that for the highest organic content
almost quantitative conversion had been achieved. Analysis by SEC revealed that the
dispersities of polymers remained narrow (Ð = 1.08) with a mono-modal chromatogram
and good correlation between experimental and theoretical molecular weights.
Figure 3.14. SEC (DMF) analysis for synthesis of poly(mPEGA)20 in different solventcombinations and 1H NMR (D2O) analysis of polymer synthesised in 80 % DMSO (99 % conv.,Mn: 11600, Ð: 1.08) with an expansion of the vinyl peaks showing disappearance of monomer.
Solubility studies on the dithiophenolmaleimide initiator showed that it remained in
solution at DMSO content above 75 %, confirming that the 80 % DMSO (20 % aqueous)
conditions evaluated are relevant for the synthesis of desired α-end functional polymers. 
Following on from the results with an initiator soluble in both solvents, a test
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polymerisation was conducted using solvent conditions of 80 % DMSO in water with a non-
water soluble initiator (ethyl-2-bromoisobutyrate: EBiB) exhibiting similar aqueous
solubility to the desired dithiophenolmaleimide initiator (scheme 3.7). Two different sizes
of polymers were synthesised using [M]:[I] of 20 & 100 giving predicted molecular weights
of 10 kDa and 50 kDa (table 3.3).
Scheme 3.7. Polymerisation of mPEGA480 with EBiB using [M]:[I]:[CuBr]:[Me6TREN] =1:20/100:0.4:0.4 in DMSO:Water (4:1).
Table 3.3. Polymerisation data from synthesis of poly(mPEGA480)n using EBiB
[M]:[I] Conversion (%)
(NMR)
Mn (Da)
(SEC)
Ð
(SEC)
Solubility
20 94 12200 1.06 Miscible
100 98 36600 1.25 Immiscible
An interesting observation for the higher molecular weight polymer was the phase
separation/polymer precipitation of the larger molecular weight polymer under these
conditions (figure 3.15). This led to the appearance of a clear blue solution as the top layer
and a colourless bottom layer. This is particularly interesting as polymerisations of mPEGA
do not show this behaviour if the polymerisation is carried out in either a purely aqueous
or purely DMSO based system.
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Figure 3.15. SEC chromatograms for synthesis of EBiB-poly(mPEGA)s with accompanying highconversion NMR, and photograph of polymer phase separation.
After 24 hours the polymerisations had reached high conversions whilst retaining narrow
mono-modal molecular weight distributions (Ð < 1.3). This is particularly notable for the
phase-separated polymers, as controlled polymerisation was achieved even when the
polymer was no longer soluble in the solvent combination used.
These results (using two different initiators) show that it was possible to synthesise
controlled polymers using the disproportionation of Cu(I)Br in water, with the addition of a
non-disproportionating solvent after generation of the catalyst system. This is promising in
providing information towards what might be expected during the polymerisation when an
initiator for direct post-polymerisation peptide modification is used (such as the
dithiophenolmaleimide initiator previously described).
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3.2.3.1. Synthesis of α-dithiophenolmaleimide polymers
The polymerisation was subsequently carried out for the synthesis of α-
dithiophenolmaleimide functional poly(mPEGA480) polymers using Cu(I)Br with Me6TREN in
water: DMSO (1:4), using ([I]:[CuBr]:[Me6TREN] = 1:0.4:0.4) (scheme 3.8). Molecular
weights were targeting 10 kDa (DPn 20), 25 kDa (DPn 50) and 50 kDa (DPn 100). Cu(I)Br was
first allowed to fully disproportionate in water before the addition of a degassed
monomer/initiator solution in DMSO.
Scheme 3.8. Polymerisation of mPEGA480 with dithiophenolmaleimide initiator using[M]:[I]:[CuBr]:[Me6TREN] = 1:n:0.4:0.4 in DMSO:Water (4:1).
Table 3.4. Polymerisation data for synthesis of poly(mPEGA480) using DTM initiator.
[M]:[I] Conversion (%)
(NMR)
Mn (Da)
(SEC)
Ð
(SEC)
Solubility
20 90 11600 1.20 Miscible
50 96 22300 1.25 Immiscible
100 97 36000 1.36 Immiscible
Aliquots were removed from the polymerisation solution after 24 hours for 1H NMR (D2O)
conversion and SEC (DMF) molecular weight data (table 3.4). The polymerisation
conversion was calculated by a comparison between the vinyl protons of the monomer
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and the CH2 next to the ester of the PEG repeat unit. This revealed that within 24 hours
high conversions (> 90 %) had been achieved for all three polymers.
SEC analysis showed that the polymers still retained low dispersities, although as
molecular weight increased the presence of high molecular weight peak tailing was
observed. This has previously been ascribed to trace impurities of diacrylate within the
monomer reagent.30,32 As observed for the polymerisation with EBiB, the molecular
weights observed from SEC deviate from the theoretical molecular weights as the DPn
increases. This is most likely due to the SEC calibration being relative to narrow PMMA
standards and the difference between the hydrodynamic volume of these poly(mPEGA)
‘combs’ and the calibration standards. Another notable point for the synthesis of these
dithiophenolmaleimide functional polymers is that due to the nature of the α-end group, 
the polymers are highly UV active, and the UV response on SEC is highly prominent. The RI
and UV responses overlay, showing that the DTM functionality is still present on the
polymer (figure 3.16).
Figure 3.16. SEC analysis of DPn 20, 50 and 100 DTM-poly(mPEGA480)20 and RI/UV overlay ofSEC chromatogram.
As with the previous polymerisations using EBiB under the same solvent conditions, phase
separation/polymer precipitation was observed, although due to the distinct colour of the
polymer the phenomena was more highly visible (figure 3.17). The top layer was a clear
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green solution, suggesting that it did not contain any of the dithiophenolmaleimide
functional polymer (by 1H NMR), as this has a distinct orange colour. This suggests that this
layer contains a large proportion of the catalyst system, which if true would simplify
polymer purification. The bottom layer was bright orange colour suggesting the polymer
solution was present in this layer.
Figure 3.17. Photographs showing the phase separation during polymerisation of DPn 50 or
DPn 100 poly(mPEGA480) in DMSO:Water (4:1).
The two layers were separated and 1H NMR was carried out which revealed that, although
both layers contained residual monomer, only the bottom orange layer contained any
polymer (figure 3.18). This was established by the presence of dithiophenolmaleimide
groups with peaks at 7.1 – 7.4 ppm corresponding to the aromatic phenol groups, and a
peak at 8.0 ppm from the triazole ring within the initiator. The top layer also did not show
the presence of the polymer backbone peaks found for acrylate functional polymers (δ = 
1.5 – 2.5 ppm), or the broad peak of the first CH2 from the PEG of the monomer repeat unit
on the polymer (δ = 4.2 ppm), although this peak can still be observed within the 
unreacted monomer.
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Figure 3.18. Comparison of 1H NMR (400.13 MHz, δ6-DMSO) individually measured of top andbottom layer within polymerisation, with an expansion of the vinyl/aromatic regions.
The polymers were purified by dialysis against water (for DPn 50 and DPn 100 polymers only
the bottom, polymer containing, layer needed to be purified) yielding three α-
dithiophenolmaleimide functional polymers, with molecular weights between 10 - 50 kDa.
The purified polymers were characterised by 1H NMR (δ6-DMSO), where the presence of
the aromatic groups on the dithiophenolmaleimide α-end groups are evident at δ = 7 – 7.5 
ppm, signifying that the polymers still contains functionality capable of undergoing
disulfide bridging conjugation (figure 3.19). From the NMR spectra the experimental
molecular weights of polymers could be calculated by a correlation between the 6 protons
of the isopropyl group from the initiator (δ = 1.0 ppm) and the CH2 peak next to the ester
on the PEG repeat unit (δ = 4.2 ppm). This gave experimental degrees of polymerisation of 
25, 65 & 114, compared to the theoretical values of 20, 50 and 100, implying that the
initiator efficiency was ~ 80 – 90 %.
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Figure 3.19. Assigned 1H NMR (D2O) of DTM – poly(mPEGA480)20 after purification.
The DPn 100 purified polymer was further tested for solubility in water, DMSO and
combinations of the two and found to be fully soluble in completely aqueous or DMSO
systems. When the water % was below 45 % the polymer was no longer soluble, although
solubility was again achieved at less than 15 % aqueous content. The interesting solubility
properties of these polymers and synthesis within this narrow region of insolubility mean
that initial purification of the polymers can be achieved by simple decantation of the
reaction mixture. This results in removal of a significant proportion of polymerisation
solution impurities including the catalyst system, although after separation the polymer
layer still contains a small amount of unreacted monomer.
3.2.3.2. Conjugation of α-dithiophenolmaleimide polymers
The same conjugation reactions as undertaken with the linear dibromo- and
dithiophenolmaleimide PEGs were undertaken with the α-dithiophenolmaleimide 
poly(mPEGA480)s onto oxytocin (scheme 3.9). The disulfide bond was first reduced using
TCEP, before addition of the polymers in pH 6.2 buffer and monitoring by RP-HPLC.
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Scheme 3.9. Conjugation of dithiophenolmaleimide poly(mPEGA) with reduced oxytocin.
The ‘normal’ conjugation route with purified dithiophenolmaleimide polymers proceeded
as observed for the linear conjugations. There is a retention time shift for the majority of
the broad polymer peak after conjugation alongside the appearance of a coincidental
fluorescence signal for the conjugate, not observed in the polymer (figure 3.20).
Additionally, there is the appearance of a sharp peak at retention time t = 25.3 minutes,
which represents the thiophenol lost during the conjugation/substitution reaction.
Figure 3.20. RP-HPLC analysis of DTM poly(mPEGA) conjugation onto oxytocin by UV andFLD.
It was speculated that due to specific nature of the maleimide conjugation group and high
efficiency of the conjugation reaction, that the conjugation could be conducted without
prior purification of the polymer. This results in an ‘in-situ’ method for the disulfide
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bridging conjugation of oxytocin, where only one purification step is required for the final
conjugate product.
For the ‘in-situ’ conjugation of the dithiophenolmaleimide polymers onto oxytocin, the
same initial conjugation process was used, whereby the disulfide bond of oxytocin was
reduced using TCEP (1.5 eq) generating the two free cysteine residues. Conjugation was
then performed by direct addition of an aliquot of the polymerisation solution (for the
phase separated solutions this was added as a mixture of the two layers). After stirring
overnight the reaction was analysed by RP-HPLC, which revealed a shift in retention time
from the dithiophenolmaleimide polymer, with the appearance of coincidental
fluorescence (figure 3.21). All other minor peaks observed on RP-HPLC are attributed to
impurities also observed in the polymerisation solution, except the sharp peak appearing
at retention time t = 25.4 minutes which corresponds to the thiophenol released from the
polymer during conjugation. Overall the HPLC chromatograms from the ‘in-situ’ method
are in good agreement with the ‘standard’ conjugation, suggesting the presence of
additional impurities does not prevent conjugation occurring.
Figure 3.21. RP-HPLC of ‘in-situ’ conjugation of DTM polymers onto oxytocin.
The oxytocin-polymer conjugates of the three polymers synthesised in this manner
underwent further characterisation after purification by dialysis against water (3.5 kDa
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MWCO, 3 days). This removed all impurities observed in the polymerisation solution,
resulting in conjugates that were similar to those of the ‘standard’ conjugation with
purification of a functional polymer. This shows that the exclusion of this purification step
has no apparent negative effect on peptide-polymer conjugate formation (figure 3.22).
Figure 3.22. RP-HPLC analysis of purified oxytocin conjugates showing change in retentiontime from DTM poly(mPEGA), and newly observed fluorescence.
Analysis of the polymer and conjugate by UV confirmed that, in a similar manner to that
observed during the linear PEG disulfide bridging conjugation, the wavelength for the
maleimide functionality had shifted. In this case (DPn 100 polyPEG conjugate) the λmax for
the maleimide unit changed from 424 nm, when the polymer was end capped with two
thiophenol groups, to 377 nm when the polymer was instead substituted with the peptide
alkyl chain (figure 3.23). These wavelengths are very similar to the linear N-PEG-
dithiophenolmaleimide and oxytocin conjugate, and previously reported
dithioalkylmaleimide absorbance.21 Overall, the maleimide functionality remains very
similar, as reflected by the UV λmax results, however, the N- attachment functionality (in
this case the polymer architecture) has been changed.
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Figure 3.23. UV monitoring of oxytocin, DTM polymer and disulfide bridged oxytocinpoly(mPEGA) conjugate for shift in maleimide functionality.
Fluorescence spectroscopy studies were also carried out to investigate the change of
fluorescence spectra upon conjugation.22 From RP-HPLC it was known that the polymer
does not exhibit fluorescence pre-conjugation, but that a new fluorescence peak appears
after conjugation has occurred. This was investigated for both the smallest (DPn 20) and
largest (DPn 100) polymers and their respective conjugates (figure 3.24). Fluorescence
studies were conducted on samples at a concentration of 5 mg ml-1 using λex = 341 nm (the
same as λex from RP-HPLC), with an analysis of the fluorescence spectra between 400 – 650
nm.
Figure 3.24. Fluorescence study of DTM polymers and oxytocin-polymer conjugates, showingan increase in fluorescence.
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These two fluorescence measurements show a large increase in the fluorescence after
conjugation for the two different molecular weight polymers conjugated. The emission
wavelength (λem), as expected, was approximately the same for both conjugates. The
induction of fluorescence on the peptide structure occurring gives another convenient
characterisation handle.
3.2.3.3. Reversibility of dithiophenolmaleimide disulfide
bridging
Previous research has found that a large excess of thiols (such as mercaptoethanol) can
induce the cleavage of thiol-maleimide linkages via thiol exchange, thereby changing the
nature of the thiol groups attached to the maleimide.16,17 This thiol exchange can therefore
be utilised for the release of dithiol- functional maleimides that are conjugated onto
peptides or proteins. This in effect changes the thio- functionality of the maleimide
polymer with that of the desired thiol, releasing the peptide, which, in the case of oxytocin,
can allow for reformation of the disulfide bond.
To investigate the reversibility of dithiophenolmaleimide conjugation under biologically
relevant conditions, reversibility studies were carried out using an excess of glutathione
(GSH) (scheme 3.10). Glutathione is a small tripeptide containing a cysteine group (source
of the thiol) between glutamate and glycine residues. GSH is already well known for
reducing disulfide bonds and exists in the cytoplasm of healthy animal cells at
concentrations of 0.2 – 10 mM.33 GSH has also been used previously as an example of a
thiol that is capable of reversing maleimide conjugations, and is of particular biological
relevance for potential cytoplasm based cleavage.17,34–36 In the case of the reversal of
oxytocin conjugation, GSH has been used as a model small thiol, and similar thiol
exchanges could be performed with different compounds to suit requirements.
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Scheme 3.10. Glutathione induced reversal of oxytocin poly(mPEGA) conjugation, releasing thenative peptide.
To a solution of the DPn 20 oxytocin polymer conjugate was added an excess of glutathione
equivalent to 6 mM (in the bio-relevant cell concentration range). The reaction was
sampled after 4 days and analysis by RP-HPLC revealed the appearance of a sharp peak
appearing in a coincidental position to that of the native peptide (figure 3.25). There was
also a shift in retention time for the broad fluorescent peak, which is attributable to the
formation of the double glutathione substituted maleimide polymer. This polymer retains
its fluorescence as, although the substituent has changed from oxytocin to glutathione, the
dithiolalkylmaleimide unit is still present with two alkyl thio- substituents.22
Figure 3.25. RP-HPLC trace of GSH reversal of conjugation with expansion of oxytocin region,showing the regeneration of the native peptide.
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The sharp peak (coincidental to native oxytocin observed on the RP-HPLC chromatogram)
was separated and collected by RP-HPLC, before MALDI-TOF analysis was undertaken. This
confirmed that the native peptide was being released from the polymer conjugate with the
appearance of one major mass corresponding to the native peptide at [M+Na+] = 1029.6
(difference of 0.16 Da) (figure 3.26).
Figure 3.26. MALDI-TOF analysis of released oxytocin from oxytocin-(mPEGA480)20 polymerconjugate.
Overall, the dithiophenolmaleimide chemistry provides an interesting route for the
PEGylation of oxytocin, whether in the utilisation of linear or ‘comb’ polyPEG polymers.
The resulting conjugates can be characterised by several different methods, with the
induction of fluorescence post-conjugation providing a particularly convenient handle. For
oxytocin, the disulfide bridging by maleimides is particularly convenient as this is one of
the major degradation sites for the peptide.
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3.2.4. Reduced structure targeting (thiol-ene)
Another reaction that becomes highly accessible with the reduction of the disulfide bond
releasing the two sulfhydryl groups is the reaction between the resultant thiols and an
unsaturated double bond. The reactions of thiols with unsaturated carbon-carbon bonds
are well known, and commonly referred to as thiol-ene (reaction with a double bond) or
thiol-yne (reaction with a triple bond) reactions.37–39 Thiol-ene reactions can be promoted
by different chemical processes, commonly utilised from light and/or initiator induced
radical-based additions or nucleophilic promoted reactions, and have previously been
utilised for protein/peptide modification strategies from these different routes.40–42
Jones et al. reported the phosphine promoted Michael-type addition of mPEGA (the same
reagent described previously as a monomer for polymerisations) for the double
functionalisation of the reduced disulfide bond in salmon calcitonin (a 32 amino acid
peptide).43 After reduction of the singular disulfide bond on the peptide, two separate
thiols are made available that can both react with the unsaturated double bond. This
system was expanded utilising a vinyl functional alkyl halide initiator for the synthesis of
peptide macroinitiator and subsequent ‘grafting-from’ polymerisation as an alternative
peptide modification approach.44 The reaction proceeds via a thiol-Michael addition
promoted by TCEP (phosphines have previously proven efficient for promoting thiol-ene
chemistry of acrylates) (scheme 3.11).45 TCEP is a particularly good catalyst for use in the
conjugation of vinyl functional polymers to a previously reduced disulfide bond due to
providing the initial reduction of the peptide/protein as well as acting as a catalyst for the
conjugation.
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Scheme 3.11. Mechanism of phosphine induced thiol-ene Michael addition of (meth)acrylates.
For the previously described conjugation of mPEGA onto salmon calcitonin, the activity of
the peptide was retained.43 This could in part be due to the structure of this peptide being
retained even after reduction of the disulfide bond, due to the presence of additional
peptide structure stability via an α-helix. With oxytocin, there are no secondary structural 
features within the peptide, and the conjugation of polymers in this manner would remove
cyclisation of the peptide. It is highly likely that the peptide will no longer maintain
biological function and activity, but instead allows the synthesis of an ABA triblock
copolymer, wherein the middle block is a peptide (figure 3.27). The peptide content of the
triblock can be altered by changing the length of the polymer (A) blocks. Although less
practical in the sense of synthesising polymer containing oxytocin analogues, this method
of polymer conjugation still presents an interesting methodology for the concurrent
attachment of two polymer chains to the peptide.
Figure 3.27. ABA triblock polymer, containing central peptide block from oxytocin.
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3.2.4.1. Linear PEG acrylate
Michael addition chemistry was utilised for the conjugation of two PEG chains onto each
free thiol in oxytocin following reduction of the disulfide bond. An easily accessible and low
cost source of α, β –unsaturated PEG chains is through the use of commercially available 
PEG acrylates. Three different molecular weights of poly(ethylene glycol) methyl ether
acrylate polymers (Mn = 480, 2,000, 5,000) were used for conjugation to reduced oxytocin
via phosphine mediated thiol-ene chemistry (scheme 3.12). This would yield the twice
PEGylated oxytocin, whereby the molecular weight of the conjugate was expected to
increase to 2000, 5,000 and 10,000 Da respectively.
TCEP was selected preferentially over zinc for the reduction of the disulfide bond in this
case, as it can reduce the disulfide bond in the first step and act as a catalyst in the
subsequent thiol-ene PEGylation. The disulfide bond in oxytocin was firstly treated with 2
equivalents of TCEP and a sample removed after 2.5 hours for RP-HPLC analysis confirmed
complete reduction to dithiol oxytocin with a shift in retention time from the native
peptide. The acrylate polymers were dissolved in phosphate buffer (pH 6.5, 100 mM) and
added to the reduced peptide and left to stir overnight.
Scheme 3.12. Double conjugation of mPEG acrylate onto oxytocin of different molecular weightusing TCEP as a disulfide bond reduction agent and thiol-ene catalyst.
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The conjugation reaction and reagents were analysed by RP-HPLC. For the mPEGA480
reagent a multimodal distribution was evident which was also present in the unpurified
conjugate mixture (figure 3.28). This is likely due to the different lengths chains within the
mPEGA monomer. After conjugation there is a dramatic reduction in the concentration of
oxytocin remaining in solution and the appearance of a broad conjugate peak at a higher
retention time (t = 13.4 minutes) than either of the reagents.
Figure 3.28. RP-HPLC of conjugation of (mPEGA480)2 onto oxytocin through phosphinecatalysed thiol-ene Michael addition.
Subsequently the conjugate was purified by semi-preparative RP-HPLC and analysed by
MALDI-TOF MS for confirmation that the peptide had undergone two separate
conjugations with the acrylate functional PEG polymer (figure 3.29). The MALDI-TOF
spectrum revealed the presence of a singular distribution, with a relatively small dispersity
of products relating to the doubly conjugated peptide. Each peak is attributable to a
different value of n within the PEG polymer, with differences in peaks equivalent to the
ethylene glycol repeat unit (44.03 Da). There is no evidence of any monosubstituted
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PEGylation product, which would be present at approx. 1500 Da, which could have arisen if
only one of the cysteine thiols had undergone the thiol-ene reaction with the acrylate PEG.
Figure 3.29. MALDI-TOF analysis of oxytocin-(mPEG480)2 conjugate.
Analysis of the two larger molecular weight polymer reagents (mPEGA2000 and mPEGA5000)
did not reveal the presence of any polymer peaks, or multimodal distributions (figure
3.30). Alternatively a sharp peak was observed at retention time t = 14.9 minutes in both
cases. The PEG acrylates are often utilised conventionally as PEG monomers and as such
contain inhibitors to prevent auto-polymerisation. The inhibitor added to both of these
reagents was 4-Methoxyphenol (MEHQ), and it is likely that this is what is observed in the
RP-HPLC chromatogram. On analysis of the two conjugation reaction mixtures, this sharp
peak can still be observed, alongside the formation of new peaks, highlighting successful
peptide-polymer conjugation.
The 2 kDa conjugate peak appears as mostly one single moiety (retention time t = 19.3
minutes), although there is evidence of a minor peak at a slightly lower retention time (t =
17.8 minutes). This suggests the formation of one major conjugate product. For the 5 kDa
conjugation there is, however, the clear presence of a bimodal peak (maxima at t = 19.9 &
20.3 minutes). This suggests that there are two products formed during the reaction and
that these are in an approximate 50:50 ratio.
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Figure 3.30. RP-HPLC monitoring of conjugation of mPEGA (2 kDa and 5 kDa) onto reducedoxytocin via phosphine catalysed thiol-ene Michael addition.
The conjugates were purified by dialysis against water (3,500 MWCO, 3 days), for further
analysis and confirmation of the disubstituted product. On analysis of the 2kDa conjugate
by MALDI-TOF MS, the presence of a singular distribution relating to the doubly conjugated
peptide was observed (figure 3.31). There is good agreement between the calculated
(theoretical) values and those achieved experimentally, with peak spacing representing the
repeat unit appropriately. Further inspection of the area in the MALDI-TOF spectra where
the mono-substituted PEGylation product would be present (≈ 3,000 Da) reveals some 
possible peaks with a higher intensity than the baseline. However, these are in such low
concentration compared to the major distribution that it would imply mono-substitution
occurs to a much smaller degree than di-substitution.
Figure 3.31. MALDI-TOF analysis of oxytocin-(mPEG2000)2 conjugate.
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MALDI-TOF analysis was not achieved for the 5 kDa oxytocin thiol-ene conjugate. It is likely
that the double peak observed on the RP-HPLC chromatogram was showing evidence of
the occurrence of singular substitution during the reaction. The MALDI-TOF spectrum of
the 2 kDa conjugate suggests that this is a possibility. As this has been observed to a small
degree for the 2 kDa conjugate and not within the 480 Da conjugated mPEGA it is likely
that the size of the polymer plays an important role in the efficiency of the double
conjugation.
Overall these results have shown that it is possible to conjugate linear PEG onto oxytocin
utilising a phosphine induced thiol-ene Michael addition one-pot process. Three different
molecular weights of polymer-conjugates were synthesised, and characterisation by
MALDI-TOF MS suggests that the site-selective double attachment of polymers was
achieved. The range of molecular weights of the conjugates (and % of oxytocin in the
resulting triblock) varies from 2 k Da (50 % oxytocin) to 11 kDa (9 %) oxytocin.
3.2.4.2. PolyPEG acrylate vinyl end group
Following the successful conjugation of acrylate functional linear PEGs onto oxytocin using
different molar masses of a PEG acrylate reagent, investigative studies have been
undertaken into whether analogous reactions would be possible with the use of a polyPEG
reagent. A vinyl end functional polyPEG was synthesised within our group by catalytic chain
transfer polymerisation (CCTP), promoted by a cobalt catalyst. This is a free-radical
polymerisation technique that uses cobalt macrocycles as catalytic chain transfer agents,
and is useful for synthesising polymers with unsaturated double bond end groups, which
can be utilised for post-polymerisation modifications. Vinyl end functional polymers
synthesised by CCTP have previously been modified utilising thiol-ene Michael addition
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resulting in changes to the thermal properties46 for the functionalisation of
glycopolymers47 and for the modification of biological surfaces.48
The vinyl end group functionality of the polymers was confirmed by 1H NMR, and a
comparison of vinyl peaks and the CH2 peaks next to the ester in the PEG repeat unit were
used to calculate the experimental molecular weight of 11.5 kDa (figure 3.32).
Figure 3.32. 1H NMR (MeOD) of vinyl functional poly(mPEGMA)
A test reaction was conducted in the same manner as for the conjugation with the
different linear PEG acrylates, using TCEP as both a reducing agent and as a catalyst for the
two concurrent reactions with the sulfhydryl groups. The reactions were much slower, but
RP-HPLC monitoring after several days revealed the formation of a broad peak, possibly
signifying conjugate formation (figure 3.33). The vinyl end functional polymer, when
analysed by RP-HPLC, did not show any peaks with high absorbance (max peak absorbance
0.5 mAU), even at concentrations up to 20 mg/ml. For the reaction mixture the peak area
of the broad peak is 5 x that of the remaining oxytocin in solution, and unlikely to be from
unreacted polymer, but potentially arising from the desired peptide-polymer conjugation.
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Figure 3.33. RP-HPLC of conjugation vinyl end functional poly(mPEGMA) onto oxytocin.
This initial investigation into the conjugation of polyPEGs onto oxytocin by this method is
promising, highlighting an alternative method for polymer conjugation onto oxytocin, and
warrants further investigation.
3.3. Chapter 3 Conclusions
There are several methods available for conjugation onto the thiols within peptides and
proteins, either at cysteine residues within the structure or from the reduction of a
disulfide bond. This can be advantageous compared to amino strategies, as there are likely
to be less sulfhydryls available on the peptide or protein structure, allowing a more site
specific conjugation.
Two of such approaches have been discussed which lead to the rebridging of the disulfide
bond, or the complete removal of cyclic structure. For each strategy linear and polyPEGs
can be conjugated as long as the correct conjugatable functionality is retained on the end
of the polymer.
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The conjugation of polymers at the disulfide bond, particularly by rebridging the disulfide is
beneficial as this position is the cause of a large amount of the degradation observed for
the native peptide. Whilst not explicitly discussed in this thesis, there are many other
disulfide/single cysteine conjugation methods available which could also prove feasible as
conjugation methods for the polymeric functionalisation of oxytocin.
3.4. Experimental
3.4.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received. Tris(2-carboxyethyl) phosphine
(TCEP) was purchased from Sigma Aldrich and stored at -18 °C. α-Methoxy ω-amino 
poly(ethylene glycol) was purchased from Rapp Polymere and stored at – 18 °C.
Poly(ethylene glycol) methyl ether acrylate (average Mn: 480; containing 100 ppm BHT &
100 ppm MEHQ as inhibitors) was purchased from Sigma Aldrich and stored at 4 °C.
Poly(ethylene glycol) methyl ether acrylate (average Mn: 2,000 Da/5,000 Da ; containing
MEHQ as inhibitor) was purchased from Sigma Aldrich and stored at -18 °C. Vinyl end
functional poly(poly(ethylene glycol) methyl ether methacrylate) was synthesised within
the Haddleton group by Mr Samuel Lowe. Copper (I) Bromide (CuIBr, Sigma Aldrich, 98 %)
was purified according to the method of Keller. N,N,N′,N′,N″,N″-Hexamethyl-
[tris(aminoethyl)amine] (Me6-TREN) was synthesised according to a reported procedure
and stored at -18 °C prior to use. All other reagents were purchased from Sigma Aldrich
and used without further purification.
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3.4.2. Instrumentation & Analysis
Nuclear magnetic resonance (NMR) spectra were acquired with a Bruker DPX-300 or DPX-
400 spectrometer with samples prepared in deuterated solvents (CDCl3 , MeOD or D2O).
Chemical shifts were reported in parts per million (ppm) with reference to solvent residual
peaks.
Size exclusion chromatography (SEC) was performed on either 1) Agilent Polymer
Laboratories GPC50 eluting with DMF (0.1 w/v % LiBr) at 50 °C, 1 ml min-1 flow rate, fitted
with differential refractive index and UV detectors, 2 x PLgel 5 mm Polargel M columns
(300 x 7.5 mm), 1 x Polargel 5 mm guard column (50 x 7.5 mm) and autosampler; 2) Varian
390-LC system using DMF (5 mM NH4BH4) eluent at 50 °C, 1 ml min-1 flow rate, equipped
with RI, UV, light scattering and viscometry detectors, 2 x PLgel 5 µm mixed D columns
(300 x 7.5 mm), 1 x PLgel 5 µm guard column (50 x 7.5 mm) and autosampler.
UV/Vis spectra were recorded on an Agilent Technologies Cary 60 UV-Vis using a quartz
cuvette with 10 mm optical length within the range 200 nm – 600 nm, calibrated using
water as a blank solution.
Fluorescence studies were carried out on an Agilent Cary Eclipse Fluorescence
spectrophotometer using an excitation wavelength λex = 341 nm and collecting emission
spectra between 300 nm and 680 nm. Excitation and emission bandwidths were set to 10
nm and data was collected at a scan speed of 30 nm/min with a 0.5 nm data interval.
Infrared absorption spectra were recorded on a Bruker VECTOR-22 FTIR spectrometer
using a Golden Gate diamond attenuated total reflection cell.
Analytical high performance liquid chromatography (HPLC) was performed on an Agilent
1260 infinity series stack equipped with an Agilent 1260 binary pump and degasser. 50 µl
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samples were injected using Agilent 1260 autosampler with a flow rate of 1 ml/min. The
HPLC was fitted with a phenomenex Luna C18 column (250 x 4.6 mm) with 5 micron
packing (100Ǻ). Detection was achieved using an Agilent 1260 variable wavelength 
detector monitoring at 280 nm. Mobile phase A consisted of either 100 % water containing
0.04 % TFA as an additive or 90 % water, 10 % acetonitrile containing 0.04 % TFA as an
additive. Mobile Phase B consisted of 100 % acetonitrile containing 0.04 % TFA as an
additive. The column was equilibrated by washing with the starting % of mobile phase A
for 10 minutes prior to injection for all conditions. The method gradient for HPLC
monitoring of reactions and products was: 90 % mobile phase A decreasing to 40 % mobile
phase A for 27 minutes, and remaining at 40% mobile phase A for 8 minutes, before
resetting to the starting conditions in 1 minute and remaining in these conditions for at
least 10 minutes to re-equilibrate the column before subsequent injections. Fluorescence
monitoring of RP-HPLC was achieved using the same system, gradients and column but
also equipped with an Agilent 1260 fluorescence detector with fluorescence detection at
λex = 341 nm; λem = 502 nm. Separation and collection by RP-HPLC was achieved using the
same system, gradients and column but also fitted with an Agilent 1260 fraction collector.
RP-HPL gradient 2, was carried out on the same system but with a gradient that consisted
of 95 % mobile phase A decreasing to 80 % mobile phase A after 15 minutes, followed by
decreasing to 40 % mobile phase A after a further 7 minutes and remaining at 40 % mobile
phase A for 5 minutes before resetting to 95 % mobile phase A in 1 minute, and a 10
minute column wash with the starting gradient.
MALDI-ToF mass spectrometry was conducted on a Bruker Daltonics Autoflex MALDI-ToF
mass spectrometer. MALDI-ToF samples were prepared by mixing a saturated solution of
α-Cyano-4-hydroxycinnamic acid (CHCA) in methanol as a matrix (10.8 µl), sodium iodide
in tetrahydrofuran (THF) (1.0 mg/ml) as catonisation agent (4.2 µl) and sample in THF with
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1 drop of water (1.0 mg/ml) (10.8 µl) where 0.7 µl of the mixture was applied to target
plate. Spectra were recorded in reflector mode calibrating with mPEG 2000 Da.
Electrospray ionisation mass spectra (ESI) were recorded on an Agilent 6130B Single-Quad.
3.4.3. Synthetic Procedures
3.4.3.1. Reduction of disulfide bond of oxytocin
Reduction using TCEP
Oxytocin (5 mg, 4.9 µmol) and TCEP (2.13 mg, 7.4 µmol) were dissolved in water (2 ml) and
left stirring at ambient temperature for 2.5 hours after which the reaction was sampled by
RP-HPLC.
Reduction using zinc
Oxytocin (5 mg, 4.9 µmol) was dissolved in water (1 ml) (with 1 % TFA) in an Eppendorf
tube and zinc dust (100 mg) was added and left stirring at ambient temperature for 1 hour.
After centrifugation (5 minutes) the reaction solution was removed from the metal pellet
and sampled by RP-HPLC.
3.4.3.2. Maleimide linear PEG reagent synthesis &
conjugation
The synthesis of N-poly(ethylene glycol)-3,4-dibromomaleimide and N-poly(ethylene
glycol)-3,4-dithiophenolmaleimide is modified from an existing procedure.19
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3,4-dibromomaleimide-N-PEG synthesis
To a solution of 3,4-dibromomaleimide (2.5 g, 9.8 mmol) and N-methylmorpholine (1.08
mL, 9.8 mmol) in THF (90 mL), methylchloroformate (0.75 ml, 9.8 mmol) was added and
the mixture was stirred for 20 min at room temperature. DCM (100 mL) was added, and
the organic phase was washed with H2O (2 x 100 ml), and dried with MgSO4 and the
solvent removed in vacuo, yielding a pink power (2.32 g, 7.47 mmol, 77 %).
1H NMR (CDCl3, 400.03 MHz) δ (ppm): 4.01 (3 H, s, COCH3); 13C NMR (CDCl3, 75.47 MHz) δ
(ppm): 159.2 (C=O), 146.9 (C=OOCH3), 131.4 (C=C), 54.8 (COCH3)
Without further purification, N-methoxycarbonyl-3,4-dibromomaleimide (31 mg, 0.1
mmol) was dissolved in DCM (25 ml) and amino-PEG (550 mg, 0.11 mmol) was added. The
solution was stirred under nitrogen overnight at ambient temperature after which the
solvent was removed in vacuo. The product was precipitated into hexane: diethyl ether
(1:1) yielding a pale off-white solid (440 mg, mmol, 73 %).
1H NMR (CDCl3, 400.03 MHz) δ (ppm): 3.80 (4 H, t, J = 5.02 Hz, NCH2CH2), 3.63 (480 H, s,
OCH2CH2), 3.36 (3 H, s, OCH3)
3,4-dithiophenolmaleimide-N-PEG synthesis
3,4-dibromomaleimide (5 g, 19.6 mmol) was dissolved in methanol (200 ml). NaOAc (2.09
g, 25.5 mmol) and thiophenol (4.55 ml, 44.6 mmol) were added to the solution and stirred
overnight at ambient temperature. The methanol was removed in vacuo before the
addition of EtOAc (100 ml) and the solution extracted with H2O (3 X 100 ml), dried with
MgSO4 and solvent removed in vacuo. The product was recrystallized with hexane/diethyl
ether (1:1) yielding a bright yellow powder (3.13 g, 10.0 mmol, 51 % ).
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1H NMR (CDCl3, 400.05 MHz) δ (ppm): 7.15 – 7.25 (6 H, m, SPh), 7.10 (4 H, d, 7.78 Hz, SPh);
13C NMR (CDCl3, 100.59 MHz) δ (ppm): 166.5, (C=O) 136.6 (C=C), 131.8 (SPh), 128.9 (SPh),
128.3 (SPh), 128.6 (SPh).
3,4-dithiophenolmaleimide (2 g, 6.38 mmol) was dissolved in EtOAc (70 ml) and N-
methylmorpholine (0.70 ml, 6.38 mmol) was added. Methylchloroformate (0.54 ml, 7.02
mmol) was added dropwise and solution stirred for 1 hour. The solution was washed with
H2O (2 x 100 ml) and dried with MgSO4 before the solvent was removed in vacuo yielding a
bright orange-yellow powder.
1H NMR (CDCl3, 400.03 MHz) δ (ppm): 7.25-7.35 (10 H, m, SPh), 3.91 (3 H, s, COCH3); 13C
NMR (CDCl3, 75.47 MHz) δ (ppm): 161.7 (C=O), 147.7 (C=O), 137.1 (C=C), 132.5 (SPh), 129.1
(SPh), 128.9 (SPh), 128.0 (SPh), 54.3 (COCH3)
To N-methoxycarbonyl-3,4-dithiophenolmaleimide (75 mg, 0.2 mmol), in DCM (5 ml) was
added amino-PEG (1.01 g, 0.2 mmol) in DCM (10 ml). After stirring at ambient temperature
for 30 minutes silica gel was added and the reaction mixture stirred overnight. The solution
was filtered and DTM-PEG precipitated into hexane: diethyl ether (1:1), resulting in a bright
yellow powder.
1H NMR (CDCl3, 300.13 MHz) δ (ppm): 7.10-7.55 (10 H, m, SPh), 3.86 (2 H, t, 5.09 Hz,
CONCH3), 3.62 (480 H, s, OCH2CH2), 3.36 (3 H, s, OCH3)
Conjugation of dibromo- or dithiophenolmaleimide
PEGs onto oxytocin
Oxytocin (10 mg, 9.9 µmol) was dissolved in water (2 ml) with TCEP (4.3 mg, 17.2 µmol).
After 2.5 hours a sample was removed for RP-HPLC analysis for confirmation of complete
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disulfide bond reduction. DBM or DTM PEG (70 mg, 13 µmol) in water (3 ml) was added to
the solution alongside the addition of phosphate buffer (5 ml, 100 mmol. pH 6.2), and the
reaction stirred at 10 °C for 24 hours, before further RP-HPLC monitoring.
3.4.3.3. DTM-poly(mPEGA480) synthesis & conjugation
3,4-Dithiophenolmaleimide initiator synthesis
N-Methoxycarbonyl-3,4-dithiophenolmaleimide (1.5 g, 4.04 mmol) was dissolved in DCM
(100 ml) and propargylamine (0.26 ml, 4.04 mmol) was added. After 30 minutes silica (30
g) was added to the solution and the reaction stirred overnight. The reaction mixture was
filtered, and the product purified by column chromatography (ethyl acetate: petroleum
ether 1:10).
1H NMR (CDCl3, 400.03 MHz) δ (ppm): 7.10-7.25 (10 H, m, SPh); 4.18 (2 H, s, NCH2); 2.13 (1
H, s, C≡CH); 13C NMR (CDCl3, 75.47 MHz) δ (ppm): 165.5 (C=CC=O); 136.0 (SPh); 133.2 (SPh);
129.0 (SPh; 128.5 (SPh); 128.7 (C=C); 76.7 (C≡CH); 72.8 (C≡CH); 27.7 (NCH2).
3,4-Dithiophenol-N-propynyl-maleimide (4.00 g, 11.4 mmol), 3-azidopropyl 2-bromo-2-
methylpropanoate (2.85 g, 11.4 mmol) and Cu(I)Br (163 mg, 1.14 mmol) were dissolved in
DMF (40 ml). The mixture was purged with nitrogen for 20 minutes. 2,2 Bipyridine (360 mg,
2.28 mmol) was added to the mixture with stirring and further purged with nitrogen for 20
minutes. The reaction was left stirring at ambient temperature overnight. DMF was
removed and a portion of the crude residue was purified twice by silica gel column
chromatography (diethyl ether in dichloromethane, 0% -10 %).
1H NMR (CDCl3, 400.03 MHz) δ (ppm): 7.57 (s, 1H, C=CH); 7.17- 7.32 (m, 10H, SPh); 4.82 (s,
2H,NCH2C=CH); 4.47 (t, J = 7.03 Hz, 2H, COOCH2CH2CH2); 4.20 (t, J = 6.02 Hz, 2H,
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OCOCH2CH2CH2); 2.33 (qu, J = 6.02 Hz, 7.03 Hz, 2H, OCOCH2CH2CH2); 1.96 (s, 6H,
COC(CH3)2Br).
13C NMR (CDCl3, 75.47 MHz) δ (ppm): 171.40 (OCOC(CH3)2Br; 166.24 (C=CCON); 142.36
(NCH2C=CH); 135.75 (SPhC=C); 131.90(SPh); 128.99 (SPh); 128.83 (SPh); 128.43 (SPh);
123.43 (C=CHN3); 62.25 (COOCH2CH2CH2); 55.79 (COC(CH3)2Br); 46.91(COOCH2CH2CH2);
33.81(NCH2C=CH); 30.67 (COC(CH3)2Br); 29.08 (COOCH2CH2CH2).
IR: 1159cm-1 (νC-O); 1703 cm-1 (νC=O); 1732 cm-1 (ester νC=O)
HRMS (ESI+): m/z Found: 623.0406, Calc: 623.0393 [C26H25O4N4S2Br + Na]+
Example polymerisation using EBiB or DTM
initiator in mixed solvent system
In an oven dried Schlenk tube CuBr (3.6 mg, 24.9 µmol) and water (1 ml) were added and
stirred before the addition of Me6TREN (6.6 µl) upon which there was the immediate
formation of Cu(0) powder and blue CuBr2 solution, which was degassed by nitrogen
bubbling for 30 minutes. In a separate vial, initiator (62.2 µmol) and poly(ethylene glycol)
methyl ether acrylate (DPn Eq.) were dissolved in DMSO (6 ml) and water (0.5 ml) and
degassed by nitrogen bubbling for 30 minutes. The monomer/initiator solution was then
added into the catalyst solution by injection (t = 0) and the reaction was stirred at ambient
temperature under nitrogen for 20 hours. After this time a sample was removed and
diluted with δ6-DMSO for 1H NMR analysis and DMF for GPC molecular weight data.
Polymers were purified by dialysis (1 kDa MWCO) against water for 3 days.
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Oxytocin conjugation with purified polymer
Oxytocin (5 mg, 4.97 µmol) was dissolved in water (1 ml) and TCEP (2.14 mg, 7.45 µmol) in
water (1 ml) was added. The solution was stirred for 2.5 hours, after which an aliquot was
removed (50 µl) and complete disulfide reduction was confirmed by RP-HPLC. DTM-
(mPEGA480)20 (71 mg, 5.92 µmol) was dissolved in water (2 ml) and added to the reduced
peptide solution at 10 °C. The reaction was maintained at 10 °C and stirred overnight after
which a sample was submitted for RP-HPLC analysis. This revealed the disappearance of
the polymer peak and the formation of a new conjugate peak with coincidental
fluorescence, and a sharp peak at retention time t = 25.2 minutes relating to thiophenol
released in the reaction.
In-situ polyPEG conjugation of oxytocin
Oxytocin (5 mg, 4.97 µmol) was dissolved in water (1 ml) and tris(2-
carboxyethyl)phosphine (2.14 mg, 7.45 µmol) in water (1 ml) was added. The solution was
stirred for 2.5 hours, after which an aliquot was removed (50 µl) and complete disulfide
reduction was confirmed by RP-HPLC. The polymerisation solution of DTM-(mPEGA480)20
was thoroughly mixed after which an aliquot was removed (0.708 ml, 5.46 µmol) and
diluted in water (1.3 ml) and added to the reduced peptide solution at 10 °C. The reaction
was maintained at 10 °C and stirred overnight, after which a sample was taken for RP-HPLC
analysis which showed the disappearance of the polymer peak and the formation of a new
conjugate peak with coincidental fluorescence and a sharp peak at retention time t = 25.2
minutes, attributed to thiophenol released in the reaction. Subsequent conjugates were
purified by dialysis (regenerated cellulose dialysis membrane, MWCO 1,000) against water
at ambient temperature for a minimum of 3 days with water changes 3 times daily.
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Reversibility of peptide-polymer conjugates
Oxytocin – poly(mPEGA480)20 (10 mg, 0.769 µmol) was dissolved in water (2 ml) before the
addition of reduced glutathione (3.7 mg, 12 µmol, 15 equivalents) to the stirred solution at
ambient temperature. After four days an aliquot of the reaction solution (0.2 ml) was
removed and diluted in water (0.8 ml) for RP-HPLC. This revealed the reappearance of the
reduced native peptide, and a shift in retention time from the conjugate peak to a new
glutathione substituted polymer, which retains fluorescence.
3.4.3.4. ‘Thiol-ene’ conjugation onto oxytocin
Oxytocin conjugation with PEG acrylate
Oxytocin (5 mg, 4.96 µmol) was dissolved in water (2 ml) with TCEP (2.84 mg, 9.93 µmol).
After 2 hours a sample was taken for RP-HPLC (80 µl) confirming the reduction of the
disulfide bridge. pH 6.5 phosphate buffer (10 ml, 100 mM) was added with m-PEG acrylate
(Sigma Aldrich, 5,000 Da) (99 mg, 34.72 µmol) and the reaction stirred overnight at T = 10
°C before analysis by RP-HPLC
Conjugation of vinyl functional poly(mPEGMA)
Oxytocin (4 mg, 3.97 µmol) was dissolved in water (2 ml) with TCEP (3.4 mg, 11.8 µmol).
After 2 hours a sample was taken for RP-HPLC (100 µl in 1 ml water) which confirmed
reduction of the disulfide bridge. Vinyl end functional poly(mPEGMA) (100 mg, 32 mmol) in
pH 7 phosphate buffer (2 ml, 100mM) was added and the reaction stirred overnight at
ambient temperature before analysis by RP-HPLC.
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Chapter 4
4. PEGylated oxytocin: Effects of PEGylation
on oxytocin activity and stability
The oxytocin-polymer conjugates described in Chapters 2 and 3 were investigated using
different techniques and compared to the native peptide. High temperature thermal
stability studies were conducted to investigate any improvements in stability after
conjugation. Ex vivo organ bath testing was undertaken to investigate the magnitude of
retained uterotonic activity for the polymer conjugates with respect to the native peptide.
MTT assays were conducted on breast cancer cell line MDA-MB 231 in order to investigate
the effect of oxytocin and oxytocin-polymer conjugates on cell proliferation.
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4.1. Stability testing
4.1.1. Introduction
Due to the very low thermal stability of oxytocin, the desired effect of polymer conjugation
was to reduce, or completely prevent, the thermal degradation that occurs within the
native peptide structure. There has been extensive previous research on oxytocin
degradation which has largely focussed on investigating the characteristics of
degradation.1–5 This has involved analysis of the major degradation products, thus
highlighting where most of the degradation may be taking place in the peptide structure of
native oxytocin, and other oxytocin analogues. Previous degradation studies and analysis
by Hawe et al. highlighted the formation of trisulfide, tetrasulfide, dimerization and the
formation of larger aggregates as the main degradation products, alongside deamidation at
Asn6, Gln4 and Gly9.1 Degradation studies were also carried out by Wiśniewski et al. (40 °C,
35 days) which further confirmed the formation of trisulfide and tetrasulfide by-products
and dimeric oxytocin.2
These studies (analysed by RP-HPLC and MS) highlight the disulfide bond as one of the
main sites that degradation products are known to arise from. The degradation of oxytocin
is well known to be a draw-back in the use of the therapeutic, particularly within the
developing world where cold-chain supply and storage may not always be achievable for
social or economic reasons. This has resulted in guidelines being established for oxytocin
storage: (refrigerated, under 10 °C) no more than 24 months; (not refrigerated, under 25
°C) no more than 3 months.6 It is vital that the degradation of oxytocin be reduced in order
to improve accessibility of the drug for prolonged storage, or easier transportation,
particularly within those countries that experience the highest maternal mortality rate.
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A large number of therapeutics are well known to undergo degradation via chemical and
physical pathways during storage or transportation, particularly upon exposure to
fluctuating temperatures, often leading to deterioration in activity resulting in a “shelf-life”
for each product. Additional to more commonly being used to improve the in vivo stability
and circulation time of therapeutics, attachment of poly(ethylene glycol) (PEG) has
previously been shown to improve the stability of peptide/proteins or other biomolecules
and to some level prevent denaturation.7
In the first part of this chapter, the aqueous stability of oxytocin will be investigated, and
the effect of poly(ethylene glycol) both as a linear polymer and as a ‘comb’ polyPEG is
explored. The potential use of PEG as an external non-conjugated excipient will be
analysed alongside the library of different conjugation linkages and architectures of
oxytocin-polymer conjugates synthesised in chapters 2 and 3. Of particular interest is the
effect that the covalent conjugation has on the stability or whether the addition of
inexpensive, commercially available polymers to solutions of the peptide leads to similar
improvements in stability.
4.1.2. Initial oxytocin stability tests
The stability of oxytocin was initially investigated at 50 °C where solutions of the peptide (1
mM) were dissolved in unbuffered water and left for 28 days (figure 4.1). At regular
intervals the peptide samples were removed and analysed by RP-HPLC where the % of
oxytocin remaining could be calculated by analysis of the peak area on the chromatogram.
It was found that the degradation of oxytocin at this temperature and concentration was
very rapid with a 50 % reduction in the amount of peptide after 5 days. After 28 days
analysis of the oxytocin levels by RP-HPLC found that only 2.5 % of the peak corresponding
to oxytocin (retention time t = 7.2 minutes) was observed within the chromatogram,
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suggesting that there was an almost complete degradation. After 28 days a variety of other
peaks can be observed by RP-HPLC at higher retention times than the native peptide, with
the major degradation peaks observed at retention times of t = 10.6 minutes and t = 11.9
minutes. These results concur with previous stability studies explored for the peptide
wherein HPLC analysis has been performed on the degradation products of oxytocin.1,2 In
the literature it was suggested that the peaks observed are likely from various degradation
products centred on the disulfide bond (such as trisulfide/tetrasulfide formation and
dimerization or the formation of larger aggregates), as previous studies have shown similar
RP-HPLC chromatograms.1,2
Figure 4.1. Monitoring the degradation of oxytocin at 50 °C over 28 days by RP-HPLC.
The observed rapid and almost complete destruction of the structure highlights the
importance of the need for stability enhancements on the peptide.
4.1.3. High temperature thermal assay for non-conjugated
excipients
Excipients (inactive chemicals added to formulations) can provide an inexpensive and
effective way to enhance protein stabilisation and have previously been shown to provide
non-covalent stabilisation, thereby reducing degradation of peptide/protein/drug
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formulations.8 Commonly used excipients include buffering agents, amino acids, salts,
sugars and polyols as well as low molecular weight hydrophilic polymers (such as PEGs and
polysaccharides), which aid in preventing aggregation or denaturation of therapeutics and
proteins.
Some of these commonly utilised, commercially available excipients (sugars, polyols and
polymers) were analysed to ascertain their effects on the stability of oxytocin after high
thermal stress at 80 °C. The high temperature was required so that ‘normal’ oxytocin
degradation would be achieved quickly, where only 24 hours was required to attain high %
degradation as an accelerated model for degradation at more applicable temperatures.
This results in low stability for the native peptide and allows suitable comparisons to be
attained between the solutions with and without the addition of external additives. This
temperature is also in line with previous high temperature oxytocin degradation carried
out by Avanti et al., where a temperature of 70 °C was used to confirm that the addition of
metal salts to peptide solutions aided the stability, and hence the recovery, of the active
peptide.9 An alternative RP-HPLC method was developed with a slower initial gradient. This
caused a longer retention time of the native peptide, more similar to the retention time of
the oxytocin-polymer conjugates.
4.1.3.1. Oxytocin calibration plot
In order to investigate the amount of oxytocin remaining at the end of the stability study, a
calibration plot was made of the native peptide between 1 mM and 0.01 mM (figure 4.2).
Oxytocin has a high UV (λ= 280 nm) absorption even at low concentrations, and the 
calibration was constructed to ensure the concentration of remaining oxytocin could be
reliably calculated, even with residual amounts of peptide still in solution. This linear
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calibration plot was used for calculation of the level of oxytocin remaining in all native
peptide and non-covalently attached excipient interaction studies.
Figure 4.2. Calibration plot for different concentrations of oxytocin.
The degradation of oxytocin (1 mM) monitored after 24 hours storage at 80 °C revealed
that oxytocin recovery was low (19.2 % ± 1.10), suggesting that under these conditions fast
degradation of the peptide occurred (Figure 4.3). Similarly to the previously described 28
day (50 °C) study, different degradation peaks are evident, highlighting the highly unstable
nature of this peptide.
Figure 4.3. RP-HPLC chromatogram of oxytocin before and after thermal stressing at 80 °C.
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4.1.3.2. Small excipients for stabilisation: The effect of polyols
and sugars on oxytocin degradation
Some previously reported sugar and polyol excipients were prepared as 2 mM and 200 mM
solutions and added to oxytocin (2 mM), resulting in total concentrations of 1 mM , with 1
x or 100 x molar equivalents of the excipients relative to oxytocin. The samples were then
incubated for 24 hours at 80 °C, after which analysis by RP-HPLC (UV, λ = 280 nm) was 
performed to determine remaining oxytocin content. All samples were investigated in
triplicate, with the average peak area for remaining oxytocin used to determine the % of
the native peptide remaining (% recovery) (Figure 4.4).
Table 4.1. Thermal stability study (80 °C, 24 h) of oxytocin (assessed in terms of retained %peak area of the peptide) on addition of various polyols and sugars as external additives.
Sample Sample
type
MW
(Da)
% Recovery
1 mM Oxy / Excipient
% Recovery
100 mM ExcipientOxytocin Peptide 1007 19.2 (± 1.10) -Glycerol Polyol 92.1 16.6 (± 0.65) 16.5 (± 1.65)Mannitol Polyol 182.2 15.6 (± 0.14) 14.4 (± 0.43)Sorbitol Polyol 182.2 18.5 (± 0.30) 16.4 (± 0.29)Glucose Sugar 180.2 14.9 (± 0.088) 17.0 (± 1.11)Lactose Sugar 342.3 14.1 (± 0.55) 15.5 (± 0.095)Maltose Sugar 342.3 14.3 (± 1.08) 15.5 (± 0.31)Trehalose Sugar 342.3 14.3 (± 0.37) 13.3 (± 0.63)
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Figure 4.4. Thermally stressed stability of oxytocin in the presence of polyol and saccharideexcipients at 1 and 100 molar equivalents at 80 °C for 24 hours.
The results of the stability study show that the use of these small excipients in peptide
solutions at the concentrations investigated (1 mM / 100 mM) did not provide any addition
stabilisation for oxytocin during thermal stressing. Degradation results in fact showed
marginally less stability for the native peptide in all cases, theorised to be due to some
small interactions with the peptide, allowing further degradation than for the untreated
oxytocin sample.
4.1.3.3. Non-conjugated polymer influence on thermal
stability: Non-covalently bound PEG
Polymers are also commonly utilised in peptide or protein therapeutic formulations, most
often as solubilising excipients, but can also act to non-specifically provide stability via non-
covalent interactions. A commonly used polymer in pharmaceutical formulations is
poly(ethylene glycol) (PEG), usually accessed at a low molecular weight such as PEG-300 &
PEG-400. Various linear PEGs are available commercially at a variety of different molecular
weights, as well as containing a variety of different end groups. Some additional polymers
to PEG are available which have also proven effective as conjugated or non-conjugated
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additives include zwitterionic polymers,10 non-ionic amphipols11,12 and trehalose
glycopolymers.13,14
When investigating changes in stability of oxytocin by addition of linear PEG, as an external
additive, the molecular weight of the PEG is likely to have an effect on the degradation of
the peptide. This was investigated using the same thermal degradation study (80 °C, 24 h)
as used for the polyols, where PEG molar masses were between 350 Da – 5 kDa. Firstly the
effect of 1 x and 100 x equivalents of α-methoxy-ω-hydroxy PEGs were added to solutions 
of oxytocin and heated in an oven for 24 hours at 80 °C, and compared to the solutions
without any external additives (Figure 4.5). The results showed that that upon the addition
of molar masses of PEG above 1 kDa there is no effect on the stability of the peptide,
where oxytocin recovery was similar, or equivalent to, when no PEG excipients were
present in the solution. However, at low molar masses the PEG was shown to have some
stabilising effect on the peptide with less degradation observed and oxytocin recovery
levels of up to 44 % (more than twice the 19 % achieved for additive-free native oxytocin
recovery). This is consistent with the previous use of low molecular weight PEG (such as
PEG400) as excipients of pharmaceutical solutions.
Figure 4.5. Evaluation of % of oxytocin remaining after 24 hours of thermal stressing (80 °C)containing different molecular weights of PEG.
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To investigate in more detail the effect of the molecular weight of the PEG, the study was
repeated but refocussed into investigating the effect of ‘n’, the number of ethylene glycol
repeat units within each PEG chain CH3O-(C2H4O)n-H compared to the native peptide.
Longer PEG chains have a higher number of repeat units in the polymer, increasing the size
compared to oxytocin. E.g. it would require 9.5 times the amount of a PEG550 (n ≈ 11.8) to 
achieve the number ‘n’ of ethylene glycol repeat units as that of PEG5000 (n≈ 112.8). The 
heat stressed thermal stability assay was therefore performed with respect to the number
of ethylene glycol repeat units (figure 4.6).
Figure 4.6. Evaluation of % of oxytocin remaining after 24 hours of thermal stressing (80 °C)containing different molecular weights of PEG after taking ‘n’ into consideration.
The results show that, as observed previously there is no effect on the stability of the
peptide by using higher molecular weight PEG (> 1 kDa) as an external additive for
oxytocin, however, the effect of low molecular weight PEG on the stability of the peptide is
more interesting. At low ‘n’ (n = 10), where there are only a small number of ethylene
glycol units per peptide, there is no observed effect on the stability of the peptide, with
oxytocin recovery remaining low.
Contrastingly, when ‘n’ is increased 10- or 50- fold, within these small MW PEGs, the
stability of the peptide greatly increases upon thermally stressed storage. In this study, up
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to 55 % oxytocin recovery can be attained for PEG550 and PEG750 upon carefully tuning the
amount of PEG added to the peptide solution. This is a stability improvement of almost 3
times that observed for solutions containing no external additives, and highlights the
potential of low molar mass PEGs for use in this manner. This is in agreement with the non-
conjugated low molar mass PEGs that are used widely within the pharmaceutical industry,
but have not yet been applied to improve the stability of this important therapeutic
peptide.
These results suggest that there is scope for the use of PEG as an external non-conjugated
excipient for oxytocin, with increases in stability observed of more than double that
observed for the native peptide alone. More than 50 % recovery can be established for the
peptide by the addition of commercially available, inexpensive small polymer additives.
The use of polymer excipients in solutions of oxytocin could also be advantageous in that
any loss of activity by covalent attachment to the peptide could be prevented. Although
these results seem promising, the degradation of the peptide is still evident in all samples,
highlighting the need to optimise improvement, further minimising the degradation.
4.1.4. Degradation study on different architectures of oxytocin
– PEG conjugates
It was hypothesised that the conjugation of linear and polyPEGs onto oxytocin would
improve the thermal stability of the peptide, leading to a decrease in the previously
reported degradation (and an increase in the peptide conjugate recovery). The PEGylated
oxytocin conjugates synthesised in chapters 2 and 3 were subjected to the same high
temperature stability assay and were compared to their non-conjugated counterparts. The
thermal stability should highlight the effect that PEG architecture and conjugation position
/ linkage functionality would have on improvements to stability.
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The high thermally stressed conjugate studies were carried out in the same manner as for
the excipient (non-conjugated studies), with analysis of stability carried out after 24 hours
of heating at 80 °C. For each conjugate a calibration plot was first prepared, so that the
concentrations of the remaining conjugates could be calculated in a similar manner to
oxytocin. For the majority of the linear conjugates the starting concentration was
maintained at 1 mM and for the polyPEG conjugates the concentrations for the thermal
stability assay varied between 0.05 and 0.25 mM. Calibration plots were constructed for
each conjugate to reflect this (figure 4.7).
Figure 4.7. Calibration plots of peak areas from RP-HPLC for linear and polyPEG conjugates atconcentrations used for thermally stressed stability testing.
The calibration plots also reveal useful information about the molar absorption of the
different conjugates under the RP-HPLC wavelength (λ = 280 nm), using the peak area 
(mAUs) from the chromatograms. As expected, the maleimide polymers have the highest
absorbance of all the linear and polyPEGs. The polyPEGs, in general, have a much lower
absorbance than their linear counterparts, but the molecular weights of these are
generally higher, therefore the groups with high absorbance’s become diluted within the
polymers.
Chapter 4 – PEGylated oxytocin: Effects of PEGylation on activity and stability
Jennifer Collins 179
4.1.4.1. Stability of linear oxytocin –PEG conjugates
Figure 4.8. Structures of linear PEGylated oxytocin
The linear polymers characterised by this study were investigated using the same molar
mass (5 kDa polymer: 6 kDa conjugate) so that comparisons could be made between the
different conjugation positions, or conjugation linkage chemistries. The results of the
degradation of the linear conjugates under these high temperature conditions show that
all of conjugates have a much greater stability (2.5 times to 5 times) compared to that
observed for the native peptide under the same conditions. Figure 4.9 shows the stability
results for all the linear 6 kDa PEGylated oxytocin conjugates, using 5 different conjugating
groups, additional to the previously mentioned 5 kDa PEG additive, which showed no
stabilising behaviour.
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Figure 4.9. Stability results for all linear PEGylated conjugates (6 kDa) compared to nativeoxytocin and the peptide solution containing 5 kDa PEG as a non-conjugated additive.
The worst performing conjugate that least improved the stability was the thioether
conjugate, arising from the double thiol functionalisation of oxytocin using mPEGA2000. This
conjugation approach involves the addition of two polymer chains onto oxytocin
concurrently, preventing reformation of the 20 membered ring/ cyclic structure. This
fundamental change of structure of the native peptide occurs at a position that has already
been established as vital in ensuring degradation is kept to a minimum. The disulfide bond
is where a large proportion of the degradation products arise; usually occurring as an
increase to the ring size or total loss of the ring structure (these include tri/tetrasulfide
formation and the formation of oxytocin dimers or larger aggregates). It should, however,
be noted with regards to this conjugate that, although this may be the least stable of these
linear PEG conjugates it still exhibits a 2.5 times increase in stability compared to the native
peptide. This is higher than the majority of stabilising effects observed with the
unconjugated polymer additives.
The two N-terminally targeted linear conjugates (NHS PEG resulting in amide linked
conjugate, and aldehyde PEG resulting in 2° amine linked conjugate) have similar
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stabilities, with between 70 -85 % of the conjugate remaining in the native form after 24
hours at 80 °C. This is a prominent increase in stability (3.5 to 4 times that observed for the
native peptide), and from the RP-HPLC chromatograms it is clearly evident that there is a
decrease in the observed degradation products (figure 4.10).
Figure 4.10. RP-HPLC chromatograms of succinimide and aldehyde oxytocin polymerconjugates (6 kDa) after 24 hours of storage at 80 °C.
The two maleimide disulfide bridged conjugates (which have the same conjugate structure
post-conjugation) showed the highest stability under this study, with recovery remaining
close to 100 %. This is, similarly to the other disulfide bond targeted approach, likely due to
suppression of the normally observed degradation products resulting from the disulfide
bond. However, in this case the maleimide linkage is adding additional stability to the
peptide structure in this position by the addition of a three carbon bridged linkage. This
prevents the disulfide bond from breaking, preventing the degradation into the normally
observed degradation products, as the 22 membered ring has a higher stability at the Cys1-
Cys6 bridging position.
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Figure 4.11. Diagrams showing different structures of disulfide conjugated polymers andinfluence on cyclic ring size within oxytocin.
Table 4.2. Results of thermal degradation study for linear oxytocin-polymer conjugates (6 kDa)after 24 hours storage at 80 °C compared to oxytocin, and non-conjugated PEG (5kDa).
Sample Sample type MW (Da) Conc (mM) % RecoveryOxytocin Peptide 1007 1.0 19.2 (± 1.10)mPEG 5kDa Unconjugatedlinear PEG 5000 1.0 17.7 (± 2.78)Linear Succinimide Amide linkedlinear PEG 6000 1.0 83.7 (± 1.11)Linear Aldehyde Secondary aminelinked linear PEG 6000 1.0 73.3 (± 3.55)Linear Acrylate Thioether linkedlinear PEG 6000 1.0 49.8 (± 2.08)Dithiophenolmaleimide Maleimide linkedlinear PEG 6000 1.0 112.5 (±2.92)Dibromomaleimide Maleimide linkedlinear PEG 6000 0.5 93.5 (± 3.65)
Values above 100 % are likely due to concentration errors, arising from the high
temperature used for the thermal degradation testing, and the method of data analysis. It
is theorised that the degradation of these samples remains minimal, allowing
approximately 100 % of conjugate recovery.
Chapter 4 – PEGylated oxytocin: Effects of PEGylation on activity and stability
Jennifer Collins 183
4.1.4.2. Stability of polyPEGylated oxytocin
Prior to investigating the stability of the oxytocin polyPEG conjugates under the same
thermally accelerated conditions, a non-conjugating polyPEG was synthesised as a
comparison. This would be analogous to the linear PEG additives in comparison to the
linear PEG conjugates, to discount the effects of non-covalent interactions. This is also
important as several of the conjugates contained excess PEG impurities in the solutions,
and would highlight the effect that these might have.
Poly(mPEGA480) was synthesised by Cu(0)-mediated living radical polymerisation, using
ethyl α-bromoisobutyrate (EBiB) as the initiator ([I]:[M]:[Me6Tren]:[CuBr] = 1:20:0.4:0.4)
(scheme 4.1). Cu(I)Br was allowed to disproportionate in water (1 ml) after which EBiB and
mPEGA480 were added in a solution of DMSO (6 ml) and water (1 ml). After 24 hours
samples were removed for 1H NMR (δ6-DMSO; 94 % conversion) and SEC molecular weight
(DMF; Mn = 12300, Ð = 1.06) analysis (figure 4.12).
Scheme 4.1. Copper mediated polymerisation of mPEGA480 with EBiB initiator in DMSO/H2O(4:1) ([I]:[CuBr]:[Me6TREN] = 1:0.4:0.4).
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Figure 4.12. NMR and GPC of EBiB initiated polymer used as a non-conjugating polyPEGadditive in heat stability testing of oxytocin at 80 °C.
Following purification (dialysis against water, 3.5 kDa MWCO, 3 days), the polymer was
added to a solution of oxytocin as 1:1 molar equivalents and heated for 24 hours at 80 °C.
Under the conditions of the stability assay, RP-HPLC of oxytocin solutions containing the
Poly(mPEGA480) additive revealed a small improvement (1.7 times) in the level of remaining
oxytocin present in solution after 24 hours. From the RP-HPLC chromatogram the
suppression of degradation products appearing at 21-24 minutes retention time is clear in
the sample containing the polyPEG additive (figure 4.13).This highlights that the polyPEGs
can, without covalent binding to the peptide, exhibit a small amount of protection
compared to solutions of oxytocin containing no such additive in the solution. As this
polymer was synthesised as 20 repeat units of a small (< 500 Da) PEG monomer, the
stability study was also undertaken for oxytocin containing 20 equivalents of a small linear
methoxy PEG (350 Da). This, however, revealed no stabilising effect with oxytocin recovery
remaining similar to the native peptide containing no excipients (within 1 %).
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Figure 4.13. RP-HPLC traces of oxytocin at t = 0, oxytocin after 80 °C storage (t =0) andoxytocin after 80 °C storage with addition of a polyPEG additive.
Figure 4.14. Structures of polyPEG oxytocin conjugates, and oxytocin with non-conjugatedpolymer.
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When the polyPEG conjugates (figure 4.14) were subjected to the same stability assay as
the non-covalent additives and the linear conjugates, all showed high increases in stability
compared to native oxytocin. The product return for the majority of samples was close to
100 %, which is much higher than the stability monitored on addition of any of the external
excipients (figure 4.15).
Figure 4.15. Stability results for all polyPEGylated conjugates compared to native oxytocin andthe peptide solution containing 20 Eq. 350 Da PEG, and DPn 20 polyPEG as a non-conjugatedadditive.
Due to the high stability measured under these conditions it is challenging to recognise if
there are differences between the two different conjugation positions (N-terminal, or Cys1-
Cys6 disulfide bond) with respect to improved stability (table 4.3). The polyPEG conjugate
with the lowest observed stability maintained 81 % of the conjugate structure, which still
shows a significant conjugate return, compared to that of the native peptide. The RP-HPLC
traces shown in figure 4.16 highlight this, where there is the observation of a small amount
of degradation peaks, after 80 °C storage for 24 hours, at a similar retention time to those
observed after degradation of the native peptide (between 21 – 24 minutes). The main
conjugate peaks are the same shape and size, and appear at similar retention time to the t
= 0 samples, suggesting that little degradation has occurred.
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Table 4.3. Results of thermal degradation study for oxytocin-polyPEG conjugates after 24hours storage at 80 °C, compared to relevant non-conjugated polymers.
Sample Sample type MW
(Da)
Conc
(mM)
% Recovery
Oxytocin Peptide 1007 1.0 19.2 (± 1.10)
mPEG 350 kDa (20 eq) Unconjugated linearPEG 350 1.0 19.0 (± 0.56)
PPEG DPn 20 Non-conjugatedpolyPEG 10000 1.0 33.1 (± 0.21)Succinimide PPEG DPn13 Amide linkedpolyPEG conjugate 7500 0.25 101.7 (± 4.06)Aldehyde PPEG
DPn 20 Secondary aminelinked polyPEG 11000 0.25 101.4 (± 2.44)Aldehyde PPEG
DPn 50 Secondary aminelinked polyPEG 25000 0.16 80.9 (± 2.19)DithiophenolmaleimidePPEG DPn 20 Maleimide linkedpolyPEG 11000 0.25 95.79 (± 13.33)DithiophenolmaleimidePPEG DPn 50 Maleimide linkedpolyPEG 25000 0.05 102.76 (± 5.40)
Figure 4.16. HPLC traces of degradation of oxytocin polyPEG conjugates (80 °C, 24h, 25 mM)
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4.1.4.3. Additional oxytocin conjugate stability testing
In addition to the high temperature thermally stressed stability assay, additional stability
testing was carried out on the polyPEG maleimide bridged conjugates, monitoring the
degradation across 28 days (50 °C, 1 mg ml-1) (figure 4.17). Following the degradation at
more applicable temperature across several time points gives a more appropriate idea of
how the conjugates degrade and how this might compare to the native peptide in a
tropical climate. Aliquots of the samples were removed periodically and monitored by RP-
HPLC for analysis of remaining concentration of polymer conjugate, in comparison to that
observed at t = 0. The largest and smallest polymer conjugates were tested (11 kDa & 50
kDa) to investigate whether the molecular weight had any effects on enhanced stability.
This study found that, as observed after high thermal stressing, the degradation was
largely suppressed by the conjugation of dithiophenolmaleimide polymers across the
double bond of oxytocin. The amount of oxytocin previously observed to remain after 28
days at 50 °C was 2.5 %, whereas for the polymer conjugates it was 93.5 % and 86.5 %
(oxytocin-(mPEGA480)20 and oxytocin-(mPEGA480)100 respectively). The major peaks
observed for the conjugates after 28 days coincide with the conjugate peaks observed at t
= 0. The minor peaks observed can be attributed to oxytocin or oxytocin degradation
products, suggesting very slight instability in the conjugation. The RP-HPLC traces of the
conjugate products at t = 0 and t = 28 days show that the major peak remains in the same
place, and that peak shape also does not change. This is important in determining that
polymer conjugate degradation is not occurring, rather than if degradation products were
appearing at a similar retention time.
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Figure 4.17. Stability of oxytocin polymer conjugates at 50 °C across 28 days.
4.1.5. Stability testing conclusions
The investigation of the thermal stability of the oxytocin conjugated PEG (both linear and
polyPEG) shows that polymer conjugation has a strong influence on the
stability/degradation properties of oxytocin. Non-conjugated polymers, and small
molecules added as external excipients, do not have any strong stability increasing effects,
particularly for the larger linear PEGs and all sugars/polyols. There is a potential stabilising
effect observed for high concentrations of small PEGs, and upon the addition of non-
covalently bound polyPEG, but these are minimal compared to most of the oxytocin-
polymer conjugates. These results show that polyPEGs have the highest stability enhancing
effect on oxytocin, both conjugated at the disulfide bond and via the N-terminal amine,
where all stabilities were improved by 4 - 5 X that observed for the native peptide. Overall,
these results suggest that the PEGylation of oxytocin has high potential benefits with
respect to increasing the solution thermal stability.
Chapter 4 – PEGylated oxytocin: Effects of PEGylation on activity and stability
Jennifer Collins 190
4.2. Uterotonic Experiments
4.2.1. Introduction
The primary use of oxytocin is for the induction of uterine cell contraction, particularly in
relation to pregnancy, either for labour induction, or for prevention of post-partum
haemorrhaging (PPH).15,16 Therefore, the main analysis measurement used to investigate
the retained activity of oxytocin analogues, such as the oxytocin-polymer conjugates
synthesised in previous chapters, should be in investigating the level of uterotonic
contraction induced by the polymeric oxytocin analogues, and how this compares to the
native peptide.
The mechanism by which oxytocin induces contractions within the cells arise from oxytocin
binding into the oxytocin binding receptor, on the outside of the cell which activates the G-
protein (Gαq/11) inside the cell. Gαq/11 causes activation of the voltage induced Ca2+ channel
allowing Ca2+ to enter the cell, whilst also phosphorylating the enzyme phospholipase CB
(PLCβ). PLCβ cleaves phosphatidylinositol 4,5-diphosphate (PIP2) into diacyl glycerol (DAG)
and inositol 1,4,5-triphosphate (IP3). IP3 induces the endoplasmic reticulum to release
calcium, and is then recycled as free inositol. From DAG, free arachidonic acid (AA) is
cleaved by the enzyme phospholipase A2 (PLA2), and then converted into prostaglandin F2α
by cyclooxygenase (COX2). The calcium induced within or entering the cell binds to
calmodulin, and this Ca2+-calmodulin complex activates MLC Kinase. Together a
combination of prostaglandin and MLC Kinase lead to cell contraction (figure 4.18).17,18
The cell contraction mechanism is initially stimulated by the binding of oxytocin into the
oxytocin binding receptor, which exists on the surface of many cells within the body (not
solely within uterine tissue). Ile3, Gln4, Pro7 and Leu8 are important residues required on
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oxytocin for binding into the oxytocin binding receptor, whilst Asn5 and Tyr2 are important
for the activation, which ultimately causes uterine contraction.1,19
Figure 4.18. Oxytocin mechanism for stimulating contractions and structure of oxytocinhighlighting important residues for contraction.
Previous biological evaluations assays, under which oxytocin or oxytocin analogues have
been tested for uterotonic activity retention have been undertaken by evaluating the ex-
vivo contractility of smooth muscle tissue.20–23
In the second part of this chapter, initial uterotonic studies carried out on three different
oxytocin-polymer conjugates will be investigated to probe the contractile behaviour
compared to the native peptide.
4.2.2. Uterotonic testing of oxytocin polymer conjugates Vs.
oxytocin.
The uterotonic studies on oxytocin and the oxytocin peptide conjugates were performed in
an organ bath using a force transducer to accurately measure contractions. Tissue was
freshly extracted from 3 week old Sprague-Dawley (SD) rats, and used as soon as possible
after extraction, with a maximum viability of approximately 12 hours. After the uterine
Chapter 4 – PEGylated oxytocin: Effects of PEGylation on activity and stability
Jennifer Collins 192
tissue preparation (trimmed of any connective tissues, approx. 10 mm) was suspended in
the organ bath a 10 mN force was applied. The samples were then allowed to rest for 60-
90 minutes under constant flow of oxygenated (95% O2 / 5% CO2) Krebs buffer (120.0 mM
NaCl, 5.9 mM KCl, 25.0 mM NaHCO3, 1.2 mM NaH2PO4, 2.5 mM CaCl2, 1.2 mM MgCl2, and
5.5 mM glucose) until stable contractions were reached.
Figure 4.19. Experimental organ bath set-up.
For this particular uterine tissue, spontaneous contractions were evident throughout the
study, and stimulated changes in these were monitored. After a stable baseline was
achieved, a maximal contractile response was induced by applying HiK (20 mM KCl) to the
tissue followed by a wash out with Krebs buffer for 20 minutes. Native oxytocin, oxytocin-
polymer conjugate and respective polymers were applied to the same uterine sample (10
minutes) followed by wash outs (20 minutes), for which the order was changed each run
and the tensions were constantly recorded. 10-6 M concentrations of polymer, peptide-
polymer conjugate and native oxytocin were applied to uterine tissue extracted from 5
different rats. Using this set-up three of the different oxytocin-polymer conjugates were
tested; linear aldehyde PEG –oxytocin conjugate (2 kDa), polyPEG aldehyde conjugate (DPn
20) and polyPEG maleimide conjugate (DPn 50).
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4.2.2.1. Responses of oxytocin or conjugates upon
spontaneous contractile behaviour
Due to the spontaneous nature of the contractions observed within the tissue, complete
analysis of induction of contractions is challenging, particularly with the frequency and
intensity of these baseline contractions. The highest intensity contractions are those
observed upon stimulation with HiK, which causes an ion based mechanism which induces
significant cell contractions. This is observed within the tissue as a period of very high
frequency contractions, where the peaks are occurring too quickly to return to the
baseline. This is used to confirm the viability of the tissue to cell contraction, and in some
cases can be used as the maximum contractile response, from which agonists can be
compared. Upon addition of oxytocin (10-6 M) to the organ bath set-up, it is still relatively
easy to observe that this causes a high contractile effect upon the tissue, in terms of
frequency and amplitude compared to baseline contractions (figure 4.20).
Figure 4.20. Example pictures of HiK and oxytocin induced response in uterotonic tissueshowing effect on spontaneous contractions.
The effect of both of these ‘effective’ contraction agents can be washed out leading to the
return of spontaneous contractions with similar characteristics to before the stimulation
was induced. A few minutes after initial onset of contractile behaviour caused by oxytocin
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evocation, the contractions become less intense, even before washout had begun, which is
theorised to be due to tissue fatigue.
The same observations cannot be made for the conjugate samples, whereby it becomes
much more difficult to observe a change in the spontaneous baseline contractions (figure
4.21). It was, however, initially expected that the conjugation of polymers would reduce
the oxytocin contraction effect to some degree.
Figure 4.21. Example uterotonic traces for linear aldehyde, polyPEG aldehyde and polyPEGdithiophenolmaleimide conjugates.
This is particularly prominent on observation of a whole tissue run (figure 4.22), where the
HiK is observed as the highest contractile response, followed by the oxytocin, with little
difference on addition of the conjugate. This could potentially be highlighting that
uterotonic activity is severely suppressed by the conjugation of polymers, but further
analysis of each contraction is required to make conclusions.
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Figure 4.22. Observation of contractile responses for linear aldehyde PEG conjugatemonitoring the effect of HiK, oxytocin and conjugate upon spontaneous contractions.
4.2.2.2. Analysis of results of uterotonic testing
For analysis of the effect of each of the conjugates in comparison to oxytocin (using a
tissue repeat of n = 5) the contractile peaks (from baseline contractions and induced
contractions) were monitored across the studies. At each 2 minute interval, contractions
were monitored following amplitude, integration, duration and frequency to establish
whether there were changes compared to the normal baseline contractions. All peak
analysis was carried out with respect to 2 control peaks of the baseline contractions before
addition of the samples. After analysis of the data, the most relevant time points were
plotted for comparison of the native peptide compared to the oxytocin polymer conjugate
(figure 4.23).
Upon analysis of the data from the linear aldehyde oxytocin PEG conjugate, it is clear that
oxytocin has a large effect on the amplitude and integration of contractions, with high
observed increases after 4 minutes. This effect then dissipates, with smaller contractions
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than the baseline response at 10 minutes. The non-conjugated polymer does not show any
effect on the baseline contractions, with results remaining within 15 % of the amplitude
and integration of the control peaks. The PEGylated oxytocin shows some suppression of
spontaneous contractions, particularly after a longer exposure time to the sample (4
minutes: 0.73 X amplitude, 0.75 X integration, 10 minutes: 0.58 X amplitude, 0.50 X
integration). There are not notable changes to the frequency and duration of contractions
of the polymer or conjugate compared to the baseline control; however, oxytocin does
show a slight increase in the time between contractions after 10 minutes. This, alongside
the small reduction in integration and amplitude at this time point, is likely due to tissue
fatigue, where the oxytocic response causes large contractions initially, before dissipating
after extended exposure.
Figure 4.23. Contractile peak response analysis of data for linear aldehyde PEG and oxytocinPEG conjugate with respect to amplitude, integration, frequency and duration.
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Overall, for the linear aldehyde conjugate, there is no data that the conjugates are eliciting
any contractile response from the tissue. It is likely that a high level of activity has been
lost from peptide conjugation.
The data for the aldehyde polyPEG conjugate shows similar results to the linear conjugate,
where there is very little observed difference between the polymer induced (conjugated
and non-conjugated) and the baseline contractions with respect to amplitude, integration,
duration and frequency (figure 4.24). It is still observed that oxytocin exhibits a higher
contractile response, as expected for integration and amplitude data shortly after
introduction to the tissue, and that the frequency of contractions appears to decrease
after a longer exposure. The polymer conjugate potentially shows a higher contractile
response (compared to the control contractions and those observed with the polymer)
after 4 / 10 minutes, however, this is still below the maximum response observed for the
native peptide. This points to some activity being maintained, but not to the level exhibited
by the native peptide, and that a longer time is taken for the conjugate to elicit a response.
This would likely be due to a longer time for the conjugate to bind into the receptor as,
although the residues required for receptor binding were not changed, the addition of a
large polymer onto the peptide would likely hinder the accessibility of these required
positions to the receptor.
Overall for the polyPEG aldehyde conjugate, it is challenging to elucidate useful
information about the level of retained activity of the conjugate compared to native
polymer. Initial data suggests that it is likely activity is severely reduced; however, further
investigation is required to confirm this.
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Figure 4.24. Contractile peak response analysis of data for aldehyde polyPEG and oxytocinpolyPEG conjugate with respect to amplitude, integration, frequency and duration.
In the maleimide polyPEG sample the results are similar, with few differences between the
polymer conjugate induced, polymer induced and control contractile responses (figure
4.25). This was the largest polymer conjugate evaluated, which has a 5-fold increase in
molecular weight from the native peptide, which is highly likely to diminish the contractile
activity observed for the cells.
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Figure 4.25. Contractile peak response analysis of data for dithiophenolmaleimide polyPEGand oxytocin polyPEG conjugate with respect to amplitude, integration, frequency and duration.
The information elucidated from the organ bath uterine tissue contractility is still unclear
of the effect that polymer conjugation has on the oxytocic type activity to the cells. There
is little that appears conclusive in terms of PEGylation architecture or conjugation
approach, although it generally does point towards some loss of contractile activity of all
samples post-conjugation.
4.2.2.2.1. Statistical analysis outcomes of extracted data
Statistical analysis was performed on the results of the uterotonic testing for the oxytocin
polymer conjugates (and unconjugated polymers) in comparison to oxytocin with respect
to amplitude, integration, frequency and duration. In general, statistically there were no
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significant differences between the effects of the conjugates or the polymers to the native
peptide.
Differences were, however, observed for the linear aldehyde conjugate (and unconjugated
polymer) for contraction amplitude, with both samples showing smaller responses, 4
minutes after introduction of the solutions (conjugate: 49 ± 14 %; polymer: 61 ± 11% w.r.t
oxytocin) (p<0.05). At t = 4 minutes is where the oxytocin produces maximal contraction,
so it is likely that the reduction observed suggests that no oxytocic effect is observed in
these cases. The aldehyde polyPEG oxytocin conjugate and polymer did not show any
significant differences to the native peptide across the tissue studies in any of the four
criteria.
For the dithiophenolmaleimide polyPEG conjugate there were a couple of points raised
upon statistical analysis although overall there were mostly no significant differences
evident in comparison to native oxytocin. In terms of the amplitude of contractions after 4
minutes both the polymer and polymer conjugate showed a smaller response in
comparison to the native peptide (conjugate: 59 ± 8 %; polymer: 74 ± 8 %) (p<0.05). This is
potentially due to similar reasons as suspected for the linear aldehyde PEG, whereby the
oxytocin response is strongest at this point.
A major feature raised for this conjugate was that 10 minutes after introduction to the
tissue, the conjugate showed a much greater response w.r.t oxytocin (178 ± 26 %)
(p<0.05), with the unconjugated polymer not exhibiting the same behaviour. This
potentially highlights that the conjugate does induce a contractile response, but requires
additional time. Importantly, this large response could also be washed out in the same way
that the oxytocin effects were, meaning that the receptors did not become irreversibly
blocked. There is also evidence on analysis of the integration data to support an
enhancement in contractions after an additional lag time (t = 10 minutes, conjugate: 271 ±
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49 % w.r.t oxytocin) (p<0.05). Again, no effect was observed in the polymer, highlighting
the need for oxytocin within the structure, and contractions quickly returned to baseline
responses upon wash out.
These results present potentially useful information in how these particular conjugates
might behave as uterotonic agents, although further work is required. At present, little
information has been realised on the effect of polymer architecture or conjugation
approach through these experiments, due to the challenging nature of the spontaneous
contractions observed within the tissue.
4.2.2.3. Oxytocin receptor antagonist: Atosiban
To further investigate the binding mechanism of oxytocin to the receptor, additional
uterotonic testing was carried out using a competitive oxytocin receptor antagonist,
atosiban (figure 4.26). Atosiban has a similar structure to oxytocin, and acts by causing an
inhibition of oxytocin binding thereby preventing uterine contractions and is regularly used
as a therapeutic to delay premature labour.
Figure 4.26. Comparison of the structure of oxytocin and oxytocin antagonist atosiban.
The problems encountered on analysis of oxytocin contractility data for the conjugates
were also observed whilst comparing the effects of atosiban. The same type of tissue was
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used (3 week old SD rats) and differences between oxytocin, atosiban or oxytocin +
atosiban added in a competitive mixture did not produce any definitive findings by visual
observations or analysis of data. The results with respect to amplitude, frequency, duration
and integration all remained within 10 % of those observed for spontaneous contractions.
Figure 4.27. Trace of uterotonic contractions showing the effect of atosiban upon oxytocinuterotonic activity, after initial HiK response.
4.2.3. Uterotonic testing conclusions
It is very difficult to make conclusions about to what extent the conjugation of PEG onto
oxytocin might have influenced the uterotonic activity, due to the difficulty in observing
changes for contractions in the tissue investigated. The results from these studies are
inconclusive in establishing whether the synthesised oxytocin conjugates retain any
contractile activity. The dithiophenolmaleimide polymer conjugates present a potentially
significant find as contractions seem to be evident, but require a longer time before
contraction onset.
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Another notable point is that the concentrations investigated within this work were fairly
high compared to usual oxytocin based contraction studies. Due to the observed
spontaneous contractions causing obscuration of the exact data, it was not possible to
work with lower concentrations to observe differences between these spontaneous
baseline contractions and those induced by oxytocin.
Ideally, all polymer conjugates (and their respective polymers) would be tested to analyse
uterotonic activity, in comparison to the native peptide. However, initially a suitable tissue
needs to be fully investigated that would allow for more reasonable conclusions to be
developed. At this time there is not enough evidence to confirm that the uterotonic
activity is completely diminished upon conjugation of polymers to the peptide, however, it
is very likely that the action for an effective uterotonic is severely suppressed.
4.3. Cancer cell-line studies
4.3.1. Introduction
Research carried out by Bussolati et al. in the 1990s has shown that oxytocin and a
synthetic oxytocin-analogue (atosiban, reported in this incidence under the manufacturer
code F314) have an inhibitory effect on the cell proliferation of MDA-MB231 human breast
cells.24–26 F314 has a similar structure to oxytocin (figure 4.28) with 4 main substituent
changes, and shows similar results for the reduction of growth of these cancer cells.
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Figure 4.28. Structure of oxytocin and oxytocin analogue F314 (atosiban).
The inhibitory effect was found to be specific to the MDA-MB 231 cell line, with the same
studies carried out on a colon cancer cell line (HT29) and two hormone dependant cell
lines (MCF7 and T47D), showing that cancer cell growth was not affected by oxytocin
treatment.24 After 144 hours 10-7 M oxytocin showed a 34 % inhibition of cell growth of
MDA-MB 231, with 27 % at 10-8 M and no inhibitory effect at 10-9 M.
Oxytocin and F314 were also investigated for their in-vivo effect on mouse and rat breast
cancer tumours, using mouse colon cancer as a control.26 No effect was observed for the
colon cancer, however, an inhibitory antiproliferative effect was observed for oxytocin and
F314 (10-8 M) for both the mouse and rat tissue cell lines. The % volume increase of the rat
breast cancer tissue was decreased dramatically for oxytocin (10-8 M, 52 %) and F314 (10-8
M, 20 %) compared to the control (200 %). Oxytocin receptors have previously been found
to be expressed on a variety of different cells, not specifically within the uterus and this
was found to be the case for breast cancer cells, highlighting how oxytocin could have an
effect on cell proliferation.25
It is clear that oxytocin has many important roles within different branches of biology and
physiology, including playing an important role in inhibiting the proliferation of breast
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cancer cells. Due to the oxytocin analogue F314 also proving effective for this, an
investigation was undertaken as to whether oxytocin-polymer conjugates still had an effect
on breast cancer cell growth.
4.3.2. Investigation of oxytocin and polymer conjugates on
cancer cell proliferation
The effects of oxytocin and oxytocin polymer conjugates on cell viability were tested for
the cancer cell line MDA-MB 231 at concentrations between 10-3 M and 10-10 M. The cell
line study was conducted to investigate if the previously observed decreases in cell
proliferation were found for the oxytocin conjugates as with oxytocin, and the high
concentrations of polymers and conjugates may also begin to show trends in general cell
toxicity. Analysis of the cell lines was carried out with the use of an MTT assay (a
colorimetric assay) through which the absorbance of the MTT dye (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) is observed at 590 nm, which gives an idea of
numbers of live cells.
The effect of oxytocin on the cell proliferation of MDA-MB 231 was tested at 8 different
concentrations, with analysis after 6 days (144 hours), as previously investigated in the
literature (figure 4.29).24 This revealed that there was no overall effect observed for the
concentration of oxytocin on the proliferation of cancer cell lines, with cell growth
remaining close to a control cell growth where there was no oxytocin treatment. The
concentration that proved the most effective in the literature for inhibiting cell
proliferation was 10 -7 M (34 % inhibitory growth), and this concentration was also found to
be the furthest from the control (7 % inhibitory growth). However, this difference is not as
significant as within the literature and therefore it is difficult to build conclusions that the
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cell proliferation is being affected by the addition of oxytocin, and remains within 10 % of
the growth of control cells.
Figure 4.29. Cell viability after treatment with different concentrations of oxytocin comparedto untreated control cells after 144 hours.
The oxytocin – polymer conjugates were then tested under the same conditions as the
oxytocin study (144 hours) at concentrations between 10-6 – 10-10 M. Following this another
study was undertaken investigating the effect on cell growth of higher concentrations (10-3
– 10-7) for all conjugates (both linear and polyPEG) as well as the unconjugated polymers.
Figure 4.30 shows the effect upon cell growth of each variety of oxytocin-polymer
conjugate (both architectures, from PEGylation at the N-terminal amine and the Cys1-Cys6
disulfide bond) and the native peptide, compared to untreated control cells. The results
show that for all the conjugates tested, the cell viability was below that observed for the
control cells. Overall cell growth for all samples stayed above 75 % of that observed for the
untreated cells, indicating that there wasn’t severe cell death associated with the addition
of the conjugates, although a cell toxicity of 25 % is still significant.
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The results presented here, alongside the above results for the native peptide (a lack of
inhibition behaviour) suggest it is unlikely that the values below 100 % are due to inhibitory
effects on cell proliferation.
Figure 4.30. Cell viability on treatment with different oxytocin conjugates for 144 hours.
A further cell growth study was undertaken for all the oxytocin-polymer conjugates and
their respective polymers, investigating the effect of higher concentrations (up to 10-3, 72
h). The use of higher concentrations can yield useful information about the toxicity of the
polymers and conjugates for the cell line being tested (MDA-MB231 in this investigation).
For the majority of the conjugates tested the highest concentration of oxytocin-polymer
conjugate (10-3) used to treat the cancer cells showed the least cell viability after 72 hours.
This is likely due to cell toxicity, which is known to occur at very high concentrations of
polymers. For the linear conjugates (excluding the linear aldehyde conjugate which could
only be carried out on a concentration of 10-5 or lower) the 10-3 samples, although showing
the lowest value of cell viability, still remained over 75 % of that observed for control cells
indicating that 25 % of the cells had died compared to the control.
In comparison when the high (10-3 M) concentrations of the polyPEG conjugates are
examined, most of the samples had a cell viability of 65 % or less, with the two higher
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molecular weight DTM polyPEG conjugates causing complete cell death. This suggests
these DTM polymers are toxic at these concentrations to the MDA-MB231 cells. At
concentrations of 10-4 or above none of the oxytocin-polymer conjugates were observed to
exhibit this level of toxicity with cell viability remaining above 75 % for all other samples.
Figure 4.31. Cell viability of all linear and polyPEG oxytocin conjugates w.r.t untreated controlafter 72 hours of cell growth.
The cell viability on treatment of the cells with the unconjugated polymers was also
performed using polymer concentrations from 10-3 – 10-7 M, which would further provide
evidence of the toxicity for the MDA-MB231 cells. This showed similar trends for the 10-3 M
concentrations observed for these unconjugated polymers compared to the oxytocin
polymer conjugates, in that the dithiophenol polyPEGs prove toxic to the cells at a 10-3
concentration, independent of the molecular weight (viability < 9 %). As a comparison, the
aldehyde functional polyPEGs of the same molecular weights do not have the same
extreme toxicity, with the viability remaining about 75 % even at 10-3 M. For all the linear
polymers the cell viability remained between 65 – 90 % even at high concentrations,
suggesting less toxicity of the polymers.
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Figure 4.32. Cell viability of all polymers after 72 hours w.r.t untreated control.
4.3.3. Cancer cell line study conclusions
Although the results of the cancer cell line study with oxytocin do not support the same
inhibition of proliferation conclusions as to those observed by Bussolati et al., it is difficult
to determine what effect oxytocin has on this line of breast cancer cells. Regardless of this
unobserved effect, important data is established regarding the overall toxicity trends of the
polymers and conjugates. For this cell line the samples synthesised in chapters 2 and 3
show only moderate levels of toxicity (less than 25 %) until concentrations become very
high, where total cell death can be observed. It should be noted that toxicity of 25 %
however is still fairly significant, and this must be considered.
This is promising data as the toxicity of the conjugates is highly important to the
application for providing an oxytocin alternative as a therapeutic. It would be beneficial to
run further cell line studies to confirm that the toxicity remains low with a more
appropriate classification of cells, but the results from the tested cell line are positive in
this respect.
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4.4. Chapter 4 Conclusions
Three different methods were utilised to investigate the effect that conjugation has on the
properties of oxytocin with regard to enhancements in stability, retained uterotonic
activity and any potential inhibitory effect on the cancer cell line MDA-MB-231.
As one of the main aims of the project was to improve the heat stability of oxytocin, high
thermal stability assays were carried out on all of the conjugates in comparison to the
native peptide. It was found that all of the conjugates were less prone to degradation
under the heat stability assay than the native peptide. The polyPEG conjugates were
particularly stable with recoveries remaining above 80 % in all cases. The addition of non-
covalently bound polymers or other commonly found excipients, for the majority do not
have a large effect on improving the stability of the native peptide, although small
molecular weight PEGs can show some promising characteristics. These results show that
one of the major aims of this project has been achieved and that the PEGylation of
oxytocin, respective of the conjugation chemistry used or architecture of the polymer can
have a high influence on the thermal stability.
As it has been established that the oxytocin polymer conjugates do have highly increased
heat stability, an investigation was undertaken to assess to what degree uterotonic activity
was retained. Due to the spontaneous contractile behaviour of the tissue examined, the
uterotonic activity testing is so far inconclusive as to whether the peptide retains any
activity after the conjugation of linear or polyPEG. The activity shows a reduction when
compared to the native peptide in terms of the observation of contractions and on analysis
of the contractile data. The maleimide polyPEG conjugate shows that onset to contractions
is extended, but that contractions can still be obtained, however, further studies are
required to confirm these results.
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The cancer cell line studies did not show an inhibitory effect of oxytocin on the
proliferation MDA-MB 231 cancer cells. The conjugates compared well to the native
peptide by remaining around 100 % cell viability, relative to untreated control cells when
low concentrations were used. Upon the addition of high concentrations of polymer or
peptide-polymer conjugates, some toxicity can be observed leading to decreases in
observed cell growth or potential cell death.
In conclusion oxytocin is a highly important peptide with many different roles within
medicine and biology, other than just in those relating to childbirth. The functionalisation
of this peptide, and the effect this might have on these various applications, as well as on
general oxytocin properties (such as susceptibility to degradation) is therefore of high
interest to a range of scientific fields.
4.5. Experimental
4.5.1. High temperature thermal stability tests
4.5.1.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received. All additives (PEG / other
excipients) were purchased from Sigma Aldrich and used as received.
4.5.1.2. Instrumentation & Analysis
High performance liquid chromatography (HPLC) was performed on Agilent 1260 Infinity
series stack equipped with an Agilent 1260 binary pump and degasser. 50 µl samples were
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injected using Agilent 1260 autosampler with a flow rate of 1 ml/min. The HPLC was fitted
with a Phenomenex Luna C18 column (250 x 4.6 mm) with 5 micron packing (100Ǻ).  
Detection was achieved using an Agilent 1260 variable wavelength detector monitoring at
280 nm. Mobile phase A consisted of 100 % water containing 0.04 % TFA and mobile Phase
B consisted of 100 % acetonitrile containing 0.04 % TFA as an additive. The column was
equilibrated by washing with the starting % of mobile phase A for 10 minutes prior to
injection for all conditions. The method used was as follows: 95 % mobile phase A
decreasing to 80 % mobile phase A after 15 minutes, followed by decreasing to 40 %
mobile phase A after a further 7 minutes and remaining at 40 % mobile phase A for 5
minutes before resetting to 95 % mobile phase A in 1 minute.
4.5.1.3. Heat Stability assay procedure
Each of the conjugate samples were run at 5 different concentrations on RP-HPLC (UV:
λ=280 nm) as dilutions of the concentration used for the stability assay of [1.0], [0.8], [0.6], 
[0.4] & [0.2]. The native peptide was also run at each of these concentrations as well as
[0.1], [0.05] & [0.01] for increased reliability of low oxytocin levels. A linear calibration plot
was produced from the concentrations vs. the peak area (mAUs) for all samples.
Oxytocin and oxytocin polymer conjugates were dissolved in HPLC grade water at the
concentrations between 0.05 mM and 1 mM. For the excipient studies the additives (2 mM
or 200 mM) were added to solutions of oxytocin (2 mM) giving total concentration of
oxytocin as 1 mM with excipients in 1 x or 100 x molar excess.
The solutions were placed in a Thermo Scientific Heratherm oven set to 80 °C and left for
24 hours. After this time the samples were cooled to room temperature before being
submitted for RP-HPLC. The % remaining of oxytocin or the oxytocin conjugates was
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calculated from the absorbance of oxytocin (or the conjugate) with respect to the
calibration curve.
4.5.1.4. Synthesis of non-conjugating poly(mPEGA480)20
In an oven dried Schlenk tube, CuBr (3.6 mg, 24.9 µmol) and water (1 ml) were added and
stirred before the addition of tris[2-(dimethylamino)ethyl]amine (6.6 µl) upon which there
was the immediate formation of Cu(0) powder and blue CuBr2 solution which was
degassed by nitrogen bubbling for 30 minutes. In a separate vial, EBiB (9.1 µl, 62.2 µmol)
and poly(ethylene glycol) methyl ether acrylate (Mw = 480, 0.548 ml, 1.24 mmol) were
dissolved in DMSO (6 ml) and water (0.5 ml) and degassed by nitrogen bubbling for 30
minutes. The monomer/initiator solution was then added into the catalyst solution by
injection (t = 0) and the reaction was stirred at ambient temperature under nitrogen for 20
hours. After this time a sample was removed and diluted with δ6-DMSO for 1H NMR
analysis and DMF for GPC molecular weight data. The polymer was purified by dialysis (1
kDa MWCO) for 3 days against water, before lyophilisation.
4.5.2. Uterotonic testing of oxytocin and oxytocin conjugates
N.B. This work was carried out by the author at Monash University, Melbourne, Australia as
part of an 11 week research visit.
No animal ethics approval or animal ethics committee (AEC) notification was required for
the uterotonic work as the tissues were scavenged post-mortem from rats that were
scheduled to be culled from Monash animal research platform (MARP) stocks under their
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approved ethics protocol. This is as set out in the guidelines for the conduct of animal
ethics committees (Victoria) and Monash University ethical research and approvals policy.
4.5.2.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received. Krebs buffer was freshly prepared
and consisted of 120.0 mM NaCl, 5.9 mM KCl, 25.0 mM NaHCO3, 1.2 mM NaH2PO4, 2.5 mM
CaCl2, 1.2 mM MgCl2, and 5.5 mM glucose. The synthesis of peptide-polymer conjugates
and unconjugated polymers are described within this thesis in chapters 2 and 3.
4.5.2.2. Experimental Procedures
For the investigation of uterotonic activity of oxytocin and oxytocin-polymer conjugates ex-
vivo organ bath analysis was carried out using uterotonic tissue freshly scavenged from 3
week old Sprague Dawley rats. The right uterine horn was promptly removed post mortem
and immediately stored in Krebs solution. The tissue was trimmed to 10 mm and
suspended in the organ bath after which a force of 10 mN was applied. The organ bath was
perfused at a constant rate of 4 ml/min with Krebs solution whilst the temperature was
maintained at 37 °C and the solutions constantly aerated with 95 % O2/5 % CO2.
Tensions were constantly recorded and monitored using LabChart software connected to
the PowerLab instrument (ADL instruments).
4.5.3. Cancer cell line study
N.B. The cancer cell line study was carried out by Danielle Senyschyn in the presence of the
author at Monash University, Melbourne, Australia as part of an 11 week research visit.
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4.5.3.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received. The synthesis of peptide-polymer
conjugates and unconjugated polymers are described within this thesis in chapters 2 and 3.
Media formulation consisted of Dulbecco's modified eagle medium (DMEM, high glucose,
GlutaMAX™, Gibco), 10% fetal bovine serum (FBS, Life Technologies) and penicillin-
streptomycin 100X (10,000 U/mL, Life Technologies) and was kept at 37 °C prior to
immediate use and stored at 4 °C.
4.5.3.2. Experimental Procedures
4.5.3.2.1. Cell line preparation
Cells removed from liquid nitrogen and thawed in 37 °C water bath, and added to media
(10 % cell solution). Cells spun for 5 minutes at 125 - 130 x g, before removal of media, and
repetition of procedure. Pellet suspended in 1 ml media and added to flask containing 4 ml
media, for incubation at 37.5 °C / 5 % CO2 for 3 days.
Media was removed from flask and cells washed with 5 ml PBS before addition of 5 ml
Trypsin (0.25 %, Life Technologies) and placed in incubator at 37 °C for a few minutes. 10
ml media was added, and an aliquot removed for cell counting and remainder of solution
span in centrifuge for 5 mins at 125 – 130 x g, before removal of media. Fresh media was
added so concentration of cells was 50,000 per ml, and 96 well plate seeded with 100 µl of
this solution per well. 24 hours after seeding, media removed and replaced with 80 µl fresh
media before treating cells with oxytocin, oxytocin-polymer conjugates or unconjugated
polymers (10 -3 – 10 -9 M) and leaving for 72 or 144 hours.
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4.5.3.2.2. MTT assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was reconstituted in
PBS at 5 mg ml-1 and sterile filtered, before dilution in fresh media to 0.5 mg ml-1. Media
was removed from cells and 100 µl of MTT solution added to each well. Plate was
incubated at 37.5 °C / 5 % CO2 for 2 hours, before removal of MTT and addition of 100 µl
DMSO and plate shaken for 5 – 10 minutes. The absorbance of cells was read with a plate
reader at 590 nm.
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Chapter 5
5. Synthesis and post-polymerisation peptide
conjugation of functional polymers
There is considerable scope within polymer synthesis and conjugation chemistry for the
incorporation of a wide variety of different polymers for a variety of tailored functions.
Using the copper mediated polymer synthesis and post-polymerisation peptide conjugation
strategies introduced in chapters 2 & 3; different functional polymers were incorporated
site-specifically onto oxytocin and a second small peptide. Three different classes of
polymers are described all of which could provide interesting or advantageous properties
within the biomedical field of protein / peptide modification and polymer therapeutics.
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5.1. Potential alternatives to PEG
PEG is still one of the most popular polymers utilised for a variety of different biomedical
applications (including in the pharmaceutical market, where multiple PEG products have
achieved FDA approval), and is the gold standard in the field of polymeric drug delivery.1–3
A multitude of advantageous properties are evident including stealth behaviour, prolonged
blood circulation, which, coupled with a high biocompatibility lead to its success within the
biomedical field and on the commercial market.4–6 However, the use of PEG is not without
disadvantages including a lack of biodegradability leading to potential accumulation within
tissues as well as the possibility of interaction with the immune system.3,7,8
Many natural polymers have been utilised in various drug-delivery systems but more
recently there has been a substantial amount of research focused on developing synthetic
alternative polymers to PEG.9 This is with an overall aim to reproducing some of the highly
desirable PEG characteristics but with potential suppression of some of these unfavourable
side effects. These can generally be placed into two classes: biodegradable and non-
biodegradable polymers (figure 5.1). Biodegradable polymers generally contain backbone
functionality capable of undergoing the desired degradation and several examples are
derived from amino acids, such as poly(glutamic acid), poly(hydroxyethyl-glutamine) and
poly(hydroxyethyl-asparagine).10,11 These degrade into their amino acid units, which can
simply be metabolised within the body, and thus have been utilised as drug-delivery
alternatives to PEG.
Non-biodegradable PEG alternatives generally possess similar problems to PEG with
respect to accumulation within organs, but can also provide highly desirable PEG-type
characteristics. Various non-biodegradable PEGs have been investigated which include
similarities to PEG with the inclusion of heteroatoms in the backbone chain such as
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polyglycerols,12,13 poly(2-methyl-2-oxazoline) and poly(2-ethyl-2-oxazoline).14–16 These have
proven to have comparable advantages to PEG including good biocompatibility, but some
of the disadvantages for PEG are still evident with the potential for bioaccumulation and
immune activation.9 Other PEG alternatives wherein the use of vinyl monomers creates a
polymer backbone with a repeating unit consisting of the side chains are also available,
similar to the polyPEGs discussed in previous chapters. These include
poly(vinylpyrrolidone),17 poly(acrylamide),17,18 and poly(N-(2-
hydroxypropyl)methacrylamide)19,20 with varying levels of success in biomedical
applications. As with PEG, high biocompatibility can be achieved but there are still
drawbacks associated with accumulation of polymers and immunological behaviour.
Figure 5.1. PEG, polyPEG and some different biodegradable and non-biodegradable PEGalternatives.
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In the first sub-section of this chapter, the synthesis of one other PEG alternative will be
explored using copper mediated living radical polymerisation. The post-polymerisation
conjugation of this polymer onto the N-terminal amine of oxytocin will then be evaluated
in comparison to the PEGylation strategies described in chapter 2.
5.1.1. Poly(2-oxazolines): A valuable PEG alternative?
One of these promising PEG alternatives that has received considerable investigation
within the literature is poly(2-oxazoline)s (POx), a highly functional class of polymers that
are themselves also biocompatible.16 POx are synthesised by cationic ring opening
polymerisation (CROP) of 2-substituted-2-oxazolines, and depending on the 2-substituent
functionality, different properties can be obtained. Poly(2-oxazoline)s have previously
shown promise as anti-fouling polymers and for ‘stealth’ behaviour and this, coupled with
their biocompatibility, has expanded the use of these polymers for a variety of purposes.14
The structure and functionality of polymers can also be effectively tailored to purpose by
careful selection of initiation and termination reagents for the incorporation of a variety of
functionalities in the chain.21 Linear POx polymers have previously been studied for peptide
and protein modifications with successful conjugations reported with carboxylate, alkyne
and aldehyde functional polymers, often of ethyl or methyl poly(2-oxazolines).15
In a similar manner to PEG, as well as proving highly useful as a linear polymer, ‘comb’ type
polymers can be synthesised utilising an oxazoline based macromonomer.22–24 Upon
polymerisation this yields a polymer backbone with short oxazoline based side chain
‘teeth’, the functionality of which is determined by the 2-substituent on the 2-oxazoline
monomer. POx macromonomers have previously been used in controlled radical
polymerisation techniques, such as reversible addition-fragmentation chain-transfer
polymerisation (RAFT) and atom transfer radical polymerisation (ATRP), although synthesis
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have previously proved challenging.23,25 Little work, however, has been carried out on the
functionalisation of peptides or proteins with comb poly(POx) based polymers, using
traditional conjugation approaches, even with large amounts of interest generated in the
highly successful conjugation of linear POx. There have, however, been some incidences of
repeat unit ‘teeth’ functionalisation for the synthesis of glycosylated or antibody
conjugated poly(POx), but this was targeted at a general decoration of poly(POx) with
biomolecules of interest.26,27 This therefore leads to the potential exploitation of this
relatively unexplored area within polymeric therapeutic conjugation of the effects that this
comb poly(POx) might have upon the biomolecules, particularly in comparison to
equivalent poly(PEG)s, which have been well studied. The various methods of polyPEG
synthesis and conjugation described in chapters 2 & 3 can be applied to the synthesis and
oxytocin conjugation of poly(POx) for the incorporation of a potentially highly valuable, but
relatively unexplored PEG alternative.
5.1.1.1. Synthesis of poly(OEtOxMA)
Scheme 5.1. Oligo(2-ethyl-2-oxzoline)methacrylate macromonomer synthesis with initiationby methyl tosylate and termination by methacrylic acid.
Oligo(2-ethyl-2-oxazoline)methacrylate (OEtOxMA) (DPn = 5, Mn = 600 g mol-1) was
synthesised within our group by CROP, with initiation by methyl tosylate and termination
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with methacrylic acid, which results in a methacrylic monomer containing a short side
chain of oligo(2-ethyl-2-oxazoline) (scheme 5.1).24 This resulted in a macromonomer with a
molecular weight of 600 g mol-1 (CHCl3 NMR), whilst maintaining a narrow dispersity (Ð =
1.21, CHCl3 SEC) (figure 5.2).
Figure 5.2. 1H NMR (CDCl3) and SEC (CHCl3) of oligo(2-ethyl-2-oxazoline) methacrylatemacromonomer.
Previous polymerisations described in chapter 3 utilised the disproportionation of Cu(I)Br
with Me6TREN in aqueous solutions for the controlled synthesis of poly(mPEGA), an acrylic
macromonomer.28–30 When utilising the disproportionation of copper(I) in aqueous
solutions as a polymerisation technique for the synthesis of methacrylates, it has
previously been found that for control to be maintained a few adaptations must be made
to the polymerisation system.31 The replacement of CuBr with CuCl is beneficial in
improving polymerisation control. More termination can usually be observed with the
polymerisation of methacrylates compared to acrylates (due to a lower kp) further
disadvantaged by the weak nature of the Cu-Br bond. It is also useful to use a less
activating ligand for the polymerisation of methacrylates and hence Me6TREN (which is a
very proficient ligand for the synthesis of poly(acrylate)s) was substituted for PMDETA.28
Additionally, the inclusion of a halide salt (NaCl) as an external additive to the
polymerisation solutions has been shown to improve the control of polymerisations by
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preventing halide dissociation from the copper complex,32 and can influence the ω-Cl end 
group retention.31
OEtOxMA was polymerised at 25 °C in water/methanol (1.5:2) with the addition of 1.6 M
NaCl ([I]:[CuCl]:[PMDETA] = 1:0.8:0.8). Two different molecular weight poly(OEtOxMA)
polymers were targeted at [M]:[I] ratio of 10 and 20 (target molecular weights of 6 and 12
kDa) using two different initiators, with reaction sampling after 24 hours (scheme 5.2).
Scheme 5.2. Polymerisation of oligo(2-ethyl-2-oxazoline) in water/methanol containing 1.6 MNaCl salt using two different initiators with [I]:[CuCl]:[PMDETA] = 1:0.8:0.8.
Initially a water soluble initiator (WSI, 2,3-dihydroxypropyl 2-bromo-2-
methylpropanoate),33 which has been well established for aqueous Cu(0) mediated
polymerisations,29 was utilised using the optimised (CuCl/PMDETA/NaCl) polymerisation
conditions. After 24 hours an almost quantitative conversion was attained at both
molecular weights. The conversion was calculated by a comparison between the monomer
vinyl peaks (δ = 5.6 – 6.0 ppm) and the 10 protons from the CH2 within the ethyl chain of
the macromonomer (δ = 2.29 ppm). Molecular weight distributions were narrow (Ð < 1.12) 
and mono-modal, with molecular weights estimated by SEC as 7.5 and 11 kDa (figure 5.3).
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Figure 5.3. 1H NMR (CHCl3, 400 MHz) and SEC (CHCl3) of poly(OEtOxMA) at t = 24 hourssynthesised with WSI ([I]:[CuCl]:[PMDETA] = 1:0.8:0.8 , MeOH/H2O , 1.6 M NaCl).
5.1.1.2. Synthesis of α-aldehyde functional poly(OEtOxMA)
The protected aldehyde (PALD) initiator34,35 utilised for the synthesis and conjugation onto
oxytocin of aldehyde α-end group functional poly(mPEGA) in chapter 2 was then applied 
under the same conditions ([I]:[CuCl]:[PMDETA] = 1:0.8:0.8; [M]:[I] = 10 / 20). As with the
polymerisations using the water soluble initiator, quantitative conversions were attained
after 24 hours at 25 °C. SEC analysis of the resulting polymers displayed mono-modal peaks
with narrow dispersities (Ð < 1.10) (figure 5.4).
Figure 5.4. 1H NMR (CHCl3 , 400 MHz) and SEC (CHCl3) of poly(OEtOxMA) at t = 24 hourssynthesised with PALD initiator ([I]:[CuCl]:[PMDETA] = 1:0.8:0.8 , MeOH/H2O , 1.6 M NaCl).
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The controlled synthesis of these polymers to quantitative conversions under benign
conditions present clear advantages over previous polymerisation techniques which have
been described for the OEtOxMA monomer. Within the literature, polymerisations have
often struggled to achieve full monomer conversions or have required much higher
equivalencies of copper salts and ligands.23,25
The molecular weight of the DPn 20 polymer (particularly for synthesis with PALD initiator)
by SEC analysis (Mn = 8 kDa) deviated slightly from the theoretical target (12 kDa), this is
ascribed to the differences in the hydrodynamic volume of polymers and the SEC PMMA
calibration. On further analysis of the purified polymers (dialysis against water, 1 kDa
MWCO, 3 days) by 1H NMR (δ6-DMSO) (figure 5.5) the exact molecular weights could be
evaluated by a comparison of the (CH3O)2CH peak (δ = 4.42 ppm) of the initiating group, 
and the CH2 group within the macromonomer repeat unit within the polymer (δ = 2.9 
ppm). This gave resulting experimental molecular weights of 7.8 kDa and 12.4 kDa for the
DPn 10 and DPn 20 PALD polymers, which are in agreement with the theoretical values.
After purification there was a small increase in the dispersity of polymers, but the
molecular weight distributions still remained narrow (Ð < 1.25).
Figure 5.5. 1H NMR (δ6-DMSO, 400 MHz) of PALD-poly(OEtOxMA)10 polymer after purification.
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The α-acetal protecting group of the polymer was removed by treatment in aqueous 
solutions of trifluoroacetic acid (50 % v/v) for 3 days, resulting in α-aldehyde functional 
polymers (figure 5.6). The end group was confirmed by 1H NMR, where there was a
complete disappearance of the peaks representing the acetal protecting group (δ = 4.42 
ppm) with the appearance of characteristic aldehyde peaks (δ = 9.57 ppm). 
After deprotection, analysis by SEC confirmed there was no decrease in molecular weight
of the polymers, verifying that there was no cleavage of the oligo(2-ethyl-2-oxazoline) side
chains from the polymer backbone. This resulted in two different molecular weights of α-
end aldehyde functional poly(OEtOxMA), which could subsequently be grafted onto a
peptide or protein at an amine group in a ‘grafting-to’process.34
Figure 5.6. 1H NMR (δ6-DMSO) and SEC (CHCl3) after deprotection of acetal protected aldehydeend group functionality.
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Table 5.1. Polymerisation data for the synthesis of poly(OEtOxMA) in MeOH/H2O (2:1.5)containing 1.6 M NaCl with CuCl and PMDETA.
Initiator TargetDPn
Target
MW (Da)
Conversion
% (NMR)
Mn
(Da)
(SEC)
Ð
(SEC)
Mn
(Da)(SEC)
Deprotected
Ð (SEC)
Deprotected
WSI 10 6000 >99.9 7500 1.08 - -
WSI 20 12000 >99.9 10900 1.12 - -
PALD 10 6000 >99.9 6000 1.23 6500 1.14
PALD 20 12000 >99.9 8000 1.18 7900 1.15
5.1.1.3. Peptide conjugation reactions of α-aldehyde
poly(OEtOxMA)
Initially, a dipeptide (NH2-Gly-Tyr-COOH) [Gly-Tyr] was used as a model peptide for the
reductive amination reaction of α-aldehyde functional poly(OEtOxMA). As with oxytocin 
[Gly-Ty] does not contain any amino groups other than that of the N-terminal amine of the
peptide and thus conjugation would occur in a singular and site-specific manner (figure
5.7).
After 5 days the conjugation reaction was monitored by RP-HPLC which revealed the
disappearance of the Gly-Tyr signal alongside the appearance of a broad conjugate peak at
a higher retention time to the native peptide. The polymer conjugate was then purified by
dialysis to remove any residual dipeptide and 1H NMR analysis revealed the appearance of
aromatic peaks (δ = 6.5 – 7.0 ppm) consistent with the tyrosine signals observed within the 
dipeptide confirming that the [Gly-Tyr] group was now present on the polymer.
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Figure 5.7. Conjugation reaction of [Gly-Ty] with α-aldehyde poly(OEtOxMA) monitored by RP-
HPLC (λ = 280 nm) and 1H NMR (δ6-DMSO, 300 MHz).
The aldehyde α-end functional poly(OEtOxMA)s were then conjugated onto oxytocin via
reductive amination, with the addition of NaCNBH3 as a reducing agent (scheme 5.3).
Scheme 5.3. Reductive amination conjugation of aldehyde poly(OEtOxMA) onto oxytocin withaddition of NaCNBH3.
After 4 days a sample was removed from the reaction and analysed by RP-HPLC which
revealed the disappearance of the majority of the native peptide (retention time t = 12.5
minutes) and the appearance of a new, broad peak at a higher retention time (DPn 10: t =
20.8 minutes; DPn 20: t = 21.4 minutes) (figure 5.8). As previously explored with the
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reductive amination of aldehyde functional linear PEG and polyPEG onto oxytocin, there is
only one amino group present at the Cys1 amino terminus, and therefore polymer
conjugation is singular and site-specific. For the conjugation of these polymers onto
oxytocin, the reaction was more efficient than with the reductive amination of the α- 
aldehyde poly(mPEGA)s observed in chapter 2, with less unreacted peptide remaining
within the solutions.
Figure 5.8. RP-HPLC of reductive amination of aldehyde functional poly(OEtOxMA) ontooxytocin after addition of NaCNBH3.
It must be noted that the polymer, prior to conjugation, shows a small broad peak in a
similar region, but when the same concentration of polymer and oxytocin-polymer
conjugate were analysed (λ = 280 nm) the absorbance increased approximately 20 times 
post conjugation (figure 5.9). There is also a very minor shift in the retention time of the
peak from the polymer to the conjugate (DPn 10: 21.6 to 20.8 minutes; DPn 20: 21.9 to 21.4
minutes). This, alongside the disappearance of the native peptide observed on RP-HPLC,
suggests that polymer conjugation has occurred and that the absorbance of the polymer
conjugate RP-HPLC chromatogram is larger due to a change in molar extinction coefficient
(most likely due to the high absorbance of the peptide at λ = 280 nm). 
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Figure 5.9. RP-HPLC monitoring of aldehyde functional poly(OEtOxMA) (DPn 10 and 20) beforeand after conjugation onto oxytocin.
The reversibly linked Schiff base conjugates (without the addition of NaCNBH3) were
synthesised in the same manner as by reductive amination with an exclusion of the
reducing agent (scheme 5.4). The conjugation was much slower than for the reductive
amination conjugation, but the appearance of broad conjugate peaks can still be observed
by RP-HPLC, with a new conjugate peak clearly visible at t= 4 days. After 14 days there was
a further appreciable decrease in the oxytocin peak (further 66 % decrease compared to t=
4 days). Although there is still unreacted peptide remaining within the solution, there is an
accompanying (2 X) increase in the amount of conjugate (figure 5.10).
Scheme 5.4. Reversible (Schiff base) conjugation of aldehyde poly(OEtOxMA) onto oxytocin.
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Figure 5.10. RP-HPLC monitoring of the formation of oxytocin-poly(OEtOxMA)20 Schiff baseconjugate.
5.1.1.4. Schiff base reversibility studies of oxytocin-
poly(OEtOxMA) conjugates
As with the Schiff base linked poly(mPEGA) oxytocin conjugates, described in chapter 2,
reversibility studies were undertaken to establish whether the native peptide could be
released under stimulated conditions. When the polyPEG Schiff base conjugates were
studied these were found not be reversible under the conditions evaluated, whereas
similar linear polymers did have reversible characteristics, suggesting that architecture
plays an important role. The poly(OEtOxMA) conjugates were analysed to determine
whether the different macromonomer behaved differently, which would highlight further
details about the stability of this aldehyde linkage.
The reversibility of the DPn 10 and DPn 20 polymers were analysed at pH 5 (citrate buffer,
0.1 M) and pH 7.4 (phosphate buffer, 0.1 M) at t = 4 days and t = 14 days. The experiments
were performed at ambient temperature (T < 20 °C) as with the poly(mPEGA) samples and
at T = 37 °C, to examine whether temperature played a role in the reversal. This revealed
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that there was no significant reversal of the Schiff base linkage for any of the samples, with
the conjugate peak remaining in the same position, and peak area not decreasing
significantly (figure 5.11).
Figure 5.11. RP-HPLC monitoring of reversal of oxytocin-poly(OEtOxMA)20 conjugates at pH 5and pH 7.4 after 14 days at ambient temperature or at T = 37 °C.
The higher temperature studies showed minor shifts within the conjugate peak, as well as
the potential appearance of some other products at retention times t = 10.4 minutes and t
= 13.4 minutes. However, any changes in peak area remain below 15 % of the total
conjugate area, which does not suggest that appreciable reversible characteristics were
achieved.
This shows very similar characteristics to the attempted reversibility of polyPEG Schiff base
linked oxytocin conjugates. It is believed that this is possibly due to the linker length
between the aldehyde and highly polymer dense ‘comb’ type structure. In chapter 2 the
polymer (or non-polymer) architecture was found to be highly vital in allowing the
reversible nature of this linkage to be exploited. As two different polymers synthesised
from respective macromonomers (poly(mPEGA) and poly(OEtOxMA)) have both been
found to show difficulties in stimulating the reversible nature, from this particular
protected aldehyde initiator, it has been shown that the incorporation of these
architectures suppresses peptide release.
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5.1.1.5. Degradation studies on reduced oxytocin-
poly(OEtOxMA) conjugates
The degradation of the poly(OEtOxMA) oxytocin conjugates was monitored after 24 hours
of storage at 80 °C (figure 5.12). The stability, with respect to retained conjugate peak area
remained at close to 100 %, as previously observed for poly(mPEGA) oxytocin conjugates,
with little differences between repeats of samples.
Figure 5.12. Bar chart and RP-HPLC traces showing degradation of oxytocin-poly(OEtOxMA)conjugates in comparison to native peptide after 24 h at 80 °C.
On closer inspection of the RP-HPLC traces, however, there are some differences between
the chromatograms at t = 0 and after 24 hours of high temperature storage for the
polymer conjugates with regard to peak shape and retention time. This could be indicative
that there has been some distortion or degradation within the polymer conjugate at this
temperature; however, with no loss of oxytocin or diminishment of absorbance it is
difficult to confirm. Whilst there is only a minor shift of the peak, this highlights a challenge
of this high temperature degradation study as a method of testing the conjugate stability.
Further it must be noted for the synthesis of 2-ethyl-2-oxazoline based polymers that LCST
(lower critical solution temperature) transitions can often be observed, whereby cloud
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points can be exhibited, particularly for linear polymers of 2-ethyl-2-oxazoline.36 The cloud
point temperatures of poly(2-R-2-oxazoline)s vary depending on the R substituent. For
linear POx polymers; poly(2-methyl-2-oxazoline) does not have an observed cloud point in
aqueous solutions, whereas the cloud points of poly(2-ethyl-2-oxazoline), poly(2-n-propyl-
2-oxazoline) and poly(2-iso-propyl-2-oxazoline) are all very different. This allows tuning of
LCST behaviour to a desired temperature to be achieved by changing the monomer, or
allowing the synthesis of a copolymer, where each monomer exhibits different thermally
responsive temperatures. The LCST behaviour of poly(POx) ‘comb’ polymers has also
previously been evaluated, with large differences observed between different
macromonomer sizes and depending on the pH of the solution.25
As the degradation studies are performed at elevated temperatures, this could be reaching
close to the cloud point of these polymer conjugate solutions. To investigate this, cloud
point measurements were undertaken with the two oxytocin-polymer conjugates
monitoring the absorbance at λ = 500 nm, between 20 °C and 90 °C (figure 5.13).  
Figure 5.13. Cloud point measurements of oxytocin –poly(OEtOxMA) conjugates in water (5mg ml-1) at λ = 500 nm.
By observing the point where the transmission is at 50 % within the third heating run, the
cloud points for the oxytocin polymers conjugate solutions (5 mg ml-1) were determined as
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83.1 °C (DPn 10) and 77.8 °C (DPn 20). These are close to the temperature used for the
degradation study, and it is likely that some of this thermoresponsive behaviour is present
when measuring the stability of both conjugates in this manner. Previously a DPn 20
poly(OEtOxMA) prepared by RAFT (33 % conversion, Mn = 7100 Da, Ð = 1.18) of the same
size macromonomer (DPn = 5) was evaluated as having a cloud point as 84.4 °C (5 mg ml-1,
H2O).25 The similarity in value suggests that polymers synthesised in different manners can
show similar cloud points, and the end group functionality, regardless of whether this is a
peptide or small molecule does not have a large effect on the temperature of non-
solubility.
The polyPEGs that were analysed by the same 80 °C degradation study do not show a cloud
point around this temperature (previously reported cloud points > 90 °C), therefore the
possible thermoresponsive nature does not create similar issues for the thermal stability
described in chapter 4. In conclusion, the thermal behaviour of these poly(POx) polymers
must be considered when performing high temperature stability studies. This is particularly
important when polymers are being evaluated as potential alternatives for PEGylation in
respect of prioritising increasing the thermal stability.
5.1.2. Potential alternatives to PEG conclusions
There are many strategies available for the synthesis and conjugation of a variety of
polymers that can act as alternatives to PEG for a multitude of purposes. In this chapter so
far we have explored the potential use of poly(POx) for the synthesis of peptide polymer
conjugates and how these compare to the well-studied poly(PEG)s with regard to
improving the degradation profile of a dramatically unstable, but globally well-utilised
therapeutic peptide.
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In this work these polymers have been synthesised in a controlled manner, utilising an
optimised copper mediated polymerisation technique to contain α-aldehyde end group 
functionality. Succeeding the synthesis, post-polymerisation modification and two
subsequent conjugations onto the Cys1 amino terminus of oxytocin were achieved via
reductive amination and Schiff base chemistry. The Schiff base reversal studies show
similar results to those previously observed for the conjugation of polyPEGs in that the
reversible reaction is hard to stimulate under acidic conditions.
It would be beneficial to further synthesise other alternatives to PEG and evaluate the
properties that polymer-conjugates may possess, post-conjugation, as a comparison. There
is a large library of different polymers that can exhibit PEG-like properties, where the same
polymer synthesis and conjugation chemistry could be easily adapted for the investigation
of new polymers for conjugation onto therapeutics.
5.2. Thermoresponsive polymers for peptide
conjugation
The incorporation of stimuli-responsive functionalities into polymers (such as temperature-
, pH-, redox- and light-responsive) is a field that has received large amounts of attention
within the literature.37,38 Thermoresponsive polymers exhibit a change in properties upon
stimulation with temperature, such as a rapid change in solubility in a medium upon
reaching a critical temperature (LCST, lower critical solution temperature; UCST, upper
critical solution temperature). This behaviour has previously been utilised for a variety of
applications, and is particularly notable within the field of polymer therapeutics such as for
drug delivery.39–42
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The development of living radical polymerisation (LRP) techniques has allowed the
synthesis of thermoresponsive polymer bioconjugates to be rapidly developed.43 Different
functional monomers are available which, when incorporated into (co)polymers, can
exhibit interesting phase transitions at elevated temperatures. A popular example of a
monomer regularly utilised in LCST systems is N-isopropylacrylamide (NiPAm). Poly(NiPAm)
is a useful thermoresponsive polymer with a biologically relevant thermal solubility
transition at ~32 °C in aqueous solutions, generally independent of molecular weight and
concentration.44,45 A coil-to-globule transition is stimulated on heating, which is
entropically favourable and driven by the formation of hydrogen bonds and water
expulsion.46 A second class of polymers that have received a lot of interest are the
utilisation of copolymers of monomers exhibiting highly different phase transition
temperatures. These prove very useful as these can be specifically tailored as desired by
varying the relative component ratios. One of such copolymer mixtures is poly(oligo
ethylene glycol)(meth)acrylates.47,48 The solubility transitions of shorter (meth)acrylate
oligo ethylene glycol monomers are relatively low (MEO2MA = ~26 °C), whereas for longer
PEG monomers this is much higher (8/9 ethylene glycol units < 90 °C). Therefore, by
altering the ratio of the monomers, any temperature for an LCST transition can be attained
between these two temperatures.
The attachment of thermoresponsive (or other stimuli-reactive polymers) onto
biomolecules, including proteins and peptides, can provide an interesting class of
bioconjugates.43 The properties of the attached polymers can be lent to the biomolecules,
and due to the large library of thermoresponsive polymers available, this can be tailored to
a suited purpose. Stimuli responsive conjugates have previously been reported wherein
conjugation was performed utilising a grafting-from or grafting-to approach, with
biomolecule targeting including both amino and thiol routes. Stimuli responsive protein-
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polymer conjugates can prove useful in allowing tuning or control of biomolecular
processes, by using external changes to alter function for a range of applications. One
example of a thermally induced biomolecule response, described in the 1990s by
Hoffman, was a thermoresponsive enzyme conjugate which had the ability to mask the
active site, altering enzyme activity and thereby preventing or allowing active site
binding.49,50
Within this next sub-chapter the synthesis of dithiophenolmaleimide α-end functional 
thermoresponsive polymers is presented which could be utilised for disulfide rebridging
conjugation via a post-polymerisation conjugation (‘grafting-to’) type technique. This
would result in more thermally resistant peptide polymer conjugates, which should retain
some of the thermoresponsive behaviour of the post-conjugation polymers.
5.2.1. Optimisation of reaction conditions and
synthesis of thermoresponsive polymers
The copper mediated living radical polymerisation method utilising the prior
disproportionation of Cu(I)Br with Me6TREN in aqueous solvents was used to prepare
thermoresponsive dithiophenolmaleimide polymers. Due to the insolubility of the initiator
in aqueous solutions a reasonable cosolvent system had to be developed which could be
used in a similar manner to the DMSO/H2O polymerisation described for the synthesis of
DTM polyPEGs in chapter 3, for the controlled synthesis of thermoresponsive polymers.
Firstly, the solubility of the initiator was investigated in various organic solvents and found
to remain soluble as long as the water content remained below 25 % in DMSO, 35 % in
MeOH and 45 % in EtOH. As a cosolvent is required, the solvent conditions were initially
optimised for the polymerisation, and this optimisation was performed using the
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completely water soluble initiator (WSI) mentioned previously, which has been well
reported for these types of polymerisations.29 As a starting point polymerisations were
conducted in a DMSO/H2O system using a similar method to that described in chapter 3 for
the synthesis of DTM α-end functional poly(mPEGA).   
Two different classes of polymers exhibiting potentially biologically relevant LCSTs were
investigated, N-isopropylacrylamide (NiPAm), and a copolymer of poly(ethylene glycol)
methyl ether acrylate (mPEGA) and di(ethylene glycol)ethyl ether acrylate (eDEGA). The
cloud point observed for the poly[(mPEGA)x(eDEGA)1-x] copolymer is entirely tuneable by
changing the ratio between the monomers. Homopolymers of poly(mPEGA) generally
exhibit high cloud points (> 90 °C), whereas homopolymers of DEGA are lower (≈ 10 °C), 
therefore copolymers can be synthesised which have a desired cloud point within this
range, by changing the monomer ratio.47 Copolymerisations varying the ratios of these
monomers with evaluation of resultant cloud point temperatures have previously been
reported by Lutz et al. using copper mediated polymerisation (ATRP)51–53 and by Davis et al.
using RAFT.54,55 For the cloud point to be biologically relevant at approximately 32 - 37 °C,
(a similar temperature to that observed for poly(NiPAm) ~ 32 °C) the ratio required is
between 5 – 20 % of the PEGA macromonomer.
An important step in the polymerisation is the initial disproportionation of Cu(I)Br with
Me6TREN forming a blue Cu(II) solution and Cu(0) particles, before the addition of the
initiator or monomer. This step was carried out in pure water to ensure full
disproportionation was achieved, as organic solvents dramatically affect the extent of
disproportionation,30 after which the monomer and initiator could be added in the
cosolvent. The resulting solution was 80 % DMSO, which is within the range of solubility
deemed suitable for the dithiophenolmaleimide initiator.
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Scheme 5.5. Polymerisation of mPEGA and DEGA with WSI in water – organic solvents.
For the polymerisations in DMSO, a molar mass of 7500 Da was targeted for
homopolymers of eDEGA, mPEGA and NiPAm as well as two random copolymers of
eDEGA/mPEGA containing 10 % and 5 % of the PEG monomer (scheme 5.5). CuBr and
Me6TREN were allowed to disproportionate fully in 0.75 ml water, and the solution
degassed under nitrogen bubbling, after which a degassed solution of the monomer and
initiator in 4 ml DMSO and 0.25 ml water were added under the flow of nitrogen ([I]:
[CuBr]:[Me6TREN] = 1:0.4:0.4). After 24 hours a sample was removed and diluted with D2O
for 1H NMR conversion and DMF for SEC molecular weight analysis (table 5.2).
Table 5.2. Polymerisation data for synthesis of eDEGA, mPEGA, NiPAm and copolymers ofmPEGA and eDEGA using WSI in DMSO/H2O (5:1) using [I]:[CuBr]:[Me6TREN] = 1:0.4:0.4,
Monomer(s) Target MW(Da) Conversion % (NMR)
Mn (Da)
(SEC) Ð (SEC)
mPEGA480 7500 100 10200 1.08
mPEGA480: eDEGA(1:9) (10 % PEGA) 7500 98 10500 1.22mPEGA480: eDEGA(1:19) (5 % PEGA) 7500 99 10900 1.31
eDEGA 7500 99 11400 1.37
NiPAm 7500 17 3230 1.91
Chapter 5 – Synthesis and peptide conjugation of functional polymers
Jennifer Collins 242
The polymerisations for eDEGA and mPEGA480 (and copolymers of the two) showed
quantitative or almost quantitative conversions, with analysis by SEC showing symmetrical
and monomodal peaks (figure 5.14). The SEC molecular weight distributions although
starting to approach Ð = 1.4, remained acceptably narrow, showing some control over the
polymerisation. It is, however, evident that upon higher ratios of eDEGA within the
copolymer (and for the eDEGA homopolymers) the molecular weight distribution is
broadening. The polymerisation of NiPAm was not as successful, with 1H NMR analysis
showing less than 20 % conversion attained after 24 hours, although some presence of
polymer peaks was evident within the spectra. SEC analysis shows a bimolecular peak with
high molecular weight tailing, theorised to be due to the presence of termination events
and a lack of control.
Figure 5.14. SEC analysis of poly[(mPEGA)x(eDEGA)1-x] for x = 1, 0.1, 0.05 & 0 and SEC analysisof synthesis of poly(NiPAm) in DMSO/H2O .
Acrylamides have previously been successfully synthesised in a controlled manner by
utilising the prior disproportionation of Cu(I)Br with N-donor aliphatic ligands (such as
Me6TREN) in purely aqueous, mixed aqueous/alcoholic solutions and biologically relevant
conditions.29,56–58 It would be beneficial to devise a polymerisation system that allows the
synthesis of these two different classes of thermoresponsive polymers, which could also
utilise a non-water soluble initiator such as the dithiophenolmaleimide initiator.
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As a result, the cosolvent in the reaction was changed from DMSO to methanol for the
monomer / initiator solution. Again, it is important that full disproportionation was
allowed to occur under purely aqueous conditions, prior to the addition of
monomer/initiator. Methanol as a cosolvent showed promising behaviour in the
polymerisations of OEtOxMA described earlier in this chapter. For all polymerisations
[M]:[I] ratios (targeted degrees of polymerisation) were set to 50, and polymerisations
were performed on homopolymers of eDEGA and NiPAm and one copolymer of eDEGA and
mPEGA.
Table 5.3. Polymerisation data for synthesis of eDEGA, NiPAm and one copolymer of mPEGAand eDEGA using WSI in MeOH/H2O (5:1) using [I]:[CuBr]:[Me6TREN] = 1:0.4:0.4.
Monomer(s) Target MW(Da) Conversion % (NMR)
Mn (Da)
(SEC) Ð (SEC)mPEGA480: DEGA(1:9) (10 % PEGA) 11000 65 7600 1.06
eDEGA 10000 0 - -
NiPAm 6000 39 3500 1.10
The polymerisations in methanol were not successful and after 24 hours zero conversion
was observed for the polymerisation of eDEGA. The addition of an mPEGA monomer
improves the polymerisation, resulting in a narrow molecular weight distribution, although
the conversion was still much below quantitative. The polymerisation of NiPAm proved
more successful than for the analogous polymerisation using DMSO as a cosolvent, with a
higher molecular weight attained, and dispersity remaining low (Ð = 1.10), however, the
conversion attained was still low (≈ 40 %). 
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As high conversions are not achieved using methanol as a cosolvent, and due to these
unsatisfactory conversions for the synthesis of either of the desired thermoresponsive
polymers of poly((mPEGA480)(eDEGA)) or polyNiPAm, the solvent system was changed
again, this time to ethanol. An alternative initiator ethyl 2-bromoisobutyrate (EBiB) was
investigated for polymerisation under these conditions as EBiB has a comparable solubility
in ethanol-water solutions to the dithiophenolmaleimide initiator (≈ 50 % water content). 
The homopolymer of eDEGA was first polymerised, as this has proven challenging under
the previous two cosolvent conditions investigated. A targeted DPn of 50 (9.5 kDa) was
synthesised, and after 24 a sample submitted for 1H NMR showed that the polymerisation
had reached 95 % conversion. SEC analysis (DMF) revealed a peak with a narrow dispersity
and Mn close to the targeted molecular weight, although there is some evidence of high
molecular weight tailing upon inspection of the SEC chromatogram (figure 5.15).
Figure 5.15. SEC (DMF) and 1H NMR (δ6-DMSO) at t = 24 hours for homopolymerisation ofeDEGA in ethanol/water (4:1).
After a successful polymerisation of eDEGA had been achieved, three different copolymers
of eDEGA and mPEGA were synthesised alongside a homopolymer of NiPAm (scheme 5.6).
All polymers were synthesised using a monomer: initiator ratios of 100: 1, with samples
removed after 24 hours for 1H NMR conversion and SEC molecular weight analysis data.
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Scheme 5.6. Copolymerisation of mPEGA /eDEGA and homopolymerisation of NiPAm inethanol/water (4:1) using EBiB as initiator ([I]:[M]:[CuBr]:[Me6TREN] = 1:100:0.4:0.4)
Table 5.4. Polymerisation data for the synthesis of thermoresponsive polymers in ethanol /water (4:1) using EBiB as initiator
Monomer(s) Target MW(Da) Conversion % (NMR)
Mn (Da)
(SEC) Ð (SEC)
eDEGA 9500 95 9800 1.12
mPEGA480: eDEGA(1:4) (20 % PEGA) 24800 97 22100 1.18mPEGA480: eDEGA(15 % PEGA) 23400 94 21800 1.12mPEGA480: eDEGA(1:9) (10 % PEGA) 21900 95 20100 1.15
NiPAm 11300 97 11400 1.08
For all polymerisations high conversions were attained (> 94 % conversion), including for
the polymerisation of NiPAm, the first cosolvent condition to achieve a conversion higher
than 50 %. On analysis of SEC data, all molecular weight distributions were narrow (Ð <
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1.18) and mono-modal, although there is the presence of some high molecular weight
peak tailing for the poly[(mPEGA)x(eDEGA)1-x] copolymers (figure 5.16).
Figure 5.16. SEC analysis of different copolymers of mPEGA and eDEGA, and a NiPAmhomopolymer synthesised with EBiB in ethanol/water (4:1).
5.2.1.1. Cloud point measurements
These polymers were then purified by dialysis against water (1 kDa MWCO), and after
lyophilisation resulted in colourless oils (poly[(mPEGA480)x(DEGA) 1-x] copolymers) and a
white powder (poly(NiPAm)). The polymers were dissolved at a concentration of 1 mg ml-1
in phosphate buffered saline (PBS) and investigated for their cloud point behaviour, by
monitoring the absorbance at λ = 500 nm between 20 °C and 80 °C .  
Figure 5.17. Transmittance responses of ethyl end functional thermoresponsive polymers inPBS between 20 °C and 80 °C.
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The cloud point was measured as the temperature where the polymer showed a 50 %
transmission response on the third heating cycle, where this revealed that all 4 polymers
had cloud points within expected regions with all measurements occurring between 30 –
50 °C (figure 5.17). Importantly, the trend for the poly[(mPEGA)x(eDEGA)1-x] copolymers
showed that, as expected, the higher concentration of PEG within the polymer, the higher
the observed cloud point. This can be used to tailor polymers for targeting a specific
temperature for thermoresponsive behaviour to be observed.
Table 5.5. Molecular weight data and cloud point measurements for 1 mg ml-1 solutions ofcopolymers of eDEGA and mPEGA and polyNiPAm.
Polymer Mn (Da)(SEC)
Ð
(SEC)
Cloud Point
(°C)
EBiB – [(mPEGA480)0.2-(eDEGA)0.8]100 22100 1.18 46.5
EBiB – [(mPEGA480)0.15-(eDEGA)0.85]100 21800 1.12 40.1
EBiB – [(mPEGA480)0.1-(eDEGA)0.9]100 20100 1.15 31.7
EBiB – (NiPAm)100 11400 1.08 39.0
5.2.2. Dithiophenolmaleimide α-end functional
polymers with thermoresponsive behaviour
After successful polymerisations of both poly[(mPEGA480)(DEGA)]) and (poly(NiPAm)) being
achieved via copper mediated polymerisation in water ethanol mixtures using EBiB as an
initiator, the reactions were carried out using the dithiophenolmaleimide initiator for post-
polymerisation conjugation. Three different polymers were synthesised, polyNiPAm and
two copolymers of mPEGA and eDEGA, containing 10 and 20 % mPEGA respectively. The
Chapter 5 – Synthesis and peptide conjugation of functional polymers
Jennifer Collins 248
degree of polymerisation was targeted at 100, using 0.4 eq. of CuBr and Me6TREN and
approx. 80 wt % of the mixed solvents, with the polymerisations carried out at 25 °C
(scheme 5.7).
Scheme 5.7. Polymerisation reactions for synthesis of copolymers of eDGA and mPEGA and ahompolymer of NiPAm using dithiophenolmaleimide initiator in EtOH/H2O (4:1).
After 24 hours the reactions were sampled for 1H NMR (δ6-DMSO) conversion analysis
which highlighted that the majority of the monomer(s) had disappeared with high
conversions (> 95 %) for all three polymerisations. SEC analysis (DMF) revealed the
synthesis of controlled polymers maintaining narrow and mono-modal molecular weight
distributions (Ð < 1.25) (figure 5.18). The nature of this initiator gives rise to highly
coloured (yellow-orange) polymerisation solutions and resulting polymers, signifying the
incorporation of dithiophenolmaleimide α-end group functionality. This is evident by 
analysis of the SEC UV detector chromatogram where, a coincidental peak is observed to
the RI detector, suggesting a highly UV active polymer at this molecular weight.
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Figure 5.18. SEC (DMF) analysis of DTM functional thermoresponsive polymers synthesised inEtOH/H2O (4:1).
Table 5.6. Polymerisation data for synthesis of thermoresponsive dithiophenolmaleimidepolymers
Monomer(s) Target MW(Da) Conversion % (NMR)
Mn (Da)
(SEC) Ð (SEC)mPEGA480: eDEGA(1:4) (20 % PEGA) 24800 88 19800 1.19mPEGA480: eDEGA(1:9) (10 % PEGA) 21900 90 18500 1.23
NiPAm 11300 98 9200 1.12
The polymers were purified by dialysis against water (3.5 kDa MWCO, 3 days) and after
lyophilisation this resulted in two strongly coloured yellow oils (mPEGA480-eDEGA
copolymers) and a yellow powder (polyNiPAm). NMR analysis of the polymers revealed
that the dithiophenolmaleimide end group was still present, where the aromatic peaks of
the phenol groups and the triazole within the end group are clearly identifiable (figure
5.19). This confirms that the polymer still retains the conjugatable functionality required
for the post-polymerisation disulfide bridging conjugation of the peptide.
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Figure 5.19. 1H NMR (δ6 – DMSO) of purified DTM- poly[(mPEGA)0.2(eDEGA)0.8] and DTM-poly(NiPAm)100 showing presence of α-DTM functionality. 
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5.2.2.1. Cloud point measurement of dithiophenolmaleimide
polymers
Similar cloud point measurements were undertaken for the dithiophenolmaleimide end
functional thermoresponsive polymers as for the polymers initiated with EBiB, where
similar behaviour was observed (figure 5.20). For the dithiophenolmaleimide functional
poly(NiPAm)100 the transmittance does not initially start at 100 %, but at 72 % in the cloud
point measurements. This relates to a starting absorbance of 0.14, suggesting that the
polymer was not entirely soluble, although there is still the observation of LCST behaviour
for which a cloud point can be evaluated.
Figure 5.20. Transmittance of thermoresponsive DTM functional polymers between 20 °C and80 °C, and photographs of polymer solutions below and above cloud point.
The cloud point measurements of the α-end functional dithiophenolmaleimide polymers 
are similar to those measured for those same polymers initiated with EBiB. The expected
trend was observed where the cloud point measured increased on increasing the amount
of mPEGA in the PEG-DEG copolymers, and all results are within 30 °C – 50 °C. The cloud
point measured for poly(NiPAm) differs by the highest margin from 39.0 °C (EBiB) to 30.0
°C (DTM), likely due to an increase in the hydrophobicity of the polymer after addition of
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the DTM α-end group functionality. However, results for these and for the 9:1 ratio of 
eDEGA:mPEGA are both consistent with a bio relevant region cloud point temperature
(approximately 37 °C).
Table 5.7. Cloud point measurements of DTM α-end functional thermoresponsive polymers. 
Polymer Mn(SEC, Da)
Ð
(SEC)
Cloud Point
(°C)
DTM – [(mPEGA480)0.2-(eDEGA)0.8]100 19800 1.19 46.6
DTM – [(mPEGA480)0.1-(eDEGA)0.9]100 18500 1.23 34.3
DTM – (NiPAm)100 9200 1.12 30.0
5.2.3. Disulfide bridging conjugation of
thermoresponsive polymers onto oxytocin
The conjugation reaction of the synthesised dithiophenolmaleimide end functional
poly[(mPEGA480)(eDEGA)]) and poly(NiPAm) were carried out in the same manner as for
the poly(PEG) conjugations described in chapter 3. Initially the conjugations were
performed using the ‘without purification/in-situ’ method through which, after firstly
reducing the disulfide bond of oxytocin using TCEP, an aliquot of the polymerisation
solution is added to rebridge the two sulfhydryl residues with the unpurified polymer.
After 24 hours the reactions were analysed by RP-HPLC, although there was no appearance
of a conjugate peak by either UV or fluorescence. The experiments were repeated again
using the same polymers, but with prior purification, before addition to the reduced
peptide solution. Analysis by RP-HPLC again showed no appearance of conjugate peaks, or
corresponding fluorescence as expected within these conjugations. Analysis of the non-
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conjugated polymer under the same conditions also did not show any obvious polymer
peaks, possibly indicating that it could be due to the thermoresponsive nature of the
polymers (figure 5.21). The standard HPLC conditions used for analysis of the conjugates
involve the use of a column oven heated to 25 °C. To counter any potential heat effects,
RP-HPLC analysis was instead performed where the column was cooled to 10 °C. At this
temperature, there was no change to the chromatogram, and there was still no
observation of peaks in the UV or fluorescence that might be related to either the
dithiophenolmaleimide polymer or the oxytocin-polymer conjugate.
Figure 5.21.  RP-HPLC analysis (UV, λ = 280 nm) of  oxytocin  conjugation of purified DTM-poly[(mPEGA)x(eDEGA)1-x]100.
A different approach was then pursued where the native peptide and polymer are added
together, before adding the reducing agent, hence the disulfide bond is still maintained in
the structure. It was hoped that once the reducing agent is added, as the disulfide bond
breaks, there is a very large excess of the dithiophenolmaleimide functional polymer and
disulfide bridging should occur immediately. This method has previously been utilised in
the disulfide bridging of Somatostatin, and prevents potential negative effects on peptide
structure by limiting the amount of time the cysteine residues are free.59 The solution was
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then allowed to stir for 24 hours before sampling for RP-HPLC analysis, which did not show
the appearance of any conjugate peaks or any corresponding fluorescence. The
chromatograms were very similar to those observed by conjugation with prior reduction of
the disulfide bond and made confirmation of conjugation very difficult.
The poly[(mPEGA480)x(eDEGA)1-x] conjugation reactions with pre-reduction of the disulfide
bond were repeated, focusing on the concentration of samples for RP-HPLC, paying
particular attention to the native peptide. This showed that upon conjugation there is a
significant decrease in the concentration of oxytocin after addition of the polymers
(poly[(mPEGA480)x(eDEGA)1-x] : 72 % reduction of oxytocin remaining in reaction solution,
independent of comonomer ratio) (figure 5.22). This suggests that some form of peptide
reaction is taking place, as the native peptide has largely been consumed, perhaps from
the conjugation of polymers across the disulfide bond.
Figure 5.22. RP-HPLC analysis of oxytocin conjugation of DTM-poly[(mPEG)x(eDEGA)1-x],specifically focussing on consumption of peptide.
5.2.3.1. Conjugation of statistical copolymers of mPEGA480 –
eDEGA onto a different peptide: Salmon calcitonin
Following on from the uncertainty and limitations of the RP-HPLC data as to the extent of
polymer conjugation onto oxytocin, an alternative small peptide, salmon calcitonin (sCT),
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was investigated as a conjugation target. sCT is a 32 amino acid hormone currently used in
the treatment of some bone conditions, including osteoporosis and hypocalcaemia. Both
dithiophenolmaleimide and dibromomaleimide small molecules and polymers have
previously been efficiently conjugated onto sCT.60,61 Similarly to oxytocin, sCT contains one
disulfide bridge (Cys1 – Cys7) although, due to the increased size of the polypeptide, it also
contains an alpha helix chain that adds structural rigidity.
After complete reduction of the disulfide bond with TCEP, as observed by RP-HPLC, the two
different ratio DTM-[(mPEGA480)x(eDEGA)1-x] polymers were added to the peptide in pH 6.2
phosphate buffer (100 mM). Analysis of the reaction mixtures after 24 hours and after 5
days revealed that there was no observed presence of a new conjugate peak, or any
corresponding fluorescence, as observed for the conjugation with oxytocin. There was,
however, also a significant decrease in the peak representative of the native peptide in
both samples, suggesting some consumption of the native peptide (figure 5.23). This
decrease in sCT was represented by a peptide concentration change of 35 – 40 % which,
although less than observed for the conjugation with oxytocin, still represents a significant
disappearance of native peptide.
Figure 5.23. RP-HPLC analysis of disulfide bridging conjugation of DTM-[(mPEGA)x(eDEGA)1-x]onto sCT.
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5.2.3.2. Further characterisation of oxytocin conjugated
thermoresponsive polymers.
As the disulfide bridging peptide conjugations of the thermoresponsive polymers did not
show any obvious peak appearances signifying conjugation by RP-HPLC analysis under any
of the conditions tested to either of the peptides investigated, further methods of
characterisation had to be developed. The disappearance of the peptide peak observed by
RP-HPLC for both oxytocin and salmon calcitonin suggests that some reaction has taken
place, consuming the peptide in its native form; however, this cannot be confirmed using
the usual HPLC analysis methods.
A close inspection of the conjugation reaction revealed that a moderate colour change
could be observed within the first few minutes of addition of the yellow polymer to the
reduced peptide (figure 5.24). The DTM polymer has a high intensity yellow colour, which
can be observed before addition to the reduced peptide. On stirring at ambient
temperature for a few minutes this colour starts to disappear significantly, leaving a
solution that is still yellow, but with a less intense colour.
Figure 5.24. Images showing colour change from the bright yellow of thedithiophenolmaleimide polymer to a less intense colour, observed during the conjugationreaction.
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Another characterisation method for the conjugation of disubstituted maleimde polymers
is UV-vis spectroscopy.62 The UV absorption of the maleimide unit is known to change
wavelength depending on the thiol functionality, and this was observed in chapter 3 for
the characterisation of dibromo- and dithiophenolmaleimide PEGs upon conjugation to
oxytocin. When the polymer contains the dithiophenolmaleimide end group a
characteristic peak is observed at λ≈ 420 nm whereas this peak shifts to λ≈ 390 nm upon 
conjugation, due to loss of the aromatic functionality. The UV absorbance within this
region was investigated for the two DTM-[(mPEGA480)x – (eDEGA)1-x] polymers, upon
addition to disulfide bridged solutions of both oxytocin and salmon calcitonin, where
similar behaviour was observed for each (figure 5.25).
Figure 5.25. UV shifts of DTM functional poly[(mPEGA)x(eDEGA)1-x] and upon addition toreduced sCT and oxytocin.
This highlights that the α-end group functionality of the polymers is changing from that of 
the dithiophenolmaleimide, and this potentially indicates that the peptide has successfully
undergone polymer conjugation. The same result being observed for both peptides
suggests that the disulfide bridge has been reacted in the same manner, as the UV
wavelength after conjugation would be expected to be similar for both.
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Another possible method of analysis for the confirmation of conjugation of the
dithiophenolmaleimide polymers onto oxytocin is the use of SEC, to observe changes in the
average molecular weight, or molecular weight distributions, of the polymers before and
after conjugation. For the conjugation of polymers onto oxytocin the increase in molecular
weight of the polymer upon conjugation is only anticipated to be 1007 Da (the molar mass
of oxytocin), as conjugation is singular and site specific. During the reaction, however,
there was an excess of polymer added, and this combined with the reaction not going to
100 % completion would result in the presence of the dithiophenolmaleimide polymer
alongside any potential peptide conjugate. On SEC analysis of the native peptide, a higher
molecular weight distribution is observed than anticipated (theoretical: 1 kDa; SEC: 1.6
kDa) due to the differences between the hydrodynamic volume of oxytocin and the PMMA
calibrants.
SEC analysis of the conjugation of both DTM α-end functional NiPAm and poly[(mPEGA)-
co-(eDEGA)] reveals an increase in molecular weight after the conjugation reaction has
been undertaken (figure 5.26). The chromatogram of the ‘conjugate’ shows the
appearance of bimodal behaviour, which would suggest a peak of larger molecular weight,
alongside the remaining unconjugated polymer. It is known that these reactions are not
100 % efficient, as some peptide can still be observed by RP-HPLC and therefore a
significant amount of the DTM functional polymer remains in the solution. The appearance
of the higher molecular weight species in the solution, however, is significant in proving
the formation of peptide polymer conjugate. Overall this appears to further confirm that
some conjugation has occurred, leading to a higher molecular weight species.
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Figure 5.26. SEC analysis of DTM functional thermoresponsive polymers before and afterdisulfide bridging conjugation of oxytocin.
5.2.4. Thermoresponsive polymer conjugates
conclusions
Several polymers with thermoresponsive properties can be synthesised by copper
mediated polymerisations with functionality capable of undergoing post-polymerisation
conjugation. The aqueous disproportionation of Cu(I)Br is tolerant of aromatic end groups
and the use of co-solvents, (even at 80 % organic) allowing the controlled synthesis of the
desired thermoresponsive polymers. The cloud point behaviour for copolymers of
mPEGA480 and eDEGA can be tuned by altering the ratio between the comonomers to
achieve a specific temperature range under which a soluble to non-soluble transition may
occur.
Although the traditional characterisation method used throughout this thesis for the
conjugation of polymers onto peptides has been through the observance of conjugate
peaks on RP-HPLC, for these polymers, no conjugate peaks were observed. Instead a
variety of different characterisation techniques have been evaluated for providing
evidence of potential conjugation onto the peptide. Visual observances of the solutions,
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and peak shifts by UV spectroscopy suggest that the maleimide functionality at the α-end 
of the polymer chain has undergone some substitution. There is a large consumption of
peptide observed by RP-HPLC suggesting that a reaction has taken place, whether by
conjugation or otherwise, and this was observed for two different small disulfide bond
containing peptides. Increases in molecular weights observed by SEC analysis also suggest
that some conjugation has occurred, leading to higher molecular weight species, although
there is still evidence of high amounts of unreacted polymers.
5.3. Glycopolymers
The synthesis of polymers featuring carbohydrate functionalities is an ever-expanding area
within polymer science, which consistently generates high interest within various
biological, biomedical and biomaterials fields. The tailored, well-defined incorporation of
saccharide functionalities, such as in glycopolymers or glyconanomaterials, can be
prepared with an aim to mimic nature for the use in a variety of bio-related applications,
particularly with regards to biomolecular recognition.
The ability to prepare precision glycopolymers containing pendant carbohydrate
functionalities has been particularly accessible since the development of controlled
polymerisation methods. A variety of different carbohydrate based monomers (consisting
of acetylated or deprotected functionality) are available incorporating acrylate,
methacrylate, acrylamide and vinyl ester groups as required. These have previously been
successfully polymerised by NMP, RAFT, ATRP and SET-LRP, resulting in a variety of
saccharide containing polymers of different compositions and architectures.
The attachment of glycopolymers onto peptides or proteins allows the synthesis of new
types of biomolecules to be prepared, usually with a particular application or function
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targeted. The usual method for synthesis of biomolecule conjugates of glycopolymers is
first the synthesis of the polymer to contain desired saccharide functionality followed by
post-polymerisation modification with the biomolecule, resulting in polymer attachment.
Glycopolymer-biomolecule conjugates have previously been prepared by utilisation of a
variety of different pendant saccharide functionalities (including monosaccharide,
disaccharide and trisaccharides) with a variety of different biomolecule conjugation
targets. Biotin terminated glycopolymers have be prepared via different polymerisation
techniques (including controlled polymerisation techniques RAFT & ATRP), which, post-
polymerisation, could be used to conjugate to streptavidin alongside other proteins or
surfaces.63–67 Maynard et al. prepared glycopolymer conjugates by RAFT which utilised
pendant trehalose functionalities that, when conjugated onto lysozyme, were proven
successful in improving protein stability to thermally stressing and lyophilisation cycles.68,69
Glycopolymer conjugates utilising different sugar functionalities have also been
synthesised which have induced or amplified immune responses.70,71 The conjugation of
glycopolymers onto small peptides have also been described, including the synthesis of
pyridyldisulfide end functional glycopolymers by RAFT polymerisation followed by
subsequent conjugation onto the tripeptide glutathione. After peptide conjugation,
specific carbohydrate - protein recognition is achieved to the protein Concanavalin A
alongside the incorporation of antioxidant activity.72
Within this final sub-chapter the synthesis and subsequent copper mediated
polymerisation of a previously utilised mannose containing macromonomer is described.
Dithiophenolmaleimide α-end group functionality can be easily incorporated as previously 
described in this thesis, and used to rebridge an internal disulfide bond within a peptide (in
this case the model peptide salmon calcitonin). The relatively simple and controlled
polymer synthesis and conjugation show a facile route to the synthesis of peptide-
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glycopolymer conjugates, which after conjugation also exhibit fluorescence as a smart
labelling tool for confirmation of carbohydrate functional maleimide bridging.
5.3.1. Synthesis of α-end functional glycopolymers
5.3.1.1. Synthesis of sugar monomers
The synthesis of acrylate functional monosaccharide monomers have previously been
described and used directly for copper mediated controlled radical polymerisation.73
Utilising monomers without the requirement for protecting groups on the sugar can be
beneficial as controlled polymerisations can occur without extensive post-polymerisation
functionalisation. This results in a polymer that has pendant carbohydrate functionality
along the (non-carbohydrate) backbone chain, where the saccharides along the chain can
be designed and selected to suit the purpose or application, maintaining some of the
sugar-specific binding characteristics.
For the synthesis of mannose functional acrylate monomers the monosaccharide was
firstly functionalised to contain an alkyne group using Fischer-glycosylation (utilising H2SO4
immobilised on silica gel as a highly effective catalyst for the reaction).74 The reaction was
performed neat using a five-fold excess of propargyl alcohol which specifically and
singularly functionalises the hydroxyl at the anomeric position, although this does lead to a
mixture of the α and β product. The exact ratio can be calculated, and the two anomers 
separated, if desired, by carrying out hydroxyl protection chemistry and separation.
Following sugar functionalisation the glycomonomer is synthesised by the copper(I)
catalysed azide alkyne ‘click’ reaction (CuAAC) between this alkyne functional mannose
and an azide functional acrylate monomer, which has previously been reported for direct
polymerisation by ATRP.75
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Scheme 5.8. Synthesis of mannose glycomonomer.
Figure 5.27. 1H and 13C NMR (MeOD) of mannose functional glycomonomer.
1H NMR (MeOD) clearly shows the appearance of vinyl peaks (δ= 5.8 - 6.5) associated with 
the acrylate functional monomer, additional to the mannose sugar peaks (δ≈ 3.5 - 4.0 ppm) 
and the characteristic peak of the triazole ring (δ = 8.05 ppm) (figure 5.27). The monomer 
synthesis results in an excess of the α-anomer with respect to the β-anomer, although both 
products are still present.
5.3.1.2. SET-LRP of glycopolymers
Previously these mannose functional glycomonomers have successfully undergone copper
mediated living radical polymerisation, resulting in the controlled formation of polymers
containing pendant sugar functionalities. Haddleton et al. utilised this for the synthesis of
copolymers, wherein the sugar unit within each block could be tailored with the addition of
different glycomonomers (in this case mannose, glucose or fucose), resulting in a degree of
sequence control within the polymers.73
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Using the dithiophenolmaleimide initiator previously described in chapter 3, and earlier
within this chapter, the direct copper mediated polymerisation of the described mannose
glycomonomer resulting in α-end functionality capable of undergoing disulfide bridging 
peptide conjugation was performed. These reactions were carried out in DMSO using
Cu(II)Br2, Cu(0) wire and Me6TREN as ligand ([I]:[Me6TREN]:[CuBr2] = 1:0.18:0.1). As with
the other DTM polymer syntheses described previously, the solutions during
polymerisation remained a bright orange-yellow colour throughout due to the presence of
the dithiophenolmaleimide initiator. Two different [M]:[I] ratios were used for the
synthesis of two different molecular weights of polymer: 7.5 kDa (DPn 20) and 15 kDa (DPn
40).
Scheme 5.9. Polymerisation of mannose monomer with DTM initiator in DMSO([I]:[Cu(II)Br2]:[Me6TREN] = 1:0.1:0.18, 5 cm Cu(0) wire).
After 24 hours the polymerisations were sampled for 1H NMR conversion analysis (δ6-
DMSO) and SEC molecular weight data (DMF) (figure 5.28). Conversions were calculated by
comparing the vinyl groups (δ = 5.5 – 6.5 ppm) with the peak from the triazole ring (δ = 8.1 
ppm) on the monomer or alternatively the first CH2 group in the monomer next to the
acrylate polymer backbone (δ = 4.0 ppm). Although full monomer consumption was not 
attained (DPn 20 = 87 %; DPn 40 = 95 %), high conversions were reached with the
appearance of characteristic polymer peaks in the NMR spectrum. SEC analysis of the
polymers showed mono-modal molecular weight distributions with low dispersities
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attained (Ð < 1.15) suggesting that the polymer synthesis remained controlled. The
molecular weights (Mn) given by SEC were slightly different from those targeted,
particularly for the low molecular weight polymer, but this is largely due to the differences
in the structure between the glycopolymer, and the PMMA calibrants. This results in a
large difference observed for the hydrodynamic volume within the DMF solvent,
potentially due to the hydrophilic nature of the glycopolymer resulting from the large
number of hydroxyl groups present.
Figure 5.28. SEC (DMF) chromatograms and 1H NMR analysis of polymerisation of mannoseglycomonomers with dithiophenolmaleimide initiator after 24 hours.
Table 5.8. Molecular weight and conversion data for dithiophenolmaleimide end functionalpoly(mannose)
The polymers were purified by dialysis against water (1 kDa MWCO, 3 days) and after
lyophilisation the products were obtained as yellow powders. 1H NMR analysis of the
Entry TargetMW (Da)
Conversion
(NMR)
Mn (Da)
(NMR)
Mn (Da)
(SEC)
Ð
(SEC)Glycopolymer 1
DPn 20 7500 87 % 6600 10200 1.09Glycopolymer 2
DPn 40 15000 95 % 15000 15500 1.14
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polymer confirmed the presence of the dithiophenolmaleimide end groups with aromatic
peaks in the region (δ= 7.20 – 7.35 ppm), with a small peak representing the triazole peak 
from the initiator (δ= 8.05 ppm) appearing next to the larger triazole peak of the monomer 
(δ= 8.10 ppm) (figure 5.29). By comparison of these aromatic thiophenol peaks with the 
triazole peak of the monomer (taking into consideration this triazole peak on the initiator)
the average DPn for each polymer were calculated as 16 and 39 respectively. This yielded
experimental molecular weights of 6.6 kDa and 15 kDa, which were consistent with the
molecular weights targeted.
Figure 5.29. 1H NMR analysis (δ6-DMSO) of purified dithiophenolmaleimide α-end functional poly(mannose).
As a comparison, poly(mPEGA480) (DPn 50) was synthesised under the same conditions
with the DTM initiator (DMSO with 5 cm Cu(0) wire,[I]:[M]:[Cu(II)Br2][Me6TREN]:
1:50:0.1:0.18). After 24 hours the conversion by 1H NMR was 87 % and analysis by SEC
revealed an Mn of 21000 and dispersity of 1.18. The conversion is less than in previously
described work (the conditions used here are different to those previously described for
the synthesis of DTM-poly(mPEGA480) in chapter 3), but a controlled synthesis was still
attained, with narrow and mono-modal molecular weight distribution. The triazole peak
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and aromatic peaks of the DTM initiator can still be observed on the α-end of the polymer, 
therefore it is available for post-polymerisation disulfide bridging conjugation (figure 5.30).
Figure 5.30. 1H NMR (δ6 DMSO) and SEC (DMF) of purified dithiophenolmaleimide α-end functional poly(mPEGA480)50.
5.3.2. DTM-poly(mannose) and DTM-poly(mPEGA)
disulfide bridging conjugation
A model peptide (salmon calcitonin, sCT) was utilised to evaluate the success of
conjugation of glycopolymers using dithiophenolmaleimide disulfide bridging chemistry, as
sCT has previously been reported for polymers synthesised with a similar initiator by
ATRP.61 This was performed in a very similar manner to the disulfide bridging conjugations
described for the PEGylation of oxytocin in chapter 3 and the synthesis of
thermoresponsive conjugates of oxytocin or sCT described earlier in this chapter. The
reduction of the disulfide bridge to yield two free sulfhydryl groups was achieved using
TCEP, with complete reduction within 30 minutes, as monitored by RP-HPLC. After this
reduction was observed, the pH of the solution was adjusted using phosphate buffer (pH
6.2, 100 mM) and the glycopolymer was added.
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Scheme 5.10. Disulfide bridging conjugation of DTM glycopolymer onto sCT.
The conjugation reaction was allowed to proceed overnight at ambient temperature after
which a sample was removed for analysis by RP-HPLC. This revealed a shift in the retention
time of the broad polymer peak as well as the appearance of coincidental fluorescence
which was not present in the unconjugated polymer. As observed in previous work, as the
maleimide functionality on the end group of the polymer changes from dithiophenol to
dithioalkyl (where the peptide is acting as a long alkyl chain), fluorescence is induced
within the conjugate structure which had previous been quenched by the presence of the
aromatic groups.76 Also observed in the RP-HPLC spectrum is the appearance of a new
sharp peak at retention time t= 25.4 minutes, which is attributable to the thiophenol that
is substituted away from the maleimide and released during the conjugation.
In comparison to the sCT-polyPEG conjugate the sCT-poly(mannose) conjugates have much
smaller retention times by RP-HPLC analysis due to the hydrophilic nature of the multiple
hydroxyl groups on sugars being much less likely to interact with the long alkyl chain
substituents within the HPLC column. From the chromatogram the unconjugated polymer
appears at retention time t = 9.8 minutes (DPn 20) / 8.4 minutes (DPn 40) shifting by a few
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minutes to a slightly longer retention time after conjugation onto sCT (DPn 20: t = 10.9
minutes / DPn 40 t = 10.6 minutes) (figure 5.31).
Figure 5.31. RP-HPLC analysis of conjugation of dithiophenolmaleimide poly(mannose) onto
salmon calcitonin (UV λ= 280 nm; FLD λex: 341 nm, λem: 502 nm).
The conjugation of polyPEG onto sCT occurred in a very similar manner, with a shift in
retention time of the broad peak relating to the polymer after conjugation and the
appearance of coincidental fluorescence (figure 5.32). These results were also very
comparable to the conjugation of polyPEG onto oxytocin described in chapter 3, showing
that this procedure is applicable to more than one disulfide bond containing peptide, with
the polymers and conjugates appearing at similar positions in the RP-HPLC spectrum.
Figure 5.32. RP-HPLC analysis of conjugation of dithiophenolmaleimide poly(mPEGA480)50 ontosalmon calcitonin.
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The conjugation of these polymers onto sCT has much higher reaction efficiency than the
reactions previously observed for the disulfide bridging of oxytocin, and after 24 hours
there was a severe reduction in the native peptide peak. This is likely due to the structural
differences between the two peptides, in oxytocin a reduction of the disulfide bond loses
all structure for the small (9 amino acid) peptide, whereas in sCT the presence of the α 
helix maintains some of the structural integrity, allowing for easier disulfide bridging
conjugation. The sCT-glycopolymer and sCT-PEG conjugates were purified by dialysis
(water, 3 days, 1 kDa MWCO), and after lyophilisation the resulting products were a much
lighter yellow colour compared to the intense yellow unconjugated polymers. Fluorescence
spectroscopy was carried out on all three of the conjugates revealing the excitation and
emission wavelengths post conjugation. Initially the excitation wavelength was set to that
of the fluorescence detector on the HPLC (λex : 341 nm), as this showed a highly increased
level of fluorescence post conjugation in comparison to the native polymer (figure 5.33).
Figure 5.33. Fluorescence spectra of sCT-poly(mannose)20 with excitation at λex = 341 nm and
λex = 410 nm.
Although a minor peak was observed in the region expected (500 -550 nm), the intensity of
fluorescence emitted was not particularly prominent, and thus some different excitation
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wavelengths were investigated. When the excitation wavelength was λex = 410 nm this
trebled the observed emitted fluorescence, further clarifying that the polymer conjugates
do exhibit the fluorescent behaviour previously described for maleimide insertions into the
disulfide bond for sCT. The emission spectra were run for the three polymer conjugate
(two glycopolymers and polyPEG) with this excitation wavelength (λex : 410 nm), which
revealed different maximal emissions (but within the same region) for the polymer
conjugates. Excitation spectra performed using the wavelengths revealed maximal
excitation wavelengths between 410 - 415 nm, highlighting that the fluorescence
behaviour was similar for the polymer conjugates regardless of the monomer (figure 5.34).
Figure 5.34. Emission (λex = 410 nm) and excitation (λem = 536 – 547 nm) spectra of sCTpolymer conjugates.
5.3.3. Glycopolymer conjugates conclusions
An acrylate monomer containing mannose functionality was synthesised and could be
directly polymerised using copper mediated controlled radical polymerisation in DMSO
utilising an initiator capable of efficient conjugation. This resulted in α-end 
dithiophenolmaleimide functionality on the polymer capable of undergoing post
polymerisation disulfide bridging peptide conjugation, with pendant sugar functionality
along the polymer. The polymers were conjugated onto a model peptide, salmon
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calcitonin, using disulfide targeted maleimide bridging chemistry, resulting in
glycopolymer- peptide conjugates. The conjugations were monitored by RP-HPLC which
confirmed the appearance of fluorescence post conjugation, which was further monitored
by fluorescence spectroscopy and provides a smart labelling tool and confirmation of
conjugation.
5.4. Chapter 5 conclusions
Various different monomers are available that can be used in the synthesis of polymers
with a wide variety of properties or functions. The α-end group functionality can be easily 
designated with desired functionality able to undergo post-polymerisation grafting onto a
desired protein or peptide. This chapter has described the synthesis of three different
classes of polymers that can have benefits in pharmaceuticals for therapeutics. Whether
the targeted function is for PEG alternatives in the use of similar (and biocompatible)
macromonomers, in drug delivery or nanoparticle type assemblies, or for specific targeting
with a more biological function in mind, different approaches can be designed.
Using the polymer synthesis and conjugation approaches introduced in chapters 2 & 3, any
of these polymers can easily be incorporated with α-end group functionality for the 
specific targeting of amine groups at the N-terminus or on lysine groups and thiol targeting
of cysteine residues, whether native or with first the reduction of the disulfide bond. All
polymer synthesis remained controlled, leading to narrow molecular weight distributions
for polymers, although sometimes polymerisation system optimisation is required. This
leads to polymers of targeted molecular weights, with α-end functionality and repeat units 
designed with targeted functions and applications. After conjugation various techniques
are available for characterisation of peptide polymer conjugates, when certain analyses
may not be accessible.
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5.5. Experimental
5.5.1. Materials
Oxytocin (c- [Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2) was gifted from PolyPeptide
laboratories (Hillerød, Denmark) and used as received.
Copper(0) wire was pre-treated by washing in hydrochloric acid (35%) for 20 min, then
rinsed with water and dried under nitrogen immediately prior to use. N,N,N′,N′,N″,N″-
Hexamethyl-[tris(aminoethyl)amine] (Me6-TREN) and N,N,N′,N′′,N′′-
pentamethyldiethylenetriamine (PMDETA) were synthesised according to a previously
reported procedure and stored at -18 °C prior to use.77 Cu(I)Br and Cu(I)Cl were purified
according to the method of Keller.78 WSI was synthesised according to a literature
procedure.33 Oligo(2-ethyl-2-oxazoline)methacrylate monomer (OEtOxMA) (DPn = 5, Mn =
600 g mol-1, Ð = 1.21) was synthesised within our group by CROP, by Dr Kristian Kempe
according to a literature procedure.22 Protected aldehyde initiator and
dithiophenolmaleimide initiator were synthesised as described in earlier chapters. Alkyne
mannose was synthesised within our group according to a previously reported
procedure.73
5.5.2. Instrumentation & Analysis
Nuclear magnetic resonance (NMR) spectra were acquired with a Bruker DPX-300, Bruker
DPX-400, Bruker HD-300 and Bruker HD-400 spectrometers with samples prepared in
deuterated solvents (CDCl3, δ6-DMSO, or D2O) and chemical shifts were reported in parts
per million (ppm) with reference to solvent residual peaks.
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Size exclusion chromatography (SEC) was performed on either 1) Agilent Polymer
Laboratories GPC50 eluting with DMF (0.1 w/v % LiBr) at 50°C, 1 ml min-1 flow rate, fitted
with differential refractive index and UV detectors, 2 x PLgel 5 mm mixed D columns (300 x
7.5 mm), 1 x PLgel 5 mm guard column (50 x 7.5 mm) and autosampler; 2) Varian 390-LC
system using DMF (5 mM NH4BH4) eluent at 50 °C, 1 ml min-1 flow rate, equipped with RI,
UV, light scattering and viscometry detectors, 2 x PLgel 5 mm mixed D columns (300 x 7.5
mm), 1 x PLgel 5 mm guard column (50 x 7.5 mm) and autosampler DMF 3) Varian 390-LC
system eluting with CHCl3 (2 % TEA v/v) at 30 °C, 1 ml min-1 flow rate, equipped with
refractive index, UV, viscometry and light scattering detectors, 2 x PLgel 5 mm mixed C
columns (300 x 7.5 mm), 1 x PLgel 5mm guard column (50 x 7.5 mm)and autosampler. All
molecular weights were calculated relative to narrow PMMA standards (550 – 955,000 g
mol-1) and fitted with a 3rd order polynomial. All samples were passed through 0.2 µm
filters prior to analysis.
Infrared absorption spectra were recorded on a Bruker VECTOR-22 FTIR spectrometer
using a Golden Gate diamond attenuated total reflection cell.
UV/Vis spectra were recorded on Agilent Technologies Cary 60 UV-Vis using a quartz
cuvette with 10 mm optical length within the range 200 nm – 600 nm. Cloud point
temperature measurements were recorded on Agilent Technologies Cary 60 UV-Vis at a
wavelength of 500nm using a quartz cuvette with a 1 cm path length. The polymers were
dissolved in PBS or water at concentrations of 5 mg ml-1 or 1 mg ml-1 and were heated and
cooled between 20 – 90 °C at a rate of 1 °C min-1 while stirring at 1200 rpm. The cloud
point was determined as the temperature at 50 % transmittance on the third heating cycle.
Fluorescence spectra were collected on a PerkinElmer LS 55 Fluorescence Spectrometer.
Analytical high performance liquid chromatography (HPLC) was performed on Agilent 1260
infinity series stack equipped with an Agilent 1260 binary pump and degasser. 50 µl
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samples were injected using Agilent 1260 autosampler with a flow rate of 1 ml/min. The
HPLC was fitted with a Phenomenex Luna C18 column (250 x 4.6 mm) with 5 micron
packing (100Ǻ).  Detection was achieved using an Agilent 1260 variable wavelength 
detector monitoring at 280 nm. Mobile phase A consisted of either 100 % water containing
0.04 % TFA as an additive or 90 % water, 10 % acetonitrile containing 0.04 % TFA as an
additive. Mobile Phase B consisted of 100 % acetonitrile containing 0.04 % TFA as an
additive. The column was equilibrated by washing with the starting % of mobile phase A
for 10 minutes prior to injection for all conditions. The method gradient (1) HPLC analysis:
90 % mobile phase A decreasing to 40 % mobile phase A over 27 minutes, and remaining at
40% mobile phase A for 8 minutes, before resetting to the starting conditions in 1 minute,
and remaining in these conditions for at least 10 minutes to re-equilibrate the column
before subsequent injections. The method gradient (2) HPLC analysis: 95 % mobile phase
A decreasing to 80 % mobile phase A across 15 minutes, and to 40 % mobile phase A at 22
minutes and remaining at 40% mobile phase A for 5 minutes, before resetting to the
starting conditions in 1 minute, and remaining in these conditions for at least 10 minutes
to re-equilibrate the column before subsequent injections.
5.5.3. Synthetic Procedures
5.5.3.1. Poly(ethylene glycol) alternatives
Polymerisation of OEtOxMA with WSI or PALD initiator
To an oven dried Schlenk tube fitted with a magnetic stirring bar and rubber septum was
added Cu(I)Cl (0.8 eq.), PMDETA (0.8 eq.), NaCl (0.234 g, 4 mmol) and H2O (0.5 ml).
Separately to a vial fitted with a rubber septum was added initiator (1 eq.), OEtOxMA
monomer (400 mg, DPn eq.), MeOH (1 ml) and H2O (1 ml). Both solutions were allowed to
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deoxygenate with nitrogen for 20 minutes, before the monomer/initiator solution was
cannulated into the Schlenk tube and the reaction left to polymerise at 25 °C. After 24
hours samples were removed, and the solvent allowed to evaporate before dilution with
CDCl3 for 1H NMR analysis and CHCl3 for SEC analysis. Polymers were purified by dialysis
against water (1 kDa MWCO, 3 days).
Deprotection of PALD poly(OEtOxMA)
Acetal functional polymers (250 mg) were deprotected by stirring in aqueous solutions of
trifluoroacetic acid (50 % v/v, 15 ml) for 3 days. Polymers were purified by dialysis against
water (1 kDa MWCO, 3 days).
Reductive amination conjugation onto oxytocin of poly(OEtOxMA)
Reductive amination conjugation was performed by separately dissolving aldehyde
functional polymer (e.g. poly(OEtOxMA)20, 71.5 mg, 6.0 µmol, 1.5 Eq.) and oxytocin (4 mg,
4.0 µmol, 1 Eq.) in phosphate buffer (pH 6.2, 0.1 M) and adding the solutions together at
25 °C, with a freshly prepared solution of NaCNBH3 (0.25 ml, 40 mM, 2.5 Eq.) (for an overall
oxytocin concentration of 2 mM). After 4 days a sample was removed for RP-HPLC
monitoring. Following conjugation samples were purified by dialysis against water (1 kDa
MWCO, 3 days).
Schiff base conjugation onto oxytocin of poly(OEtOxMA)
Schiff base conjugation was performed by separately dissolving aldehyde functional
polymer (e.g. poly(OEtOxMA)20, 71.5 mg, 6.0 µmol, 1.5 Eq.) and oxytocin (4 mg, 4.0 µmol, 1
Eq.) in phosphate buffer (pH 6.2, 0.1 M) and adding the solutions together at 25 °C. After 1
and 4 days a sample was removed for RP-HPLC monitoring. Following conjugation samples
were purified by dialysis against water (1 kDa MWCO, 3 days).
Chapter 5 – Synthesis and peptide conjugation of functional polymers
Jennifer Collins 277
Reversibility studies of Schiff base linked oxytocin-poly(OEtOxMA)
Schiff base conjugates were dissolved in buffer (pH 5 citrate buffer or pH 7.4 phosphate
buffer, 5 mg ml-1) and left stirring (ambient temperature or 37 °C) before RP-HPLC
monitoring at t = 4 days and t = 14 days.
Thermal degradation of oxytocin-poly(OEtOxMA)
The conjugates alongside native oxytocin were separately dissolved in water (in triplicate)
before placing in an oven at 80 °C for 24 hours. The samples were monitored by RP-HPLC
for changes in concentration compared to a t = 0 sample.
5.5.3.2. Thermoresponsive polymers for peptide conjugation
Example thermoresponsive polymer synthesis in cosolvent system
Cu(I)Br and Me6TREN were added to H2O (0.75 ml) and degassed under nitrogen flow.
Monomer(s) and initiator (WSI, EBiB or DTM) were added to an organic cosolvent (4 ml)
with H2O (0.25 ml) and degassed under nitrogen flow. After 20 minutes the two solutions
were added together and allowed to polymerise at room temperature. After 24 hours
samples were removed for 1H NMR conversion analysis and SEC molecular weight data.
Polymers were purified by dialysis against water (3 days, 1 kDa MWCO).
Example polymer conjugation without purification onto disulfide
containing peptide
To the native peptide (5 mg, 5 µmol) in water was added TCEP (1.8 mg, 7.5 µmol), and the
solution allowed to stir for 2.5 hours. After complete disulfide bond reduction was
observed (by RP-HPLC) the dithiophenolmaleimide polymers were added directly as an
aliquot of polymerisation solution (1.5 equivalents). After 24 hours an aliquot was removed
for RP-HPLC analysis of UV and fluorescence.
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Example polymer conjugation onto disulfide containing peptide
To the native peptide (5 mg, 5 µmol) in water was added TCEP (1.8 mg, 7.5 µmol), and the
solution allowed to stir for 2.5 hours. After complete disulfide bond reduction was
observed (by RP-HPLC) the dithiophenolmaleimide polymers were added (1.5 equivalents).
After 24 hours an aliquot was removed for RP-HPLC analysis of UV and fluorescence.
Example ‘in-situ’ polymer conjugation onto disulfide containing
peptide
To the native peptide (5 mg, 5 µmol) in water was added the purified
dithiophenolmaleimide polymer (1.5 eq.), and the solution allowed to stir 10 minutes.
TCEP(1.8 mg, 7.5 µmol) was then added and after 24 hours an aliquot was removed for RP-
HPLC analysis of UV and fluorescence.
5.5.3.3. Glycopolymers
Mannose glycomonomer
To a mixture of alkyne sugar (2.33 g, 10.7 mmol) and 3-azidopropyl acrylate (2 g, 12.9
mmol) in H2O:MeOH (1:2, 75 ml), CuSO4.5H2O (0.201 g, 8.1 g) and sodium L-ascorbate
(0.212 g, 10.7 mmol) were sequentially added. The mixture was stirred for 24 hours at
ambient temperature after which the methanol was removed under reduced pressure and
the mixture freeze dried for removal of water. The resulting green compound was
dissolved in methanol and purified by silica column chromatography (methanol:
dichloromethane 1:10). The volatiles were removed under reduced pressure resulting in an
off-white solid (2.28g, 6.11 mmol, 57%).
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1H NMR (MeOD, 300.1 MHz) δ (ppm): 2.30 (2H, m, N3-CH2CH2), 3.50 – 3.78 (5H, overlapped
mannose CH ), 4.19 (2H, t, J = 6.0 Hz,N3CH2CH2CH2), 4.54 (2H, t, J = 6.8 Hz, N3CH2), 4.64-4.80
(2 H, overlap H2O, CH2O ), 5.90 ( 1 H, dd, J = 1.5, 9.0 Hz, HC=CH2), 6.13 ( 1 H, q, J = 7.2, 10.2
Hz, HC=CH2 ), 6.37 ( 1H, dd, J = 1.9, 15.4 Hz, HC=CH2 ), 8.05 (1H, s, NCH=C); 13C NMR (75.4
MHz, MeOD): 30.5 (N3-CH2CH2), 54.9 (N3-CH2CH2), 60.8 (N3-CH2CH2CH2), 62.8 (CH2OH), 63.1
(OCH2CHN3), 68.8, 72.2, 72.6, 75.1 (mannose), 100.8, 100.9 (α, β anomers of mannose), 
125.7 (N-CH=C), 129.4 (CH2=C), 132.0 (CH2=C), 145.5 (N-CH=C), 167.6 (C=O);
FT-IR (cm-1): 3335 (νOH), 2890 (νC=C-H), 1717 (νC=O), 1194 (νC-O); ESI-MS m/z: calculated for
C15H23N3O8 (M + Na)+ 396.1, found 396.1;
Synthesis of DTM functional poly(mannose) or polyPEG
Mannose glycomonomer (373 mg, 1 mmol) was dissolved in 1 ml DMSO and
dithiophenolmaleimide initiator (30 mg, 50 μmol,), CuBr2 (1.12 mg, 5 μmol) and Me6TREN 
(2.4 μl, 9 μmol) were sequentially added. The solution was degassed with nitrogen for 30 
minutes and stayed an orange-yellow colour. A stirrer bar wrapped with activated copper
wire was added to initiate polymerisation and the flask sealed. The reaction was allowed to
run overnight before a sample was taken via degassed syringe and dissolved in δ-DMSO for 
NMR analysis and DMF for SEC molecular weight data. The resultant polymer was dialysed
(MWCO, 1 kDa) against water for 3 days, before the solution was freeze dried yielding a
yellow powder.
Conjugation of glycopolymers and PEG onto salmon calcitonin
Salmon Calcitonin (sCT) (2 mg, 0.58 μmol) was dissolved in 300 μl of H2O along with tris(2-
carboxyethyl)phosphine (TCEP) (0.2 mg, 0.64 μmol). Upon reduction of disulfide bond (30 
minutes) monitored by RP-HPLC, phosphate buffer (2 ml, pH 6.2, 100 mM) was added to
the solution followed by the dithiophenolmaleimide functional polymer (Mn= 6.5 kDa) (4.2
mg, 0.64 μmol) dissolved in 1 ml of the same buffer. The solution was left to stir for 20 
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minutes before a sample was taken for RP-HPLC, which showed the formation of a new
product, as well as showing a fluorescence response.
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6. Overview and outlook
Throughout this thesis the general theme has been on the synthesis of peptide-polymer
conjugates, utilising a variety of the different conjugation chemistries that have previously
been described. The overall aim was to influence the properties (and specifically the shelf-
life stability) of the small peptide therapeutic oxytocin. The conjugation techniques
described have utilised the reactions at both amino (in this case found specifically at the N-
terminal amine) and thiol (from a reduction of the disulfide bond) functionalities in a site-
specific manner. Very little polymer modification research has previously been applied to
oxytocin, particularly with an aim to improving the stability of aqueous formulations and as
such these previously well-reported strategies were employed with investigations of the
conjugation chemistries and effect this might have on enhancements in stability.
Throughout this work, in general the focus has been on the PEGylation of oxytocin, due to
the multitude of advantages that PEG exhibits, which has previously led to PEGylated
products being FDA approved. There are two different architectures of polymers described
throughout this thesis, which allow easy comparisons between the effect that the PEG
density may have on the conjugation efficiency and on the conjugate characteristics. A
variety of linear PEGs are easily, and at relatively low cost, available commercially (or from
simple synthesis procedures), which allow the attachment of polymers onto the peptide
using straightforward conjugation chemistries.
Comb polymers can be synthesised by copper mediated polymerisation under various
conditions (specifically using different (co)solvents and copper sources) resulting in
polymers with narrow dispersity and tuned molecular weights. By utilising a PEG acrylate
monomer the resulting ‘comb’ PEG polymers, are comparable to their linear counterparts.
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Depending on the desired site of conjugation (amino or thiol), the initiator can be modified
to allow the simple incorporation of the α-end functionality capable of undertaking the 
conjugation approaches utilised in the linear polymers.
Following on from the synthesis of a variety of oxytocin-PEG conjugates, the effect of
conjugation was assessed in terms of thermal stability of aqueous solutions, uterotonic
testing and effect on cell proliferation of cancer cells. Overall the stability improvements
post-conjugation surpassed expectations, with the ‘comb’ PEG conjugates showing very
limited degradations under the highly thermally stressed stability assay. The addition of a
variety of different non-conjugated excipients into the solutions, although showing some
improvements in stability did not show near the level of promise exhibited by the
conjugates, promoting the covalent attachment as important in enhancing stability.
A lack of valid and definitive biological activity is disappointing, as the retained uterotonic
activity of the conjugates compared to the native peptide is vital in confirming the
applicability of this chemistry. If any activity was remaining post-conjugation this would be
a large improvement over the native degraded peptide, which shows a complete absence
of activity.
Following on from the successful conjugations of PEG and polyPEG at two different
positions on oxytocin the scope of the project was again widened. The development of
suitable polymerisation conditions with different initiators/solvents the systems could
easily be adapted for the synthesis of a variety of different monomers to suit certain
purposes or applications. This can further be expanded to a wider range of functional
monomers or different initiators, for the synthesis of a larger library of different oxytocin
conjugates, altering the peptide properties although attaining biological data is of vital
importance for the expansion of this work.
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